Modified amine lipids
Amine-containing lipids in lipid nanoparticle compositions address the challenge of delivering CRISPR/Cas components by enhancing stability and cellular uptake, facilitating efficient gene editing.
Patent Information
- Application Number
- JP2024146107
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-05
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing compositions struggle to effectively deliver biologically active agents, particularly large oligonucleotides like mRNA and CRISPR/Cas components, across cell membranes for gene editing, necessitating improved lipid nanoparticle formulations.
Development of amine-containing lipids formulated into lipid nanoparticle compositions that enhance the delivery of nucleic acid cargos, such as CRISPR/Cas gene editing components, by stabilizing and facilitating cellular uptake.
The amine-containing lipids improve the efficiency and stability of nucleic acid delivery, enabling effective gene editing processes within cells.
Smart Images

Figure 2024167309000479 
Figure 2024167309000480 
Figure 2024167309000481
Abstract
Description
[Technical Field]
[0001] Technical Field The present invention relates to modified amine lipids.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 775,783, filed December 5, 2018, the entire contents of which are incorporated herein by reference. [Background technology]
[0003] Lipid nanoparticles formulated with ionizable amine-containing lipids can serve as cargo vehicles for delivering bioactive substances, particularly polynucleotides such as RNA, mRNA, and guide RNA, into cells. LNP compositions containing ionizable lipids can facilitate the delivery of oligonucleotide agents across cell membranes and can be used to introduce gene editing components and compositions into living cells. Bioactive substances that are particularly difficult to deliver into cells include proteins, nucleic acid-based drugs, and their derivatives, particularly drugs containing relatively large oligonucleotides such as mRNA. Compositions for delivering promising gene editing technologies into cells, such as CRISPR / Cas9 system components, are of particular interest (e.g., mRNAs encoding nucleases and associated guide RNAs (gRNAs)).
[0004] There is a need for compositions for delivering CRISPR / Cas protein and nucleic acid components to cells, such as patient cells. In particular, compositions for delivering mRNA encoding CRISPR protein components and for delivering CRISPR guide RNA are of particular interest. Compositions that can stabilize and deliver RNA components and have properties useful for in vitro and in vivo delivery are also of particular interest. Summary of the Invention
[0005] The present disclosure provides amine-containing lipids useful for formulating lipid nanoparticle (LNP) compositions that may have advantageous properties for delivering nucleic acid cargo, such as CRISPR / Cas gene editing components, into cells.
[0006] In certain embodiments, the present disclosure provides a compound of formula (IA): [ka] having the structure wherein, independently for each occurrence: X 1 But C 1-3 alkylene or [ka] and X 2 is selected from O, NH, NMe, and a bond; X 3 But C 2-4 is alkylene, X 4 is a C1 alkylene or a bond; X 5 is a C1 alkylene or a bond; R 1 But C 1-3 is alkyl, R 2 But C 1-3 is alkyl, or R 2 is a nitrogen atom, and R 1 Or X 3 together with any of the carbon atoms of Y 1 is selected from a bond, —CH═CH—, —(C═O)O—, and —O(C═O)—; Y 2 is selected from -CH2-CH=CH- and C3-C4 alkylene; R 3 But H, C 5-7 Cycloalkyl, C8-C 10 Alkenyl, and C3-18 alkyl, R 4 But C 4-8 is alkyl, compound, or a salt thereof, However, R 2 is Me and R 3 But linear C 12 is alkyl, and X 1 is a C2 alkylene, and X 2 is O and X 3 is a C3 alkylene, and X 4 is a bond, and X 5 is C1 alkylene, and Y 1 is cis-CH=CH-, and -Y 2 -R 4 is cis-CH2-CH=CH-(C5-alkyl), then R 1 But C 2-3 provided that it is alkyl; The present invention relates to the compound or a salt thereof.
[0007] In certain embodiments, the present disclosure provides a compound of formula (I): [ka] wherein, independently for each occurrence: X 1 But C 2-3 is alkylene, X 2 is selected from O, NH, NMe, and a bond; X 3 But C 2-4 is alkylene, X 4 is a C1 alkylene or a bond; X 5 is a C1 alkylene or a bond; R 1 But C 1-2 is alkyl, R 2 But C 1-2 is alkyl, or R2 is a nitrogen atom, and R 1 Or X 3 together with any of the carbon atoms of Y 1 is selected from —CH═CH—, —(C═O)O—, and —O(C═O)—; R 3 But H, C 5-7 Cycloalkyl, and C 3-18 alkyl, R 4 But C 4-7 is alkyl, compound or a salt thereof, However, R 2 is Me and R 3 But linear C 12 is alkyl, and X 1 is a C2 alkylene, and X 2 is O and X 3 is a C3 alkylene, and X 4 is a bond, and X 5 is C1 alkylene, and Y 1 is cis-CH=CH-, and R 4 is a C5 alkyl, then R 1 is C2 alkyl, or a salt thereof, such as a pharmaceutically acceptable salt thereof.
[0008] In certain embodiments, the compound is a compound of formula (I), wherein R 2 is Me and R 3 But linear C 12 is alkyl, and X 1 is a C2 alkylene, and X 2 is O and X 3 is a C3 alkylene, and X 4 is a bond, and X 5 is C1 alkylene, and Y 1 is cis-CH=CH-, then R 1 is a C2 alkyl.
[0009] In certain embodiments, X 1 is a straight chain C2 alkylene. In other embodiments, X 1 is C alkylene. In some embodiments, X 1 is a straight chain C3 alkylene or a branched chain C3 alkylene.
[0010] In some other embodiments, X 2 is NH or O. In certain preferred embodiments, X 2 is O and X 3 is C 3-4 In some embodiments, X is alkylene. 3 is C 2-3 In certain embodiments, X is alkylene. 2 is NMe or a bond.
[0011] In certain embodiments, R 2 and X 3 and the carbon atoms of R taken together form a four-membered ring. 2 and X 3 and the carbon atoms of R taken together form a five-membered ring. 2 and X 3 and the carbon atoms of R form a six-membered ring. 2 may be C2 alkyl. In some cases, R 2 is C alkyl. In some embodiments, R 2 is substituted with, for example, a hydroxy group, and R 2 Examples include hydroxy-substituted C2 alkyl.
[0012] In certain embodiments, R 1 is C1 alkyl. Alternatively, R 1 may be C alkyl. In some embodiments, R 1 is substituted with, for example, a hydroxy group, and R 1 Examples of R include hydroxy-substituted C alkyl. In other embodiments, R 1 and R 2and together form a four-membered ring. In another embodiment, R 1 and R 2 and together form a five-membered ring. In yet another embodiment, R 1 and R 2 together form a six-membered ring.
[0013] In some embodiments, R 3 is a linear C 8-16 Alkyl, e.g., linear C 7-9 Linear C such as alkyl 7-12 alkyl; or R 3 is a linear C 3-6 In some embodiments, R 3 is a branched chain C 6-10 In another embodiment, R 3 is C 5-7 cycloalkyl, for example, C cycloalkyl. In some embodiments, R 3 is H. In some embodiments, R 3 is C 8-10 It is alkenyl.
[0014] In certain embodiments, R 4 is a linear C 5-6 It is alkyl.
[0015] In some embodiments, X 4 is a bond.
[0016] In certain embodiments, X 5 is a C1 alkylene.
[0017] In some embodiments, Y 2 -R 4 is -CH2-CH=CH-R 4 is.
[0018] In other embodiments, Y 2 is a straight chain C3 alkylene.
[0019] In some embodiments, Y 1 is selected from a bond, —CH═CH—, and —O(C═O)—, for example, —CH═CH— and —O(C═O)—.
[0020] In certain embodiments, the compound has Formula II [ka] wherein the variables are defined as in formula (IA).
[0021] In certain embodiments, the compound has formula III [ka] wherein the variables are defined as in formula (IA).
[0022] Representative compounds of formula (IA) or (I) include: [ka] JPEG2024167309000007.jpg208162JPEG2024167309000008.jpg211148JPEG2024167309000009.jpg214148JPEG2024167309 000010.jpg215149JPEG2024167309000011.jpg215149JPEG2024167309000012.jpg227149JPEG2024167309000013.jpg23115 0JPEG2024167309000014.jpg211149JPEG2024167309000015.jpg215150JPEG2024167309000016.jpg225152JPEG202416730 9000017.jpg213153JPEG2024167309000018.jpg218156JPEG2024167309000019.jpg224159JPEG2024167309000020.jpg2191 59JPEG2024167309000021.jpg219159JPEG2024167309000022.jpg226161JPEG2024167309000023.jpg223152JPEG20241673 09000024.jpg223152JPEG2024167309000025.jpg223152JPEG2024167309000026.jpg223152JPEG2024167309000027.jpg223 152JPEG2024167309000028.jpg223152JPEG2024167309000029.jpg226154JPEG2024167309000030.jpg229155JPEG2024167309000031.jpg229155JPEG2024167309000032.jpg229155JPEG2024167309000033.jpg240158, or a salt thereof, preferably a pharmaceutically acceptable salt.
[0023] In some embodiments, the compound is selected from: [ka] JPEG2024167309000035.jpg224134JPEG2024167309000036.jpg114140, or any salt thereof.
[0024] In other embodiments, the compound is selected from: [ka] JPEG2024167309000038.jpg215141JPEG2024167309000039.jpg109145, or any salt thereof.
[0025] In still other embodiments, the compound is selected from: [ka] JPEG2024167309000041.jpg214150JPEG2024167309000042.jpg109151, or any salt thereof.
[0026] In certain embodiments, the present disclosure relates to any compound described herein, wherein the protonated form of the compound has a pKa of about 5.1 to about 8.0, e.g., about 5.6 to about 7.2, about 5.7 to about 6.5, or about 5.8 to about 6.2. In some embodiments, the protonated form of the compound has a pKa of about 5.5 to about 6.0. In certain embodiments, the protonated form of the compound has a pKa of about 6.1 to about 6.3.
[0027] In certain embodiments, the present disclosure relates to a composition comprising any of the compounds described herein.
[0028] In certain embodiments, the present disclosure relates to a composition comprising any compound described herein and a lipid component, e.g., about 50% by weight of a compound described herein and a lipid component, e.g., an amine lipid, preferably a compound of formula (IA), (I), (II), or (III).
[0029] In certain embodiments, the present disclosure relates to any composition described herein, wherein the composition is an LNP composition. For example, the present disclosure relates to an LNP composition comprising any compound described herein and a lipid component. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the lipid component comprises a helper lipid and a PEG-lipid. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the lipid component comprises a helper lipid, a PEG-lipid, and a neutral lipid. In certain embodiments, the present disclosure relates to any LNP composition described herein, further comprising a cryoprotectant. In certain embodiments, the present disclosure relates to any LNP composition described herein, further comprising a buffer.
[0030] In certain embodiments, the present disclosure relates to any LNP composition described herein, further comprising a nucleic acid component. In certain embodiments, the present disclosure relates to any LNP composition described herein, further comprising an RNA or DNA component. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the LNP composition has an N / P ratio of about 3 to 10, e.g., an N / P ratio of about 6±1, or an N / P ratio of about 6±0.5. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the LNP composition has an N / P ratio of about 6.
[0031] In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the RNA component comprises an mRNA. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the RNA component comprises an RNA-guided DNA-binding agent, e.g., a Cas nuclease mRNA, such as a class 2 Cas nuclease mRNA or a Cas9 nuclease mRNA.
[0032] In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the mRNA is a modified mRNA. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the RNA component comprises a gRNA nucleic acid. In certain embodiments, the present disclosure relates to any LNP composition described herein, wherein the gRNA nucleic acid is a gRNA.
[0033] In certain embodiments, the present disclosure relates to LNP compositions described herein, wherein the RNA component comprises a Class 2 Cas nuclease mRNA and a gRNA. In certain embodiments, the present disclosure relates to LNP compositions described herein, wherein the gRNA nucleic acid is or encodes a dual guide RNA (dgRNA). In certain embodiments, the present disclosure relates to LNP compositions described herein, wherein the gRNA nucleic acid is or encodes a single guide RNA (sgRNA).
[0034] In certain embodiments, the present disclosure relates to the LNP compositions described herein, wherein the gRNA is a modified gRNA. In certain embodiments, the present disclosure relates to the LNP compositions described herein, wherein the modified gRNA comprises a modification in one or more of the first five nucleotides at the 5' end. In certain embodiments, the present disclosure relates to the LNP compositions described herein, wherein the modified gRNA comprises a modification in one or more of the last five nucleotides at the 3' end.
[0035] In certain embodiments, the present disclosure relates to any of the LNP compositions described herein, further comprising at least one template nucleic acid.
[0036] In certain embodiments, the present disclosure relates to methods of gene editing comprising contacting a cell with an LNP, hi certain embodiments, the present disclosure relates to any method of gene editing described herein comprising cleaving DNA.
[0037] In certain embodiments, the present disclosure relates to a method of cleaving DNA, comprising contacting a cell with an LNP composition. In certain embodiments, the present disclosure relates to any method of cleaving DNA described herein, wherein the cleaving step comprises introducing a single-stranded DNA nick. In certain embodiments, the present disclosure relates to any method of cleaving DNA described herein, wherein the cleaving step comprises introducing a double-stranded DNA break. In certain embodiments, the present disclosure relates to any method of cleaving DNA described herein, wherein the LNP composition comprises a class 2 Cas mRNA and a guide RNA nucleic acid. In certain embodiments, the present disclosure relates to any method of cleaving DNA described herein, further comprising introducing at least one template nucleic acid into a cell. In certain embodiments, the present disclosure relates to any method of cleaving DNA described herein, comprising contacting a cell with an LNP composition comprising a template nucleic acid.
[0038] In certain embodiments, the present disclosure relates to any method of gene editing described herein, the method comprising administering an LNP composition to an animal, e.g., a human. In certain embodiments, the present disclosure relates to any method of gene editing described herein, the method comprising administering an LNP composition to a cell, such as a eukaryotic cell.
[0039] In certain embodiments, the present disclosure relates to any method of gene editing described herein, comprising administering mRNA formulated in a first LNP composition and a second LNP composition comprising one or more of mRNA, gRNA, gRNA nucleic acid, and template nucleic acid. In certain embodiments, the present disclosure relates to any method of gene editing described herein, wherein the first and second LNP compositions are administered simultaneously. In certain embodiments, the present disclosure relates to any method of gene editing described herein, wherein the first and second LNP compositions are administered sequentially. In certain embodiments, the present disclosure relates to any method of gene editing described herein, wherein the method comprises administering mRNA and guide RNA nucleic acid formulated in a single LNP composition.
[0040] In certain embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the gene editing results in a gene knockout.
[0041] In certain embodiments, the present disclosure relates to any of the methods of gene editing described herein, wherein the gene editing results in gene correction. [Brief explanation of the drawings]
[0042] [Figure 1A] 1 shows the compounds tested in the in vivo editing and assay at the TTR locus. The chemical structures of the tested compounds are described. [Figure 1B] 1 shows the compounds tested in the in vivo editing assay at the TTR locus and the percentage of editing of TTR in mouse hepatocytes after delivery. [Figure 1C] Compounds tested in the in vivo editing and assay at the TTR locus are shown. Serum TTR levels (μg / mL) after delivery are shown. [Figure 2] 1 is a graph showing the percentage of TTR editing in mouse hepatocytes after delivery using LNPs containing a compound of formula (IA) or a control compound. Dose response data is also shown. [Figure 3] 1 shows the results after delivery using LNPs containing the compound of formula (IA). A is a graph showing the percentage of TTR editing in mouse hepatocytes after delivery. B is a graph showing serum TTR (μg / mL) after delivery. [Figure 4A] 1 shows the compounds tested in the in vivo editing and assay at the TTR locus. The chemical structures of the test compounds are described. [Figure 4B] 1 shows the compounds tested in the in vivo editing assay at the TTR locus and the percentage of editing of TTR in mouse hepatocytes after delivery. [Figure 4C] Compounds tested in the in vivo editing and assay at the TTR locus are shown. Serum TTR levels (μg / mL) after delivery are shown. [Figure 5A]Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 5B] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 5C] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 6A] Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 6B] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 6C] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 7A] Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 7B] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 7C] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 8A] 1 shows compounds of formula (IA) and delivery results using the compounds. The chemical structures of the test compounds are described, where n=1, 2, or 3. [Figure 8B] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 8C] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 9A]Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 9B] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 9C] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 10A] Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 10B] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 10C] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 11A] Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 11B] Figure 1 shows compounds of formula (IA) and delivery results using the compounds.The chemical structures of the test compounds are described. [Figure 11C] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in mouse hepatocytes after delivery. [Figure 11D] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 12A] 1 shows the compound of formula (IA) and the results of delivery using the compound. 2 shows the percentage of TTR editing in rat hepatocytes after delivery. [Figure 12B] 1 shows the compound of formula (IA) and the results of delivery using the compound. Serum TTR levels (μg / mL) after delivery are shown. [Figure 13]1 shows the compound of formula (IA) and the results of delivery using the compound. A illustrates the chemical structure of the test compound. B shows the percentage of TTR editing in HUH7 cells after delivery. DETAILED DESCRIPTION OF THE INVENTION
[0043] The present disclosure provides lipids, particularly ionizable lipids, useful for delivering bioactive agents ("cargo"), including nucleic acids such as CRISPR / Cas component RNA, to cells, as well as methods for preparing and using such compositions. The lipids and pharmaceutically acceptable salts thereof are optionally provided as lipid-containing compositions, including LNP compositions. In certain embodiments, the LNP compositions may comprise a lipid component comprising a bioactive agent, e.g., an RNA component, and a compound of Formula (IA), (I), (II), or (III), as defined herein. In some embodiments, the RNA component comprises a nucleic acid. In some embodiments, the lipids are used to deliver bioactive agents, e.g., nucleic acids such as mRNA, to cells, such as hepatocytes. In certain embodiments, the RNA component comprises a gRNA and, optionally, an mRNA encoding a class 2 Cas nuclease, and, optionally, a gRNA or a nucleic acid encoding the gRNA. Methods of gene editing and methods for generating engineered cells using these compositions are also provided.
[0044] Lipid Nanoparticle Composition Disclosed herein are various LNP compositions for delivering biologically active substances, such as nucleic acids, e.g., mRNA and gRNA, including CRISPR / Cas cargo. Such LNP compositions include "ionizable amine lipids" along with neutral lipids, PEG lipids, and helper lipids. "Lipid nanoparticle" or "LNP" refers, without limitation, to a particle comprising multiple (i.e., two or more) LNP components physically bound to each other by intermolecular forces.
[0045] lipids The present disclosure provides lipids that can be used in LNP compositions.
[0046] In certain embodiments, the present disclosure provides a compound of formula (IA): [ka] having the structure wherein, independently for each occurrence: X 1 But C 1-3 alkylene or [ka] and X 2 is selected from O, NH, NMe, and a bond; X 3 But C 2-4 is alkylene, X 4 is a C1 alkylene or a bond; X 5 is a C1 alkylene or a bond; R 1 But C 1-3 is alkyl, R 2 But C 1-3 is alkyl, or R 2 is a nitrogen atom, and R 1 Or X 3 together with any of the carbon atoms of Each Y 1 is independently selected from a bond, —CH═CH—, —(C═O)O—, and —O(C═O)—; Each Y 2 is independently selected from —CH—CH═CH— and C-C alkylene; R 3 But H, C 5-7 Cycloalkyl, C8-C 10 Alkenyl, and C 3-18 alkyl, Each R 4 But on my own, C 4-8is alkyl, compound, or a salt thereof, However, R 2 is Me and R 3 But linear C 12 is alkyl, and X 1 is a C2 alkylene, and X 2 is O and X 3 is a C3 alkylene, and X 4 is a bond, and X 5 is C1 alkylene, and Y 1 is cis-CH=CH-, and -Y 2 -R 4 is cis-CH2-CH=CH-(C5-alkyl), then R 1 But C 2-3 provided that it is alkyl; The present invention relates to the compound or a salt thereof.
[0047] In certain embodiments, the compound is R 2 If Me, then R 1 C 2-3 A compound of formula (IA), provided that it is alkyl.
[0048] In certain embodiments, the compound is R 2 is not Me.
[0049] In certain embodiments, the compound is R 1 is not Me.
[0050] In certain embodiments, the compound is R 3 is a linear C 12 is a compound of formula (IA) which is not alkyl.
[0051] In certain embodiments, the compound is 1 but there is no C2 alkylene, the compound of formula (IA).
[0052] In certain embodiments, the compound is 2 is not O.
[0053] In certain embodiments, the compound is 3 but there is no C3 alkylene, the compound of formula (IA).
[0054] In certain embodiments, the compound is 4 is not a bond.
[0055] In certain embodiments, the compound is 5 where C1 alkylene is not present, the compound is of formula (IA).
[0056] In certain embodiments, the compound is 1 is not cis-CH=CH-.
[0057] In certain embodiments, the compound is -Y 2 -R 4 is not cis-CH2-CH=CH-(C5-alkyl).
[0058] In certain embodiments, the present invention provides a compound of formula (I): [ka] wherein, independently for each occurrence: X 1 But C 2-3 is alkylene, X 2 is selected from O, NH, NMe, and a bond; X 3 But C 2-4 is alkylene, X 4 is a C1 alkylene or a bond; X 5 is a C1 alkylene or a bond; R 1 But C 1-2is alkyl, R 2 But C 1-2 is alkyl, or R 2 is a nitrogen atom, and R 1 Or X 3 together with any of the carbon atoms of Y 1 is selected from —CH═CH—, —(C═O)O—, and —O(C═O)—; R 3 But H, C 5-7 Cycloalkyl, and C 3-18 alkyl, R 4 But C 4-7 is alkyl, the compound, or a salt thereof, However, R 2 is Me and R 3 But linear C 12 is alkyl, and X 1 is a C2 alkylene, and X 2 is O and X 3 is a C3 alkylene, and X 4 is a bond, and X 5 is C1 alkylene, and Y 1 is cis-CH=CH-, and R 4 is a C5 alkyl, then R 1 is C2 alkyl, or a salt thereof, e.g., a pharmaceutically acceptable salt thereof.
[0059] In certain embodiments, the compound is a compound of formula (I), wherein R 2 is Me and R 3 But linear C 12 is alkyl, and X 1 is a C2 alkylene, and X 2 is O and X 3 is a C3 alkylene, and X 4 is a bond, and X 5 is C1 alkylene, and Y1 is cis-CH=CH-, then R 1 is a C2 alkyl.
[0060] In certain embodiments, the compound is R 2 If Me, then R 1 is a C2 alkyl.
[0061] In certain embodiments, the compound is R 2 is not Me.
[0062] In certain embodiments, the compound is R 1 is not Me.
[0063] In certain embodiments, the compound is R 3 is a linear C 12 is a compound of formula (I) that is not alkyl.
[0064] In certain embodiments, the compound is 1 is not a C2 alkylene.
[0065] In certain embodiments, the compound is 2 is not O.
[0066] In certain embodiments, the compound is 3 is not a C3 alkylene.
[0067] In one embodiment, the compound is X 4 is not a bond.
[0068] In certain embodiments, the compound is 5 is not a C1 alkylene.
[0069] In certain embodiments, the compound is 1 is not cis-CH=CH-.
[0070] In some embodiments, the compound is enantiomerically enriched or diastereomerically enriched, e.g., the compound is enantiomerically enriched.
[0071] In certain embodiments, X 1 is a straight chain C2 alkylene. In other embodiments, X 1 is C alkylene. In some embodiments, X 1 is a straight chain C3 alkylene or a branched chain C3 alkylene.
[0072] In some other embodiments, X 2 is NH or O. In certain preferred embodiments, X 2 is O and X 3 is C 3-4 In some embodiments, X is alkylene. 3 is C 2-3 In certain embodiments, X is alkylene. 2 is NMe or a bond.
[0073] In certain embodiments, R 2 and X 3 and the carbon atoms of R together form a four-membered ring. 2 and X 3 and the carbon atoms of R taken together form a five-membered ring. 2 and X 3 and the carbon atoms of R form a six-membered ring. 2 may be C2 alkyl. In some cases, R 2 is C alkyl. In some embodiments, R 2 is substituted with, for example, a hydroxy group, and R 2 Examples include hydroxy-substituted C2 alkyl.
[0074] In certain embodiments, R 1 is C1 alkyl. Alternatively, R 1 may be C alkyl. In some embodiments, R 1 is substituted with, for example, a hydroxy group, and R 1 Examples of R include hydroxy-substituted C alkyl. In some embodiments, R 1 is unsubstituted. In some embodiments, R 2 is unsubstituted. In a preferred embodiment, R 1 and R 2 and are both unsubstituted. In other embodiments, R 1 and R 2 and together form a four-membered ring. In another embodiment, R 1 and R 2 and together form a five-membered ring. In another embodiment, R 1 and R 2 together form a six-membered ring.
[0075] In some embodiments, R 3 is a linear C 8-16 Alkyl, e.g., linear C 7-9 Linear C such as alkyl 7-12 alkyl; or R 3 is a linear C 3-6 In some embodiments, R 3 is a branched chain C 6-10 In another embodiment, R 3 is C 5-7 cycloalkyl, for example, C cycloalkyl. In some embodiments, R 3 is H. In some embodiments, R 3 is C 8-10 It is alkenyl.
[0076] In certain embodiments, R 4 is a linear C 5-6 It is alkyl.
[0077] In some embodiments, X 4 is a bond.
[0078] In certain embodiments, X 5 is a C1 alkylene.
[0079] In some embodiments, Y 2 -R 4 is -CH2-CH=CH-R 4 is.
[0080] In other embodiments, Y 2 is a straight chain C3 alkylene.
[0081] In some embodiments, Y 1 is selected from a bond, —CH═CH—, and —O(C═O)—, for example, —CH═CH— and —O(C═O)—.
[0082] In certain embodiments, the compound has formula II [ka] wherein the variables are defined as in formula (IA).
[0083] In certain embodiments, X 1 is a straight chain C2 alkylene. In other embodiments, X 1 is C alkylene. In some embodiments, X 1 is a straight chain C3 alkylene or a branched chain C3 alkylene.
[0084] In some embodiments, R 3 is a linear C 8-16 Alkyl, e.g., linear C 7-9 Linear C such as alkyl 7-12 alkyl; or R 3 is a linear C 3-6 In some embodiments, R 3 is a branched chain C 6-10 In another embodiment, R 3 is C 5-7cycloalkyl, for example, C cycloalkyl. In some embodiments, R 3 is H. In some embodiments, R 3 is C 8-10 It is alkenyl.
[0085] In certain embodiments, R 4 is a linear C 5-6 It is alkyl.
[0086] In some embodiments, X 4 is a bond.
[0087] In certain embodiments, X 5 is a C1 alkylene.
[0088] In some embodiments, Y 2 -R 4 is -CH2-CH=CH-R 4 is.
[0089] In other embodiments, Y 2 is a straight chain C3 alkylene.
[0090] In some embodiments, Y 1 is selected from a bond, —CH═CH—, and —O(C═O)—, for example, —CH═CH— and —O(C═O)—.
[0091] In certain embodiments, the compound is selected from: [ka] JPEG2024167309000048.jpg223162JPEG2024167309000049.jpg52168, or any salt thereof.
[0092] In certain embodiments, the compound has formula III [ka] wherein the variables are defined as in formula (IA).
[0093] In certain embodiments, X 1 is a straight chain C2 alkylene. In other embodiments, X 1 is C alkylene. In some embodiments, X 1 is a straight chain C3 alkylene or a branched chain C3 alkylene.
[0094] In some other embodiments, X 2 is NH or O. In certain preferred embodiments, X 2 is O and X 3 is C 3-4 In some embodiments, X is alkylene. 3 is C 2-3 In certain embodiments, X is alkylene. 2 is NMe or a bond.
[0095] In certain embodiments, R 2 and X 3 and the carbon atoms of R together form a four-membered ring. 2 and X 3 and the carbon atoms of R taken together form a five-membered ring. 2 and X 3 and the carbon atoms of R form a six-membered ring. 2 may be C2 alkyl. In some cases, R 2 is C alkyl. In some embodiments, R 2 is substituted with, for example, a hydroxy group, and R 2 Examples include hydroxy-substituted C2 alkyl.
[0096] In certain embodiments, R 1 is C1 alkyl. Alternatively, R 1 may be C alkyl. In some embodiments, R 1 is substituted with, for example, a hydroxy group, and R 1Examples of R include hydroxy-substituted C alkyl. In some embodiments, R 1 is unsubstituted. In some embodiments, R 2 is unsubstituted. In a preferred embodiment, R 1 and R 2 and are both unsubstituted. In other embodiments, R 1 and R 2 and together form a four-membered ring. In another embodiment, R 1 and R 2 and together form a five-membered ring. In another embodiment, R 1 and R 2 together form a six-membered ring.
[0097] In some embodiments, R 3 is a linear C 8-16 Alkyl, e.g., linear C 7-9 Linear C such as alkyl 7-12 alkyl; or R 3 is a linear C 3-6 In some embodiments, R 3 is a branched chain C 6-10 In another embodiment, R 3 is C 5-7 cycloalkyl, for example, C cycloalkyl. In some embodiments, R 3 is H. In some embodiments, R 3 is C 8-10 It is alkenyl.
[0098] In some embodiments, X 4 is a bond.
[0099] In certain embodiments, X 5 is a C1 alkylene.
[0100] Representative compounds of formula (IA) or (I) include: [ka] JPEG2024167309000052.jpg215154JPEG2024167309000053.jpg215154JPEG2024167309000054.jpg215154JPEG2024167309 000055.jpg215154JPEG2024167309000056.jpg221160JPEG2024167309000057.jpg226160JPEG2024167309000058.jpg22616 0JPEG2024167309000059.jpg226160JPEG2024167309000060.jpg226160JPEG2024167309000061.jpg226160JPEG202416730 9000062.jpg212165JPEG2024167309000063.jpg217169JPEG2024167309000064.jpg226169JPEG2024167309000065.jpg2201 70JPEG2024167309000066.jpg220170JPEG2024167309000067.jpg224170JPEG2024167309000068.jpg224170JPEG20241673 09000069.jpg224170JPEG2024167309000070.jpg224170JPEG2024167309000071.jpg224170JPEG2024167309000072.jpg224 170JPEG2024167309000073.jpg224158JPEG2024167309000074.jpg224158JPEG2024167309000075.jpg224158JPEG2024167309000076.jpg224158JPEG2024167309000077.jpg224158JPEG2024167309000078.jpg180158, or a salt thereof, for example a pharmaceutically acceptable salt thereof.
[0101] Representative compounds of formula (IA) or (I) include: [ka] JPEG2024167309000080.jpg217162JPEG2024167309000081.jpg211164JPEG2024167309000082.j pg220165JPEG2024167309000083.jpg211137JPEG2024167309000084.jpg220140JPEG20241673090 00085.jpg228141JPEG2024167309000086.jpg228141JPEG2024167309000087.jpg211146JPEG202 4167309000088.jpg227147JPEG2024167309000089.jpg227147JPEG2024167309000090.jpg211148
[0102] In some embodiments, the compound is [ka] JPEG2024167309000092.jpg225167JPEG2024167309000093.jpg110170, or any salt thereof.
[0103] In other embodiments, the compound is selected from: [ka] JPEG2024167309000095.jpg213170JPEG2024167309000096.jpg110170, or any salt thereof.
[0104] In still other embodiments, the compound is selected from: [ka] JPEG2024167309000098.jpg214152JPEG2024167309000099.jpg110152, or any salt thereof.
[0105] In certain embodiments, at least 75% of the compound of formula (IA), (I), (II), or (III) of the lipid composition formulated as disclosed herein is cleared from the plasma of the subject within 8, 10, 12, 24, or 48 hours, or within 3, 4, 5, 6, 7, or 10 days after administration. In certain embodiments, at least 50% of the lipid composition comprising a compound of formula (IA), (I), (II), or (III) disclosed herein is cleared from the plasma of the subject within 8, 10, 12, 24, or 48 hours, or within 3, 4, 5, 6, 7, or 10 days after administration. This can be determined, for example, by measuring lipids (e.g., compounds of formula (IA), (I), (II), or (III)), RNA (e.g., mRNA), or other components in the plasma. In certain embodiments, the lipid-encapsulated versus free lipid, RNA, or nucleic acid components of the lipid composition are measured.
[0106] Lipid clearance may be measured as described in the literature. See Maier, MA, et al. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics. Mol. Ther. 2013, 21(8), 1570-78 ("Maier"). For example, in Maier, an LNP-siRNA system containing siRNA targeting luciferase was administered to 6-8 week-old male C57Bl / 6 mice at 0.3 mg / kg via an intravenous bolus injection via the lateral tail vein. Blood, liver, and spleen samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, and 168 hours post-administration. Mice were perfused with saline prior to tissue collection, and blood samples were processed to obtain plasma. All samples were processed and analyzed by LC-MS. Furthermore, Maier describes a procedure for assessing the toxicity of LNP-siRNA compositions after administration. For example, siRNA targeting luciferase was administered to male Sprague-Dawley rats at 0, 1, 3, 5, and 10 mg / kg (5 animals / group) via a single intravenous bolus injection at a dose of 5 mL / kg. After 24 hours, approximately 1 mL of blood was obtained from the jugular vein of conscious animals, and serum was isolated. Seventy-two hours after administration, all animals were euthanized for necropsy. Clinical signs, body weight, serum chemistry, organ weight, and histopathology were evaluated. While Maier describes methods for assessing siRNA-LNP compositions, these methods can be applied to assessing the clearance, pharmacokinetics, and toxicity of lipid compositions of the present disclosure, such as LNP compositions.
[0107] In certain embodiments, lipid compositions using compounds of Formula (IA), (I), (II), or (III) disclosed herein exhibit increased clearance rates compared to alternative ionizable amine lipids. In some such embodiments, the clearance rate is the lipid clearance rate, e.g., the rate at which a compound of Formula (IA), (I), (II), or (III) is removed from blood, serum, or plasma. In some embodiments, the clearance rate is the clearance rate of a cargo (e.g., a biologically active substance), e.g., the rate at which a cargo component is removed from blood, serum, or plasma. In some embodiments, the clearance rate is the RNA clearance rate, e.g., the rate at which mRNA or gRNA is removed from blood, serum, or plasma. In some embodiments, the clearance rate is the rate at which LNPs are removed from blood, serum, or plasma. In some embodiments, the clearance rate is the rate at which LNPs are removed from tissues such as liver tissue or spleen tissue. Desirably, a high clearance rate may result in a safety profile without substantial adverse effects and / or reduced accumulation of LNP in the circulation and / or tissues.
[0108] The compounds of formula (IA), (I), (II), or (III) of the present disclosure may form salts depending on the pH of the medium in which they are contained. For example, in a slightly acidic medium, the compounds of formula (IA), (I), (II), or (III) may be protonated and therefore positively charged. Conversely, in a slightly basic medium, such as blood, which has a pH of about 7.35, the compounds of formula (IA), (I), (II), or (III) may not be protonated and therefore uncharged. In some embodiments, the compounds of formula (IA), (I), (II), or (III) of the present disclosure may be mostly protonated at a pH of at least about 9. In some embodiments, the compounds of formula (IA), (I), (II), or (III) of the present disclosure may be mostly protonated at a pH of at least about 10.
[0109] The pH at which a compound of Formula (IA), (I), (II), or (III) is largely protonated is related to its intrinsic pKa. In preferred embodiments, salts of compounds of Formula (IA), (I), (II), or (III) of the present disclosure have a pKa in the range of about 5.1 to about 8.0, even more preferably about 5.5 to about 7.5, e.g., about 6.1 to about 6.3. In other preferred embodiments, salts of compounds of Formula (IA), (I), (II), or (III) of the present disclosure have a pKa in the range of about 5.3 to about 8.0, e.g., about 5.6 to about 7.2, or about 5.7 to about 6.5. In other embodiments, salts of compounds of Formula (IA), (I), (II), or (III) of the present disclosure have a pKa in the range of about 5.7 to about 6.4, e.g., about 5.8 to about 6.2. In other preferred embodiments, salts of compounds of Formula (IA), (I), (II), or (III) of the present disclosure have a pKa in the range of about 5.7 to about 6.5, e.g., about 5.8 to about 6.4. Alternatively, salts of compounds of Formula (IA), (I), (II), or (III) of the present disclosure have a pKa in the range of about 5.8 to about 6.5. In some embodiments, the pKa of the protonated form of a compound of Formula (IA), (I), (II), or (III) is about 5.5 to about 6.0. Salts of compounds of Formula (IA), (I), (II), or (III) of the present disclosure may have a pKa in the range of about 6.0 to about 8.0, preferably about 6.0 to about 7.5. The pKa of a salt of a compound of Formula (IA), (I), (II), or (III) can be an important consideration when formulating an LNP, as LNPs formulated with certain lipids having a pKa in the range of about 5.5 to about 7.0 have been found to be effective for in vivo delivery of cargo, for example, to the liver. Furthermore, LNPs formulated with certain lipids having a pKa in the range of about 5.3 to about 6.4 have been found to be effective for in vivo delivery, for example, to tumors. See, e.g., WO 2014 / 136086.
[0110] In certain embodiments, the present disclosure relates to enantiomerically enriched compounds of formula (IA), (I), (II), or (III). The level of enantiomeric enrichment of a compound may be expressed as enantiomeric excess (ee). The ee of a compound can be measured by dividing the difference in the fractions of the enantiomers by the sum of the fractions of the enantiomers. For example, if a compound is found to contain 98% (S)-enantiomer and 2% (R)-enantiomer, the ee of the compound is (98-2) / (98+2), or 96%. In certain embodiments, the compound of formula (IA), (I), (II), or (III) has an ee of about 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, about 80%, about 85%, about 88%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99%, even if the ee% is greater than that of the starting material, such as 0% (racemic). In certain embodiments, the compound of formula (IA), (I), (II), or (III) is enantiopure. In certain embodiments, the compound of formula (IA), (I), (II), or (III) is enantiopure. In embodiments in which a compound has more than one stereocenter, that stereocenter may be enriched substantially independently of the stereochemical configuration / enrichment of any other stereocenter in the molecule. For example, the compounds described herein may have 30% or more de, 40% or more de, 50% or more de, 60% or more de, 70% or more de, 80% or more de, 90% or more de, 95% or more de, or even 98% or more de at a particular stereocenter.
[0111] Additional fats "Neutral lipids" suitable for use in the lipid compositions of the present disclosure include, for example, a variety of neutral, uncharged, or zwitterionic lipids. Examples of neutral phospholipids suitable for use in the present disclosure include dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), phosphocholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauryloylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1,2- These include, but are not limited to, diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine (DEPC), palmitoyloleoylphosphatidylcholine (POPC), lysophosphatidylcholine, dioleoylphosphatidylethanolamine (DOPE), dilinoleoylphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), palmitoyloleoylphosphatidylethanolamine (POPE), lysophosphatidylethanolamine, and combinations thereof. In certain embodiments, the neutral phospholipid may be selected from distearoylphosphatidylcholine (DSPC) and dimyristoylphosphatidylethanolamine (DMPE), preferably distearoylphosphatidylcholine (DSPC).
[0112] "Helper lipids" include steroids, sterols, and alkylresorcinols. Helper lipids suitable for use in the present disclosure include, but are not limited to, cholesterol, 5-heptadecylresorcinol, and cholesterol hemisuccinate. In certain embodiments, the helper lipid may be cholesterol or a derivative thereof, such as cholesterol hemisuccinate.
[0113] PEG lipids can affect the length of time nanoparticles can persist in vivo (e.g., in blood). PEG lipids can be useful in the formulation process, for example, by reducing particle aggregation and controlling particle size. PEG lipids used herein can modulate the pharmacokinetic properties of LNPs. Typically, PEG lipids comprise a lipid moiety and a PEG-based polymer moiety (sometimes referred to as poly(ethylene oxide)) (PEG moiety). PEG lipids suitable for use in lipid compositions comprising compounds of formula (IA), (I), (II), or (III) of the present disclosure, and information regarding the biochemistry of such lipids, can be found in Romberg et al., Pharmaceutical Research 25(1), 2008, pp. 55-71 and Hoekstra et al., Biochimica et Biophysica Acta 1660(2004)41-52. Additional suitable PEG lipids are disclosed, for example, in WO2015 / 095340 (page 31, line 14 to page 37, line 6), WO2006 / 007712, and WO2011 / 076807 ("stealth lipids").
[0114] In some embodiments, the lipid moiety may be derived from a diacylglycerol or diacylglycamide, including those containing a dialkylglycerol or dialkylglycamide group having an alkyl chain length independently containing from about C4 to about C40 saturated or unsaturated carbon atoms, where the chain may contain one or more functional groups, such as, for example, an amide or ester. In some embodiments, the alkyl chain length includes from about C10 to C20. The dialkylglycerol or dialkylglycamide group may further contain one or more substituted alkyl groups. The chain length may be symmetric or asymmetric.
[0115] Unless otherwise specified, as used herein, the term "PEG" refers to any polyethylene glycol or other polyalkylene ether polymer, e.g., an optionally substituted, linear or branched, polymer of ethylene glycol or ethylene oxide. In certain embodiments, the PEG moiety is unsubstituted. Alternatively, the PEG moiety may be substituted, e.g., with one or more alkyl, alkoxy, acyl, hydroxy, or aryl groups. For example, the PEG moiety may comprise a PEG copolymer, such as PEG-polyurethane or PEG-polypropylene (see, e.g., J. Milton Harris, Poly(ethylene glycol) chemistry: biotechnical and biomedical applications (1992)). Alternatively, the PEG moiety may be a PEG homopolymer. In certain embodiments, the PEG moiety has a molecular weight of about 130 to about 50,000, e.g., about 150 to about 30,000, or even about 150 to about 20,000. Similarly, the PEG moiety may have a molecular weight of about 150 to about 15,000, about 150 to about 10,000, about 150 to about 6,000, or even about 150 to about 5,000. In certain preferred embodiments, the PEG moiety has a molecular weight of about 150 to about 4,000, about 150 to about 3,000, about 300 to about 3,000, about 1,000 to about 3,000, or about 1,500 to about 2,500.
[0116] In certain preferred embodiments, the PEG moiety is "PEG-2K," also known as "PEG2000," which has an average molecular weight of about 2,000 daltons. PEG-2K is represented herein by the following formula (II): where n is 45, meaning that the number-average degree of polymerization is about 45 subunits: [ka] However, other embodiments of PEG known in the art may be used, for example, having a number average degree of polymerization of about 23 subunits (n=23) and / or 68 subunits (n=68). In some embodiments, n may range from about 30 to about 60. In some embodiments, n may range from about 35 to about 55. In some embodiments, n may range from about 40 to about 50. In some embodiments, n may range from about 42 to about 48. In some embodiments, n may be 45. In some embodiments, R may be selected from H, substituted alkyl, and unsubstituted alkyl. In some embodiments, R may be unsubstituted alkyl, such as methyl.
[0117] In any of the embodiments described herein, the PEG lipid may be PEG-dilaurylglycerol, PEG-dimyristoylglycerol (PEG-DMG) (Cat. No. GM-020, manufactured by NOF, Tokyo, Japan), PEG-dipalmitoylglycerol, PEG-distearoylglycerol (PEG-DSPE) (Cat. No. DSPE-020CN, manufactured by NOF, Tokyo, Japan), PEG-dilaurylglycamide, PEG-dimyristylglycamide, PEG-dipalmitoylglycamide, and PEG-distearoylglycerol. Ricamide, PEG-cholesterol (1-[8'-(cholest-5-ene-3[beta]-oxy)carboxamido-3',6'-dioxaotanyl]carbamoyl-[omega]-methyl-poly(ethylene glycol), PEG-DMB (3,4-ditetradecoxylbenzyl-[omega]-methyl-poly(ethylene glycol) ether), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DMG) (catalog no. 880150P, Avanti 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSPE) (catalog number 880120C, Avanti Polar Lipids, Alabaster, Alabama, USA), 1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol (PEG2k-DSG; GS-020, NOF) Tokyo, Japan), poly(ethylene glycol)-2000-dimethacrylate (PEG2k-DMA)), and 1,2-distearyloxypropyl-3-amine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSA). In certain such embodiments, the PEG lipid may be PEG2k-DMG. In some embodiments, the PEG lipid may be PEG2k-DSG. In other embodiments, the PEG lipid may be PEG2k-DSPE. In some embodiments, the PEG lipid may be PEG2k-DMA.In still other embodiments, the PEG lipid may be PEG2k-C-DMA. In certain embodiments, the PEG lipid may be compound S027, which is disclosed in WO2016 / 010840 (paragraphs
[0240] to
[0244] ). In some embodiments, the PEG lipid may be PEG2k-DSA. In other embodiments, the PEG lipid may be PEG2k-C11. In some embodiments, the PEG lipid may be PEG2k-C14. In some embodiments, the PEG lipid may be PEG2k-C16. In some embodiments, the PEG lipid may be PEG2k-C18.
[0118] Suitable cationic lipids for the lipid compositions of the present disclosure include N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)prolyl)-N,N,N-trimethylammonium chloride (DOTAP), 1,2-dioleoyl-3-dimethylammonium propane (DODAP ... N-(1-(2,3-dioleoyloxy)prolyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleoyloxy)prolyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2 Propyl)-N,N,N-trimethylammonium chloride (DOTMA), 1,2-dioleoylcarbamyl-3-dimethylammonium-propane (DOCDAP), 1,2-dilineoyl-3-dimethylammonium-propane (DLINDAP), dilauryl (C12:0) trimethylammonium-propane (DLTAP), dioctadecylamidoglycylspermine (DOGS), DC-Choi, dioleyloxy-N-[2-(spermine carbamyl)-2-methylpropane] [Dimethylamino]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DMRIE), 3-dimethylamino-2-(cholest-5-ene-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), N,N-dimethyl-2,3-dioleyloxy)propane Examples of cationic lipids include, but are not limited to, N,N-dimethyl-3,4-dioleyloxybenzylamine (DODMA), 2-[5'-(cholest-5-ene-3[beta]-oxy)-3'-oxapentoxy)-3-dimethyl-1-(cis,cis-9',1-2'-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), and 1,2-N,N'-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP). In one embodiment, the cationic lipid is DOTAP or DLTAP.
[0119] Anionic lipids suitable for use in the present disclosure include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoylphosphatidylethanolamine, N-succinylphosphatidylethanolamine, N-glutarylphosphatidylethanolamine cholesterol hemisuccinate (CHEMS), and lysylphosphatidylglycerol.
[0120] lipid composition The present disclosure provides lipid compositions comprising at least one compound of formula (IA), (I), (II), or (III) or a salt thereof (e.g., a pharmaceutically acceptable salt thereof) and at least one other lipid component. Such compositions can also include a biologically active substance, optionally in combination with one or more other lipid components. In some embodiments, the lipid composition includes a lipid component and an aqueous component containing a biologically active substance.
[0121] In one embodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof and at least one other lipid component. In another embodiment, the lipid composition further comprises a biologically active substance, optionally in combination with one or more other lipid components. In another embodiment, the lipid composition is in the form of a liposome. In another embodiment, the lipid composition is in the form of a lipid nanoparticle (LNP). In another embodiment, the lipid composition is suitable for delivery to the liver.
[0122] In one embodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof and another lipid component. Such other lipid components include, but are not limited to, a neutral lipid, a helper lipid, a PEG lipid, a cationic lipid, and an anionic lipid. In certain embodiments, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof and a neutral lipid, such as DSPC, optionally with one or more additional lipid components. In another embodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof and a helper lipid, such as cholesterol, optionally with one or more additional lipid components. In a further embodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof and a PEG lipid, optionally with one or more additional lipid components. In a further embodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, and a cationic lipid, optionally together with one or more additional lipid components. In a further embodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, and an anionic lipid, optionally together with one or more additional lipid components. In a subembodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, a helper lipid, and a PEG lipid, optionally together with a neutral lipid. In a further subembodiment, the lipid composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, a helper lipid, a PEG lipid, and a neutral lipid.
[0123] Compositions comprising lipids of formula (IA), (I), (II), or (III), or pharmaceutically acceptable salts thereof, or lipid compositions thereof, may be in various forms, including, but not limited to, particle-forming delivery agents, including microparticles, nanoparticles, and transfection agents, useful for delivering various molecules to cells. Certain compositions are effective for transfecting or delivering bioactive substances. Preferred bioactive substances are RNA and DNA. In further embodiments, the bioactive substance is selected from mRNA, gRNA, and DNA. The gRNA may be a dgRNA or sgRNA. In certain embodiments, the cargo includes an mRNA encoding an RNA-guided DNA-binding agent (e.g., a Cas nuclease, a class 2 Cas nuclease, or Cas9), a gRNA, or a nucleic acid encoding a gRNA, or a combination of mRNA and gRNA.
[0124] Exemplary compounds of Formula (IA), (I), (II), or (III) for use in the above lipid compositions are shown in Examples 2-48, 50-97, 99-103, and 105-113.
[0125] In certain embodiments, the compound of Formula (IA) is Compound 2. In certain embodiments, the compound of Formula (IA) is Compound 3. In certain embodiments, the compound of Formula (IA) is Compound 4. In certain embodiments, the compound of Formula (IA) is Compound 5. In certain embodiments, the compound of Formula (IA) is Compound 6. In certain embodiments, the compound of Formula (IA) is Compound 7. In certain embodiments, the compound of Formula (IA) is Compound 8. In certain embodiments, the compound of Formula (IA) is Compound 9. In certain embodiments, the compound of Formula (IA) is Compound 10.
[0126] In certain embodiments, the compound of Formula (IA) is Compound 11. In certain embodiments, the compound of Formula (IA) is Compound 12. In certain embodiments, the compound of Formula (IA) is Compound 13. In certain embodiments, the compound of Formula (IA) is Compound 14. In certain embodiments, the compound of Formula (IA) is Compound 15. In certain embodiments, the compound of Formula (IA) is Compound 16. In certain embodiments, the compound of Formula (IA) is Compound 17. In certain embodiments, the compound of Formula (IA) is Compound 18. In certain embodiments, the compound of Formula (IA) is Compound 19. In certain embodiments, the compound of Formula (IA) is Compound 20.
[0127] In certain embodiments, the compound of Formula (IA) is Compound 21. In certain embodiments, the compound of Formula (IA) is Compound 22. In certain embodiments, the compound of Formula (IA) is Compound 23. In certain embodiments, the compound of Formula (IA) is Compound 24. In certain embodiments, the compound of Formula (IA) is Compound 25. In certain embodiments, the compound of Formula (IA) is Compound 26. In certain embodiments, the compound of Formula (IA) is Compound 27. In certain embodiments, the compound of Formula (IA) is Compound 28. In certain embodiments, the compound of Formula (IA) is Compound 29. In certain embodiments, the compound of Formula (IA) is Compound 30.
[0128] In certain embodiments, the compound of Formula (IA) is Compound 31. In certain embodiments, the compound of Formula (IA) is Compound 32. In certain embodiments, the compound of Formula (IA) is Compound 33. In certain embodiments, the compound of Formula (IA) is Compound 34. In certain embodiments, the compound of Formula (IA) is Compound 35. In certain embodiments, the compound of Formula (IA) is Compound 36. In certain embodiments, the compound of Formula (IA) is Compound 37. In certain embodiments, the compound of Formula (IA) is Compound 38. In certain embodiments, the compound of Formula (IA) is Compound 39. In certain embodiments, the compound of Formula (IA) is Compound 40.
[0129] In certain embodiments, the compound of Formula (IA) is Compound 41. In certain embodiments, the compound of Formula (IA) is Compound 42. In certain embodiments, the compound of Formula (IA) is Compound 43. In certain embodiments, the compound of Formula (IA) is Compound 44. In certain embodiments, the compound of Formula (IA) is Compound 45. In certain embodiments, the compound of Formula (IA) is Compound 46. In certain embodiments, the compound of Formula (IA) is Compound 47. In certain embodiments, the compound of Formula (IA) is Compound 48. In certain embodiments, the compound of Formula (IA) is Compound 50.
[0130] In certain embodiments, the compound of Formula (IA) is Compound 51. In certain embodiments, the compound of Formula (IA) is Compound 52. In certain embodiments, the compound of Formula (IA) is Compound 53. In certain embodiments, the compound of Formula (IA) is Compound 54. In certain embodiments, the compound of Formula (IA) is Compound 55. In certain embodiments, the compound of Formula (IA) is Compound 56. In certain embodiments, the compound of Formula (IA) is Compound 57. In certain embodiments, the compound of Formula (IA) is Compound 58. In certain embodiments, the compound of Formula (IA) is Compound 59. In certain embodiments, the compound of Formula (IA) is Compound 60.
[0131] In certain embodiments, the compound of Formula (IA) is Compound 61. In certain embodiments, the compound of Formula (IA) is Compound 62. In certain embodiments, the compound of Formula (IA) is Compound 63. In certain embodiments, the compound of Formula (IA) is Compound 64. In certain embodiments, the compound of Formula (IA) is Compound 65. In certain embodiments, the compound of Formula (IA) is Compound 66. In certain embodiments, the compound of Formula (IA) is Compound 67. In certain embodiments, the compound of Formula (IA) is Compound 68. In certain embodiments, the compound of Formula (IA) is Compound 69. In certain embodiments, the compound of Formula (IA) is Compound 70.
[0132] In certain embodiments, the compound of Formula (IA) is Compound 71. In certain embodiments, the compound of Formula (IA) is Compound 72. In certain embodiments, the compound of Formula (IA) is Compound 73. In certain embodiments, the compound of Formula (IA) is Compound 74. In certain embodiments, the compound of Formula (IA) is Compound 75. In certain embodiments, the compound of Formula (IA) is Compound 76. In certain embodiments, the compound of Formula (IA) is Compound 77. In certain embodiments, the compound of Formula (IA) is Compound 78. In certain embodiments, the compound of Formula (IA) is Compound 79. In certain embodiments, the compound of Formula (IA) is Compound 80.
[0133] In certain embodiments, the compound of Formula (IA) is Compound 81. In certain embodiments, the compound of Formula (IA) is Compound 82. In certain embodiments, the compound of Formula (IA) is Compound 83. In certain embodiments, the compound of Formula (IA) is Compound 84. In certain embodiments, the compound of Formula (IA) is Compound 85. In certain embodiments, the compound of Formula (IA) is Compound 86. In certain embodiments, the compound of Formula (IA) is Compound 87. In certain embodiments, the compound of Formula (IA) is Compound 88. In certain embodiments, the compound of Formula (IA) is Compound 89. In certain embodiments, the compound of Formula (IA) is Compound 90.
[0134] In certain embodiments, the compound of Formula (IA) is Compound 91. In certain embodiments, the compound of Formula (IA) is Compound 92. In certain embodiments, the compound of Formula (IA) is Compound 93. In certain embodiments, the compound of Formula (IA) is Compound 94. In certain embodiments, the compound of Formula (IA) is Compound 95. In certain embodiments, the compound of Formula (IA) is Compound 96. In certain embodiments, the compound of Formula (IA) is Compound 97. In certain embodiments, the compound of Formula (IA) is Compound 99. In certain embodiments, the compound of Formula (IA) is Compound 100.
[0135] In certain embodiments, the compound of Formula (IA) is Compound 101. In certain embodiments, the compound of Formula (IA) is Compound 102. In certain embodiments, the compound of Formula (IA) is Compound 103. In certain embodiments, the compound of Formula (IA) is Compound 105. In certain embodiments, the compound of Formula (IA) is Compound 106. In certain embodiments, the compound of Formula (IA) is Compound 107. In certain embodiments, the compound of Formula (IA) is Compound 108. In certain embodiments, the compound of Formula (IA) is Compound 109. In certain embodiments, the compound of Formula (IA) is Compound 110.
[0136] In certain embodiments, the compound of Formula (IA) is Compound 111. In certain embodiments, the compound of Formula (IA) is Compound 112. In certain embodiments, the compound of Formula (IA) is Compound 113.
[0137] In certain embodiments, the compound is not Compound 1. In certain embodiments, the compound is not Compound 49. In certain embodiments, the compound is not Compound 114.
[0138] LNP composition The lipid composition may be provided as an LNP composition. The lipid nanoparticle may be, for example, a microsphere (unilamellar and multilamellar vesicle, e.g., "liposome," which in some embodiments is substantially spherical and, in more specific embodiments, comprises a lamellar phase lipid bilayer that may include an aqueous core, e.g., containing a substantial portion of RNA molecules), the dispersed phase in an emulsion, a micelle, or the internal phase in a suspension.
[0139] The LNPs range in size from about 1 to about 1,000 nm, about 10 to about 500 nm, about 20 to about 500 nm, in a subembodiment about 50 to about 400 nm, in a subembodiment about 50 to about 300 nm, in a subembodiment about 50 to about 200 nm, and in a subembodiment about 50 to about 150 nm, and in another subembodiment about 60 to about 120 nm. Preferably, the LNPs range in size from about 60 nm to about 100 nm. The average size (diameter) of fully formed LNPs can be measured by dynamic light scattering on a Malvern Zetasizer. LNP samples are diluted with phosphate-buffered saline (PBS) to achieve a count rate of about 200 to 400 kcps. Data are presented as a weighted average of intensity measurements.
[0140] Embodiments of the present disclosure provide lipid compositions described according to the respective molar ratios of component lipids in the composition. All mole percentages are expressed as the lipid component fraction of the lipid composition, or more specifically, the LNP composition. In certain embodiments, the mole percentage of the compound of Formula (IA), (I), (II), or (III) may be from about 30 mole percent to about 70 mole percent. In certain embodiments, the mole percentage of the compound of Formula (IA), (I), (II), or (III) may be at least 30 mole percent, at least 40 mole percent, at least 50 mole percent, or at least 60 mole percent.
[0141] In certain embodiments, the mole % of neutral lipids can be about 0 mole % to about 30 mole %. In certain embodiments, the mole % of neutral lipids can be about 0 mole % to about 20 mole %. In certain embodiments, the mole % of neutral lipids can be about 10 mole %. In certain embodiments, the mole % of neutral lipids can be about 9 mole %.
[0142] In certain embodiments, the mole percent of helper lipid may be about 0 mole percent to about 80 mole percent. In certain embodiments, the mole percent of helper lipid may be about 20 mole percent to about 60 mole percent. In certain embodiments, the mole percent of helper lipid may be about 30 mole percent to about 50 mole percent. In certain embodiments, the mole percent of helper lipid may be 30 mole percent to about 40 mole percent, or about 35 mole percent to about 45 mole percent. In certain embodiments, the mole percent of helper lipid is adjusted based on the compound of Formula (IA), (I), (II), or (III), neutral lipid, and / or PEG lipid concentration to bring the lipid component to 100 mole percent.
[0143] In certain embodiments, the mole % of PEG lipid may be about 1 mole % to about 10 mole %. In certain embodiments, the mole % of PEG lipid may be about 1 mole % to about 4 mole %. In certain embodiments, the mole % of PEG lipid may be about 1 mole % to about 2 mole %. In certain embodiments, the mole % of PEG lipid may be about 1.5 mole %.
[0144] In various embodiments, the LNP composition comprises a compound of Formula (IA), (I), (II), or (III) or a salt thereof (e.g., a pharmaceutically acceptable salt thereof (e.g., as disclosed herein)), a neutral lipid (e.g., DSPC), a helper lipid (e.g., cholesterol), and a PEG-lipid (e.g., PEG2k-DMG). In some embodiments, the LNP composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof (e.g., as disclosed herein), DSPC, cholesterol, and a PEG-lipid. In some such embodiments, the LNP composition comprises a PEG-lipid comprising DMG, such as PEG2k-DMG. In certain preferred embodiments, the LNP composition comprises a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, cholesterol, DSPC, and PEG2k-DMG.
[0145] In certain embodiments, lipid compositions, such as LNP compositions, include a lipid component and a nucleic acid component, e.g., an RNA component, and the molar ratio of the compound of Formula (IA), (I), (II), or (III) to the nucleic acid can be determined. Embodiments of the present disclosure also provide lipid compositions having a defined molar ratio between the positively charged amine groups (N) of a pharmaceutically acceptable salt of a compound of Formula (IA), (I), (II), or (III) and the negatively charged phosphate groups (P) of the encapsulated nucleic acid. This may be mathematically represented by the formula N / P. In some embodiments, lipid compositions, such as LNP compositions, may include a lipid component comprising a compound of Formula (IA), (I), (II), or (III), or a pharmaceutically acceptable salt thereof, and a nucleic acid component, wherein the N / P ratio is about 3-10. In some embodiments, LNP compositions may include a lipid component comprising a compound of Formula (IA), (I), (II), or (III), or a pharmaceutically acceptable salt thereof, and an RNA component, wherein the N / P ratio is about 3-10. For example, the N / P ratio may be about 4 to 7. Alternatively, the N / P ratio may be about 6, for example, 6±1, or 6±0.5.
[0146] In some embodiments, the aqueous component comprises a biologically active substance. In some embodiments, the aqueous component comprises a polypeptide, optionally in combination with a nucleic acid. In some embodiments, the aqueous component comprises a nucleic acid, such as RNA. In some embodiments, the aqueous component is a nucleic acid component. In some embodiments, the nucleic acid component comprises DNA, which may be referred to as a DNA component. In some embodiments, the nucleic acid component comprises RNA, which may be referred to as an RNA component. In some embodiments, an aqueous component, such as an RNA component, may comprise an mRNA, such as an mRNA encoding an RNA-guided DNA-binding agent. In some embodiments, the RNA-guided DNA-binding agent is a Cas nuclease. In certain embodiments, the aqueous component may comprise an mRNA encoding Cas9. In certain embodiments, the aqueous component may comprise a gRNA. In some compositions comprising an mRNA encoding an RNA-guided DNA-binding agent, the composition further comprises a gRNA nucleic acid, such as a gRNA. In some embodiments, the aqueous component comprises an RNA-guided DNA-binding agent and a gRNA. In some embodiments, the aqueous component comprises a Cas nuclease mRNA and a gRNA. In some embodiments, the aqueous component comprises a Class 2 Cas nuclease mRNA and a gRNA.
[0147] In certain embodiments, a lipid composition, such as an LNP composition, may comprise an mRNA encoding a Cas nuclease, such as a Class 2 Cas nuclease; a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof; a helper lipid; optionally, a neutral lipid; and a PEG-lipid. In certain compositions comprising an mRNA encoding a Cas nuclease, such as a Class 2 Cas nuclease, the helper lipid is cholesterol. In other compositions comprising an mRNA encoding a Cas nuclease, such as a Class 2 Cas nuclease, the neutral lipid is DSPC. In additional embodiments comprising an mRNA encoding a Cas nuclease, such as a Class 2 Cas nuclease, e.g., Cas9, the PEG-lipid is PEG2k-DMG. In certain compositions, an mRNA encoding a Cas nuclease, such as a Class 2 Cas nuclease, and a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof is comprised. In certain compositions, the composition further comprises a gRNA, such as a dgRNA or an sgRNA.
[0148] In some embodiments, a lipid composition, such as an LNP composition, may include a gRNA. In certain embodiments, the composition may include a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, a gRNA, a helper lipid, optionally a neutral lipid, and a PEG-lipid. In certain LNP compositions including a gRNA, the helper lipid is cholesterol. In some compositions including a gRNA, the neutral lipid is DSPC. In additional embodiments including a gRNA, the PEG-lipid is PEG2k-DMG. In certain compositions, the gRNA is selected from a dgRNA and an sgRNA.
[0149] In certain embodiments, a lipid composition, such as an LNP composition, comprises an mRNA and a gRNA (which may be an sgRNA) encoding an RNA-guided DNA-binding agent in an aqueous component and a compound of Formula (IA), (I), (II), or (III) in a lipid component. For example, an LNP composition may comprise a compound of Formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, an mRNA encoding a Cas nuclease, a gRNA, a helper lipid, a neutral lipid, and a PEG lipid. In certain compositions comprising an mRNA and a gRNA encoding a Cas nuclease, the helper lipid is cholesterol. In some compositions comprising an mRNA and a gRNA encoding a Cas nuclease, the neutral lipid is DSPC. In additional embodiments comprising an mRNA and a gRNA encoding a Cas nuclease, the PEG lipid is PEG2k-DMG.
[0150] In certain embodiments, a lipid composition, such as an LNP composition, comprises an RNA-guided DNA-binding agent, such as a Class 2 Cas mRNA, and at least one gRNA. In certain embodiments, the LNP composition has a ratio of gRNA to RNA-guided DNA-binding agent mRNA, such as a Class 2 Cas nuclease mRNA, of about 1:1 or about 1:2. In some embodiments, the ratio is about 25:1 to about 1:25, about 10:1 to about 1:10, about 8:1 to about 1:8, about 4:1 to about 1:4, or about 2:1 to about 1:2.
[0151] The lipid compositions disclosed herein, such as LNP compositions, may include a template nucleic acid, e.g., a DNA template. The template nucleic acid may be delivered together with or separately from a lipid composition containing a compound of formula (IA), (I), (II), or (III) or a pharmaceutically acceptable salt thereof, including as an LNP composition. In some embodiments, the template nucleic acid may be single-stranded or double-stranded, depending on the desired repair mechanism. The template may have a region of homology with the target DNA, for example, within the target DNA sequence and / or with a sequence adjacent to the target DNA.
[0152] In some embodiments, LNPs are formed by mixing an aqueous RNA solution with an organic solvent-based lipid solution. Suitable solutions or solvents may include or contain water, PBS, Tris buffer, NaCl, citrate buffer, acetate buffer, ethanol, chloroform, diethyl ether, cyclohexane, tetrahydrofuran, methanol, or isopropanol. For example, the organic solvent may be 100% ethanol. For example, a pharmaceutically acceptable buffer for in vivo administration of LNPs may be used. In certain embodiments, a buffer is used to maintain the pH of a composition comprising LNPs at pH 6.5 or above. In certain embodiments, a buffer is used to maintain the pH of a composition comprising LNPs at pH 7.0 or above. In certain embodiments, the composition has a pH in the range of about 7.2 to about 7.7. In additional embodiments, the composition has a pH in the range of about 7.3 to about 7.7 or about 7.4 to about 7.6. In further embodiments, the composition has a pH of about 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7. The pH of the composition may be measured with a micro pH probe. In certain embodiments, a cryoprotectant is included in the composition. Non-limiting examples of cryoprotectants include sucrose, trehalose, glycerol, DMSO, and ethylene glycol. Exemplary compositions may contain up to 10% cryoprotectant, such as sucrose. In certain embodiments, the composition may include tris saline sucrose (TSS). In certain embodiments, the LNP composition may contain about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% cryoprotectant. In certain embodiments, the LNP composition may contain about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% sucrose. In some embodiments, the LNP composition may include a buffer solution. In some embodiments, the buffer solution may include phosphate buffer solution (PBS), Tris buffer solution, citrate buffer solution, and mixtures thereof. In certain exemplary embodiments, the buffer solution includes NaCl. In certain embodiments, the buffer solution lacks NaCl. Exemplary amounts of NaCl may range from about 20 mM to about 45 mM.An exemplary amount of NaCl may range from about 40 mM to about 50 mM. In some embodiments, the amount of NaCl is about 45 mM. In some embodiments, the buffer is a Tris buffer. An exemplary amount of Tris may range from about 20 mM to about 60 mM. An exemplary amount of Tris may range from about 40 mM to about 60 mM. In some embodiments, the amount of Tris is about 50 mM. In some embodiments, the buffer comprises NaCl and Tris. Certain exemplary embodiments of LNP compositions contain 5% sucrose and 45 mM NaCl in a Tris buffer. In other exemplary embodiments, the composition contains about 5% w / v sucrose, about 45 mM NaCl, and about 50 mM Tris at pH 7.5. The amounts of salt, buffer, and cryoprotectant may be varied to maintain the osmolality of the overall composition. For example, the final osmolality may be maintained at less than 450 mOsm / L. In further embodiments, the osmolality is between 350 and 250 mOsm / L. Certain embodiments have a final osmolality of 300±20 mOsm / L or 310±40 mOsm / L.
[0153] In some embodiments, microfluidic mixing, T-mixing, or cross-mixing of aqueous RNA and lipid solutions in organic solvents is used. In certain aspects, the flow rate, junction size, junction shape, junction morphology, tubing diameter, solution, and / or RNA and lipid concentrations may be varied. LNPs or LNP compositions may be concentrated or purified, for example, via dialysis, centrifugal filtration, tangential flow filtration, or chromatography. LNPs may be stored, for example, as a suspension, emulsion, or lyophilized powder. In some embodiments, LNP compositions are stored at 2-8°C, and in certain aspects, LNP compositions are stored at room temperature. In additional embodiments, LNP compositions are stored frozen, for example, at -20°C or -80°C. In other embodiments, LNP compositions are stored at temperatures ranging from about 0°C to about -80°C. Frozen LNP compositions may be thawed, for example, on ice, at room temperature, or at 25°C, prior to use.
[0154] LNPs may be, for example, microspheres (unilamellar and multilamellar vesicles, e.g., "liposomes," lamellar phase lipid bilayers, which in some embodiments are substantially spherical and, in more specific embodiments, may contain an aqueous core containing, for example, the majority of RNA molecules), the dispersed phase in an emulsion, a micelle, or the internal phase in a suspension.
[0155] Preferred lipid compositions, such as LNP compositions, are biodegradable in that they do not accumulate to cytotoxic levels in vivo at therapeutically effective doses.In some embodiments, the compositions do not induce the innate immune response that causes substantial adverse effects at therapeutic dose levels.In some embodiments, the compositions provided herein do not cause toxicity at therapeutic dose levels.
[0156] In some embodiments, the LNPs disclosed herein have a polydispersity index (PDI) that may range from about 0.005 to about 0.75. In some embodiments, the LNPs may have a PDI that ranges from about 0.01 to about 0.5. In some embodiments, the LNPs may have a PDI that ranges from about 0 to about 0.4. In some embodiments, the LNPs may have a PDI that ranges from about 0 to about 0.35. In some embodiments, the LNPs may have a PDI that ranges from about 0 to about 0.3. In some embodiments, the LNPs may have a PDI that ranges from about 0 to about 0.25. In some embodiments, the LNPs may have a PDI that ranges from about 0 to about 0.2. In some embodiments, the LNPs may have a PDI that is less than about 0.08, 0.1, 0.15, 0.2, or 0.4.
[0157] The LNPs disclosed herein have a size (e.g., Z-average diameter) of about 1 to about 250 nm. In some embodiments, the LNPs are about 10 to about 200 nm in size. In further embodiments, the LNPs are about 20 to about 150 nm in size. In some embodiments, the LNPs are about 50 to about 150 nm in size. In some embodiments, the LNPs are about 50 to about 100 nm in size. In some embodiments, the LNPs are about 50 to about 120 nm in size. In some embodiments, the LNPs are about 60 to about 100 nm in size. In some embodiments, the LNPs are about 75 to about 150 nm in size. In some embodiments, the LNPs are about 75 to about 120 nm in size. In some embodiments, the LNPs are about 75 to about 100 nm in size. Unless otherwise stated, all sizes referred to herein are the average size (diameter) of fully formed nanoparticles as measured by dynamic light scattering on a Malvern Zetasizer. Nanoparticle samples are diluted in phosphate-buffered saline (PBS) to achieve a count rate of approximately 200-400 kcps. Data are presented as a weighted average of intensity measurements (Z-average diameter).
[0158] In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 50% to about 100%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 50% to about 95%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 70% to about 90%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 90% to about 100%. In some embodiments, the LNPs are formed with an average encapsulation efficiency ranging from about 75% to about 95%.
[0159] cargo The cargo delivered via the LNP composition may be a bioactive substance. In certain embodiments, the cargo may be one or more bioactive substances, such as mRNA, guide RNA, nucleic acid, expression vector, template nucleic acid, RNA-guided DNA-binding agent, antibody (e.g., monoclonal, chimeric, humanized, nanobody, and fragments thereof), cholesterol, hormone, peptide, protein, chemotherapeutic agent and other types of anti-tumor drug, low molecular weight drug, vitamin, cofactor, nucleoside, nucleotide, oligonucleotide, enzymatic nucleic acid, antisense nucleic acid, triplex-forming oligonucleotide, antisense DNA or RNA composition, chimeric DNA:RNA composition, allozyme, aptamer, ribozyme, decoy and analogs thereof, plasmid, or the like. These include or include midi and other types of vectors, as well as small nucleic acid molecules, RNAi agents, small interfering nucleic acids (siNAs), small interfering RNAs (siRNAs), double-stranded RNAs (dsRNAs), microRNAs (miRNAs), short hairpin RNAs (shRNAs), and "self-replicating RNAs" (which encode replicase enzyme activity and can induce its own replication or amplification in vivo), peptide nucleic acids (PNAs), locked nucleic acid ribonucleotides (LNAs), morpholino nucleotides, threose nucleic acids (TNAs), glycol nucleic acids (GNAs), sisiRNAs (small internal segmented interfering RNAs), and iRNAs (asymmetric interfering RNAs). The above list of biologically active agents is merely illustrative and is not intended to be limiting. Such compounds may be purified or partially purified, naturally occurring or synthetic, or chemically modified.
[0160] The cargo delivered via the LNP composition may be RNA, such as an mRNA molecule encoding a protein of interest. Examples include mRNAs for expressing proteins such as green fluorescent protein (GFP), RNA-guided DNA-binding agents, and Cas nucleases. LNP compositions are provided that include a Cas nuclease mRNA, e.g., a Class 2 Cas nuclease mRNA that enables cellular expression of a Class 2 Cas nuclease, such as Cas9 or Cpf1 protein. Additionally, the cargo may include one or more guide RNAs or nucleic acids encoding the guide RNAs. For example, a template nucleic acid for repair or recombination may also be included in the composition, or the template nucleic acid may be used in the methods described herein. In a subembodiment, the cargo includes an mRNA encoding Streptococcus pyogenes Cas9 and, optionally, an S. pyogenes gRNA. In a further subembodiment, the cargo includes an mRNA encoding Neisseria meningitidis Cas9 and, optionally, an nme gRNA.
[0161] "mRNA" refers to a polynucleotide that contains an open reading frame that can be translated into a polypeptide (i.e., can serve as a substrate for translation by ribosomes and aminoacylated tRNAs). mRNA can contain a phosphate-sugar backbone that includes ribose residues or analogs thereof, e.g., 2'-methoxyribose residues. In some embodiments, the sugars of the mRNA phosphate-sugar backbone consist essentially of ribose residues, 2'-methoxyribose residues, or combinations thereof. Generally, mRNA does not contain significant amounts of thymidine residues (e.g., 0 residues or less than 30, 20, 10, 5, 4, 3, or 2 thymidine residues, or a thymidine content of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 4%, 3%, 2%, 1%, 0.5%, 0.2%, or 0.1%). mRNA can contain modified uridines at some or all of its uridine positions.
[0162] CRISPR / Cas cargo In certain embodiments, the disclosed compositions comprise mRNA encoding an RNA-guided DNA-binding agent, such as a Cas nuclease, hi certain embodiments, the disclosed compositions comprise mRNA encoding a class 2 Cas nuclease, such as Cas9 of S. pyogenes.
[0163] As used herein, "RNA-guided DNA-binding agent" refers to a polypeptide or polypeptide complex having RNA and DNA-binding activity, or a DNA-binding subunit of such a complex, where the DNA-binding activity is sequence-specific and dependent on the sequence of the RNA. Exemplary RNA-guided DNA-binding agents include Cas cleavage enzymes / nickases and their inactivated forms ("dCas DNA-binding agents"). As used herein, "Cas nuclease" encompasses Cas cleavage enzymes, Cas nickases, and dCas DNA-binding agents. Cas cleavage enzymes / nickases and dCas DNA-binding agents include the Csm or Cmr complex of a type III CRISPR system, its Cas10, Csm1, or Cmr2 subunit, the Cascade complex of a type I CRISPR system, its Cas3 subunit, and class 2 Cas nucleases. As used herein, a "class 2 Cas nuclease" is a single-chain polypeptide with RNA-guided DNA-binding activity. Class 2 Cas nucleases include Class 2 Cas cleavage enzymes / nickases that also have RNA-guided DNA cleavage enzyme or nickase activity (e.g., H840A, D10A, or N863A mutants), and Class 2d Cas DNA-binding agents in which the cleavage enzyme / nickase activity is inactivated. Class 2 Cas nucleases include, for example, Cas9, Cpf1, C2c1, C2c2, C2c3, HF Cas9 (e.g., N497A, R661A, Q695A, Q926A variants), HypaCas9 (e.g., N692A, M694A, Q695A, H698A variants), eSPCas9(1.0) (e.g., K810A, K1003A, R1060A variants), and eSPCas9(1.1) (e.g., K848A, K1003A, R1060A variants) proteins, and modifications thereof. The Cpf1 protein, Zetsche et al., Cell, 163:1-13 (2015), is homologous to Cas9 and contains a RuvC-like nuclease domain. The Cpf1 sequence of Zetsche is incorporated by reference in its entirety, see e.g., Tables S1 and S3 of Zetsche.See, for example, Makarova et al., Nat Rev Microbiol, 13(11):722-36 (2015); Shmakov et al., Molecular Cell, 60:385-397 (2015).
[0164] As used herein, "ribonucleoprotein" (RNP) or "RNP complex" refers to a guide RNA combined with an RNA-guided DNA-binding agent, such as a Cas nuclease, e.g., a Cas cleavage enzyme, a Cas nickase, or a dCas DNA-binding agent (e.g., Cas9). In some embodiments, the guide RNA guides the RNA-guided DNA-binding agent, such as Cas9, to a target sequence, the guide RNA hybridizes to the target sequence, and a binding agent binds to the target sequence. If the binding agent is a cleavage enzyme or nickase, binding can be followed by cleavage or nicking.
[0165] In some embodiments of the present disclosure, the cargo of the LNP composition comprises at least one guide RNA comprising a guide sequence that guides an RNA-guided DNA-binding agent, which may be a nuclease (e.g., a Cas nuclease such as Cas9), to a target DNA. The gRNA may guide the Cas nuclease or a Class 2 Cas nuclease to a target sequence on a target nucleic acid molecule. In some embodiments, the gRNA binds to a Class 2 Cas nuclease, thereby providing specificity for cleavage. In some embodiments, the gRNA and Cas nuclease may form a ribonucleoprotein (RNP), e.g., a CRISPR / Cas complex, such as a CRISPR / Cas9 complex. In some embodiments, the CRISPR / Cas complex may be a Type II CRISPR / Cas9 complex. In some embodiments, the CRISPR / Cas complex may be a Type V CRISPR / Cas complex, such as a Cpf1 / guide RNA complex. The Cas nuclease and cognate gRNA may be paired. The gRNA scaffold structure paired with each Class 2 Cas nuclease varies depending on the specific CRISPR / Cas system.
[0166] "Guide RNA," "gRNA," and simply "guide" are used interchangeably herein to refer to the cognate guide nucleic acid for an RNA-guided DNA-binding agent. The gRNA may be either a crRNA (also known as CRISPR RNA) or a combination of crRNA and trRNA (also known as tracrRNA). The guide RNA may include modified RNAs described herein. The crRNA and trRNA may be associated as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). "Guide RNA" or "gRNA" refers to each type. The trRNA may be a naturally occurring sequence or a trRNA sequence with modifications or changes compared to the naturally occurring sequence.
[0167] As used herein, a "guide sequence" refers to a sequence within a guide RNA that is complementary to a target sequence and functions to guide the guide RNA to the target sequence for binding or modification (e.g., cleavage) by an RNA-guided DNA-binding agent. A "guide sequence" may also be referred to as a "target sequence" or a "spacer sequence." A guide sequence can be 20 base pairs in length, for example, in the case of Streptococcus pyogenes (i.e., Spy Cas9) and related Cas9 homologs / orthologs. Shorter or longer sequences, e.g., 15, 16, 17, 18, 19, 21, 22, 23, 24, or 25 nucleotides in length, can also be used as guides. In some embodiments, the target sequence is, for example, in a gene or on a chromosome, and is complementary to the guide sequence. In some embodiments, the degree of complementarity or identity between a guide sequence and its corresponding target sequence may be approximately or at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the guide sequence and target region may be 100% complementary or identical over a region of at least 15, 16, 17, 18, 19, or 20 contiguous nucleotides. In other embodiments, the guide sequence and target region may contain at least one mismatch. For example, the guide sequence and target sequence may contain one, two, three, or four mismatches, where the total length of the target sequence is at least 17, 18, 19, 20, or more base pairs. In some embodiments, the guide sequence and target region may contain one to four mismatches, where the guide sequence comprises at least 17, 18, 19, 20, or more nucleotides. In some embodiments, the guide sequence and the target region may contain 1, 2, 3, or 4 mismatches, where the guide sequence comprises 20 nucleotides.
[0168] Because the nucleic acid substrate of a Cas protein is a double-stranded nucleic acid, the target sequence of an RNA-guided DNA-binding protein, such as a Cas protein, includes both the plus and minus strands of genomic DNA (i.e., the given sequence and its reverse complementary strand). Thus, when a guide sequence is said to be "complementary to a target sequence," it should be understood that the guide sequence can guide a gRNA to bind to the reverse complementary strand of the target sequence. Thus, in some embodiments, when the guide sequence binds to the reverse complementary strand of the target sequence, the guide sequence is identical to certain nucleotides of the target sequence (e.g., the target sequence without the PAM) except for the substitution of T for U in the guide sequence.
[0169] The length of the targeting sequence depends on the CRISPR / Cas system and components used. For example, various Class 2 Cas nucleases derived from various bacterial species have different optimal targeting sequence lengths. Thus, the targeting sequence may comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or more than 50 nucleotides in length. In some embodiments, the length of the targeting sequence is 0, 1, 2, 3, 4, or 5 nucleotides longer or shorter than the guide sequence of a naturally occurring CRISPR / Cas system. In certain embodiments, the Cas nuclease and gRNA scaffold will be derived from the same CRISPR / Cas system. In some embodiments, the targeting sequence may comprise or consist of 18 to 24 nucleotides. In some embodiments, the targeting sequence may comprise or consist of 19 to 21 nucleotides, hi some embodiments, the targeting sequence may comprise or consist of 20 nucleotides.
[0170] In some embodiments, the sgRNA is a "Cas9 sgRNA" capable of mediating RNA-guided DNA cleavage by the Cas9 protein. In some embodiments, the sgRNA is a "Cpf1 sgRNA" capable of mediating RNA-guided DNA cleavage by the Cpf1 protein. In certain embodiments, the gRNA comprises sufficient crRNA and tracrRNA to form an active complex with the Cas9 protein and mediate RNA-guided DNA cleavage. In certain embodiments, the gRNA comprises sufficient crRNA to form an active complex with the Cpf1 protein and mediate RNA-guided DNA cleavage. See Zetsche 2015.
[0171] Certain embodiments of the present disclosure also provide nucleic acids, e.g., expression cassettes, encoding the gRNAs described herein. "Guide RNA nucleic acid" is used herein to refer to a guide RNA (e.g., sgRNA or dgRNA) and a guide RNA expression cassette, which is a nucleic acid that encodes one or more guide RNAs.
[0172] Modified RNA In certain embodiments, lipid compositions, such as LNP compositions, contain modified nucleic acids, including modified RNA. Modified nucleosides or nucleotides can be present in RNA, such as gRNA or mRNA. For example, gRNA or mRNA containing one or more modified nucleosides or nucleotides is referred to as "modified" RNA, describing the presence of one or more non-natural and / or naturally occurring components or arrangements used in place of or in addition to the standard A, G, C, and U residues. In some embodiments, modified RNA is synthesized with non-standard nucleosides or nucleotides and is referred to herein as "modified."
[0173] Modified nucleosides and modified nucleotides include those with (i) modifications in the phosphodiester backbone linkages, e.g., replacement of one or both of the non-bridging phosphate oxygens and / or one or more of the bridging phosphate oxygens (exemplary backbone modifications), (ii) modifications, e.g., replacement of a component of the ribose sugar, e.g., the 2' hydroxyl on the ribose sugar (exemplary sugar modifications), (iii) wholesale replacement of the phosphate moiety with a "dephosphorylated" linker (exemplary backbone modifications), and (iv) non-canonical nucleobases. (v) a ribose phosphate backbone replacement or modification (an exemplary backbone modification); (vi) a modification of the 3' or 5' end of the oligonucleotide, e.g., removal, modification, or replacement of a terminal phosphate group, or conjugation of a moiety, cap, or linker (such 3' or 5' cap modifications may include sugar and / or backbone modifications); and (vii) a sugar modification or replacement (an exemplary sugar modification).
[0174] Certain embodiments include modifications to the mRNA, gRNA, or nucleic acid. Certain embodiments include 5'-end modifications to the mRNA, gRNA, or nucleic acid. Certain embodiments include 3'-end modifications to the mRNA, gRNA, or nucleic acid. The modified RNA may include 5'-end and 3'-end modifications. The modified RNA may include one or more modified residues at non-terminal positions. In certain embodiments, the gRNA includes at least one modified residue. In certain embodiments, the mRNA includes at least one modified residue.
[0175] Unmodified nucleic acids may be susceptible to degradation, for example, by intracellular nucleases or nucleases found in serum. For example, nucleases can hydrolyze phosphodiester bonds of nucleic acids. Thus, in one aspect, the RNAs (e.g., mRNA, gRNA) described herein may contain one or more modified nucleosides or nucleotides, for example, to introduce stability against intracellular or serum-based nucleases. In some embodiments, the modified gRNA molecules described herein may exhibit a reduced innate immune response when introduced into a cell population both in vivo and ex vivo. The term "innate immune response" includes a cellular response to exogenous nucleic acids, including single-stranded nucleic acids, involving the induction of cytokine expression and release (particularly interferon) and cell death.
[0176] Thus, in some embodiments, the RNA or nucleic acid in the disclosed LNP compositions comprises at least one modification that confers increased or enhanced stability to the nucleic acid, including, for example, improved resistance to nuclease digestion in vivo. As used herein, the terms "modified" and "modified," when referring to the nucleic acids provided herein, preferably include at least one alteration that enhances stability and renders the RNA or nucleic acid more stable (e.g., resistant to nuclease digestion) than a wild-type or naturally occurring version of the RNA or nucleic acid. As used herein, the terms "stable" and "stability," when referring to the nucleic acids of the present disclosure, particularly with respect to RNA, refer to, for example, increased or enhanced resistance to degradation by nucleases (i.e., endonucleases or exonucleases) that are normally capable of degrading such RNA. Increased stability can include, for example, decreased susceptibility to hydrolysis or other destruction by endogenous enzymes (e.g., endonucleases or exonucleases) or conditions within a target cell or tissue, thereby increasing or enhancing the retention of such RNA or nucleic acid in the target cell, tissue, subject, and / or cytoplasm. The stabilized RNA molecules or nucleic acids provided herein exhibit a longer half-life compared to their naturally occurring, unmodified counterparts (e.g., wild-type versions of mRNA). Also contemplated by the terms "modification" and "modified" as they relate to the mRNA of the LNP compositions disclosed herein are modifications that improve or enhance translation of the mRNA nucleic acid, including, for example, the inclusion of a sequence that functions in the initiation of protein translation (e.g., a Kozak consensus sequence). (Kozak, M., Nucleic Acids Res 15(20):8125-48(1987)).
[0177] In some embodiments, the RNA or nucleic acid of the LNP compositions disclosed herein is chemically or biologically modified to make it more stable. Exemplary modifications to RNA, such as mRNA, include base depletion (e.g., by deletion or by substituting one nucleotide for another) or base modification, e.g., chemical modification of the base. As used herein, the phrase "chemical modification" includes modifications that introduce chemical properties different from those found in naturally occurring RNA or nucleic acids, such as covalent modifications such as the introduction of modified nucleotides (e.g., nucleotide analogs or pendant groups not naturally found in such RNA or nucleic acid molecules).
[0178] In some embodiments of backbone modifications, the phosphate group of the modified residue may be modified by replacing one or more oxygens with different substituents. Furthermore, modified residues, such as those present in modified nucleic acids, may contain large-scale replacement of unmodified phosphate moieties with modified phosphate groups, as described herein. In some embodiments, backbone modifications of the phosphate backbone may include modifications that result in either uncharged linkers or charged linkers with asymmetric charge distribution.
[0179] Examples of modified phosphate groups include phosphorothioates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, alkyl or aryl phosphonates, and phosphotriesters. The phosphate atom in an unmodified phosphate group is achiral. However, the phosphorus atom can be made chiral by replacing one of the non-bridging oxygens with one of the atoms or groups of atoms described above. The stereogenic phosphorus atom can possess either the "R" configuration (Rp herein) or the "S" configuration (Sp herein). The backbone can also be modified by replacing the bridging oxygen (i.e., the oxygen linking the phosphate to the nucleoside) with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), or carbon (bridged methylene phosphonates). Substitutions can occur at either or both linking oxygens. The phosphate group can be replaced with a non-phosphorus-containing linking group in certain backbone modifications. In some embodiments, the charged phosphate group can be replaced by a neutral moiety. Examples of moieties that can replace the phosphate group can include, but are not limited to, methylphosphonate, hydroxylamino, siloxane, carbonate, carboxymethyl, carbamate, amide, thioether, ethylene oxide linker, sulfonate, sulfonamide, thioformacetal, formacetal, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo, and methyleneoxymethylimino.
[0180] mRNA In some embodiments, the compositions or formulations disclosed herein comprise an mRNA comprising an open reading frame (ORF) encoding an RNA-guided DNA-binding agent, such as a Cas nuclease or Class 2 Cas nuclease, described herein. In some embodiments, an mRNA comprising an ORF encoding an RNA-guided DNA-binding agent, such as a Cas nuclease or Class 2 Cas nuclease, is provided, used, or administered. The mRNA may comprise one or more of a 5' cap, a 5' untranslated region (UTR), a 3' UTR, and a polyadenine tail. The mRNA may comprise an open reading frame that has been modified, for example, to encode a nuclear localization sequence or to encode a protein using alternative codons.
[0181] The mRNA in the disclosed LNP compositions may encode, for example, a secreted hormone, enzyme, receptor, polypeptide, peptide, or other normally secreted protein of interest. In one embodiment, the mRNA may optionally have chemical or biological modifications that, for example, improve the stability and / or half-life of such mRNA or improve or otherwise facilitate protein production.
[0182] Further, suitable modifications include changes in one or more nucleotides of a codon that encode the same amino acid but are more stable than the codon found in the wild-type version of the mRNA. For example, an inverse correlation between RNA stability and the number of cytidine (C) and / or uridine (U) residues has been demonstrated, and RNA lacking C and U residues has been found to be stable against most RNases (Heidenreich, et al. J Biol Chem 269, 2131-8 (1994)). In some embodiments, the number of C and / or U residues in the mRNA sequence is reduced. In another embodiment, the number of C and / or U residues is reduced by substituting one codon encoding a specific amino acid with another codon encoding the same or a related amino acid. Contemplated modifications to mRNA nucleic acids also include the incorporation of pseudouridine. The incorporation of pseudouridine into mRNA nucleic acids can enhance stability and translation ability and reduce immunogenicity in vivo. See, for example, Kariko, K., et al., Molecular Therapy 16(11):1833-1840 (2008). Substitutions and modifications to mRNA can be carried out by methods well known to those skilled in the art.
[0183] Constraints on reducing the number of C and U residues in a sequence may be greater in the coding regions of an mRNA compared to untranslated regions (i.e., it is likely not possible to eliminate all C and U residues present in a message while retaining the function of the message to encode a desired amino acid sequence). However, the degeneracy of the genetic code provides opportunities to allow for a reduction in the number of C and / or U residues present in a sequence while maintaining the same coding capacity (i.e., several different possibilities for modification of an RNA sequence may be possible, depending on which amino acids are encoded by the codons).
[0184] The term modified also includes, for example, the incorporation of non-nucleotide linkages or modified nucleotides into an mRNA sequence (e.g., modifications to one or both of the 3' and 5' ends of an mRNA molecule encoding a functional secreted protein or enzyme). Such modifications include the addition of bases to the mRNA sequence (e.g., inclusion of a polyA tail or a longer polyA tail), alteration of the 3' or 5' UTR, complexation of the mRNA with an agent (e.g., a protein or a complementary nucleic acid molecule), and the inclusion of elements that alter the structure of the mRNA molecule (e.g., forming secondary structures).
[0185] Poly-A tails are believed to stabilize natural messengers. Thus, in one embodiment, adding a long poly-A tail to an mRNA molecule can make the mRNA more stable. Poly-A tails can be added using various art-recognized techniques. For example, long poly-A tails can be added to synthetic or in vitro transcribed mRNA using poly-A polymerase (Yokoe, et al. Nature Biotechnology. 1996;14:1252-1256). Transcription vectors can also encode long poly-A tails. Additionally, poly-A tails can be added by direct transcription from PCR products. In one embodiment, the length of the poly-A tail is at least about 90, 200, 300, 400, or at least 500 nucleotides. In one embodiment, the length of the poly-A tail is adjusted to control the stability of the modified mRNA molecule and, therefore, protein transcription. For example, because the length of the poly-A tail can affect the half-life of an mRNA molecule, the length of the poly-A tail can be adjusted to change the level of resistance of the mRNA to nucleases, thereby controlling the time course of protein expression in cells. In one embodiment, the stabilized mRNA molecule is sufficiently resistant to in vivo degradation (e.g., by nucleases) so that it can be delivered to a target cell without a transfer vehicle.
[0186] In one embodiment, mRNA can be modified by incorporating 3' and / or 5' untranslated (UTR) sequences not naturally found in wild-type mRNA. In one embodiment, 3' and / or 5' flanking sequences naturally adjacent to the mRNA and encoding a second, unrelated protein can be incorporated into the nucleotide sequence of an mRNA molecule encoding a therapeutic or functional protein in order to modify it. For example, 3' or 5' sequences from a stable mRNA molecule (e.g., globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzyme) can be incorporated into the 3' and / or 5' regions of a sense mRNA nucleic acid molecule to increase the stability of the sense mRNA molecule. See, e.g., US2003 / 0083272.
[0187] A more detailed description of mRNA modifications is provided on pages 57-68 of US2017 / 0210698A1, the contents of which are incorporated herein by reference.
[0188] template nucleic acid The compositions and methods disclosed herein may include a template nucleic acid. The template may be used to modify or insert a nucleic acid sequence at or near a target site for an RNA-guided DNA-binding protein, such as a Cas nuclease, e.g., a class 2 Cas nuclease. In some embodiments, the method includes introducing the template into a cell. In some embodiments, a single template may be provided. In other embodiments, two or more templates may be provided so that editing can occur at two or more target sites. For example, different templates may be provided for editing a single gene in a cell or two different genes in a cell.
[0189] In some embodiments, the template may be used in homologous recombination. In some embodiments, homologous recombination may result in the integration of the template sequence or a portion of the template sequence into the target nucleic acid molecule. In other embodiments, the template may be used in homology-directed repair, which involves the invasion of a DNA strand at the cleavage site of the nucleic acid. In some embodiments, homology-directed repair may result in the inclusion of the template sequence in the edited target nucleic acid molecule. In still other embodiments, the template may be used in gene editing mediated by non-homologous end joining. In some embodiments, the template sequence is dissimilar to the nucleic acid sequence near the cleavage site. In some embodiments, the template or a portion of the template sequence is integrated. In some embodiments, the template includes adjacent inverted terminal repeat (ITR) sequences.
[0190] In some embodiments, the template sequence may correspond to, comprise, or consist of an endogenous sequence of the target cell. The template sequence may also, or alternatively, correspond to, comprise, or consist of an exogenous sequence of the target cell. As used herein, the term "endogenous sequence" refers to a sequence that is native to the cell. The term "exogenous sequence" refers to a sequence that is not native to the cell or that is located in a position different from its native location in the genome of the cell. In some embodiments, the endogenous sequence may be a genomic sequence of the cell. In some embodiments, the endogenous sequence may be a chromosomal or extrachromosomal sequence. In some embodiments, the endogenous sequence may be a plasmid sequence of the cell.
[0191] In some embodiments, the template comprises ssDNA or dsDNA containing flanking inverted terminal repeat (ITR) sequences. In some embodiments, the template is provided as a vector, a plasmid, a minicircle, a nanocircle, or a PCR product.
[0192] In some embodiments, nucleic acids are purified. In some embodiments, nucleic acids are purified using a precipitation method (e.g., LiCl precipitation, alcohol precipitation, or equivalent method, e.g., those described herein). In some embodiments, nucleic acids are purified using a chromatography-based method, such as an HPLC-based method or equivalent method (e.g., those described herein). In some embodiments, nucleic acids are purified using both a precipitation method (e.g., LiCl precipitation) and an HPLC-based method. In some embodiments, nucleic acids are purified by tangential flow filtration (TFF).
[0193] The present compounds or compositions generally, but not necessarily, contain one or more pharmaceutically acceptable excipients. The term "excipient" includes any component other than the compound(s) of the present disclosure, other lipid component(s), and biologically active substance. The excipient may impart either functional (e.g., controlling the drug release rate) and / or non-functional (e.g., processing aid or diluent) properties to the present composition. The choice of excipient will largely depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
[0194] Parenteral formulations are typically aqueous or oily solutions or suspensions. When the formulation is aqueous, the excipients may be sugars (including but not limited to glucose, mannitol, sorbitol, etc.), salts, carbohydrates, and buffers (preferably pH 3-9), but for some applications, they may be more appropriately formulated using sterile non-aqueous solutions or as a dry form used in combination with a suitable vehicle such as sterile pyrogen-free water (WFI).
[0195] While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, including equivalents of specific features, which may be included within the scope of the invention as defined by the appended claims.
[0196] Both the foregoing general and detailed descriptions, as well as the following examples, are exemplary and explanatory only and are not intended to limit the present teachings. The section headings used herein are for organizational purposes only and should not be construed as limiting the desired subject matter in any way. In the event that a document incorporated by reference conflicts with a term defined herein, the present specification shall control. Unless otherwise specified, all ranges specified in this application include their endpoints.
[0197] definition It should be noted that, as used herein, the singular forms "a," "an," and "the" include the plural forms unless the context clearly indicates otherwise. Thus, for example, a reference to "a composition" includes a plurality of compositions, a reference to "a cell" includes a plurality of cells, etc. The use of "or" is inclusive and means "and / or" unless otherwise stated.
[0198] Unless otherwise stated in the specification above, embodiments of the specification that describe "comprising" various components are also contemplated as "consisting of" or "consisting essentially of" the listed components. Embodiments of the specification that describe "consisting of" various components are also contemplated as "comprising" or "consisting essentially of" the listed components. Embodiments of the specification that describe "near" various components are also contemplated as "at" the listed components. Also, embodiments of the specification that describe "consisting essentially of" various components are also contemplated as "consisting of" or "including" the listed components (this interchangeability does not apply to the use of these terms in the claims).
[0199] Numerical ranges are inclusive of the numbers defining the range. Measured and measurable values are understood to be approximate, taking into account significant digits and the error associated with measurement. As used herein, the terms "about" and "approximately" have the meaning understood in the art, and the use of one rather than the other does not necessarily imply a different range. Unless otherwise indicated, numbers used herein, with or without modifiers such as "about" or "approximately," should be understood to encompass normal deviations and / or variations, as understood by one of ordinary skill in the relevant art. In certain embodiments, the term "approximately" or "about" refers to a range of values that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater or less) of the stated reference value, unless otherwise stated or clear from the context (except where such number exceeds 100% of possible values).
[0200] As used herein, the term "contacting" means establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means that the mammalian cell and the nanoparticle share a physical connection. Methods for contacting cells with external entities, both in vivo and ex vivo, are well known in the field of biology. For example, contacting a nanoparticle composition with mammalian cells placed within a mammal may be performed by various administration routes (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and may involve various amounts of the nanoparticle composition. Furthermore, more than one mammalian cell may be contacted by the nanoparticle composition.
[0201] As used herein, the term "delivering" means providing an entity to a destination. For example, delivering a therapeutic and / or prophylactic agent to a subject can include administering to the subject (e.g., via intravenous, intramuscular, intradermal, or subcutaneous routes) a nanoparticle composition comprising the therapeutic and / or prophylactic agent. Administering a nanoparticle composition to a mammal or mammalian cells can involve contacting one or more cells with the nanoparticle composition.
[0202] As used herein, "encapsulation efficiency" refers to the amount of a therapeutic and / or prophylactic agent that becomes part of a nanoparticle composition relative to the initial total amount of the therapeutic and / or prophylactic agent used to prepare the nanoparticle composition. For example, if 97 mg of a therapeutic and / or prophylactic agent is encapsulated in the nanoparticle composition out of a total of 100 mg of the therapeutic and / or prophylactic agent initially provided in the composition, the encapsulation efficiency can be given as 97%. As used herein, "encapsulation" can refer to complete, substantial, or partial enclosing, confining, surrounding, or packaging.
[0203] As used herein, the term "biodegradable" refers to a material that, when introduced into a cell, is broken down by cellular mechanisms (e.g., enzymatic degradation) or by hydrolysis into components that the cell can reuse or discard without significant toxic effect(s) to the cell. In certain embodiments, the components produced by degradation of the biodegradable material do not induce inflammation and / or other adverse effects in vivo. In some embodiments, the biodegradable material is enzymatically degraded. Alternatively, or in addition, in some embodiments, the biodegradable material is hydrolytically degraded.
[0204] As used herein, "N / P ratio" is the molar ratio of ionizable nitrogen atoms (within the physiological pH range) in a lipid (e.g., a compound of Formula I) to phosphate groups in an RNA, e.g., in a nanoparticle composition comprising a lipid component and RNA.
[0205] The composition may also include one or more salts of the compounds. The salt may be a pharmaceutically acceptable salt. As used herein, "pharmaceutically acceptable salt" refers to a derivative of the disclosed compound, in which the parent compound is modified by converting an existing acid or base moiety into its salt form (for example, by reacting a free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, etc. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxyethanesulfonate, Examples of suitable salts include lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Pharmaceutically acceptable salts of the present disclosure include conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or a mixture of the two (generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred). A list of suitable salts can be found in Remington's Pharmaceutical Sciences, 17. th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, P.H. Stahl and C.G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.
[0206] As used herein, "polydispersity index" is a ratio that represents the uniformity of the particle size distribution of a system. For example, a small value less than 0.3 indicates a narrow particle size distribution. In some embodiments, the polydispersity index may be less than 0.1.
[0207] As used herein, "transfection" refers to the introduction of a species (e.g., RNA) into a cell. Transfection can occur, for example, in vitro, ex vivo, or in vivo.
[0208] As used herein, the term "alkyl" refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, etc. Alkyl groups can be cyclic or acyclic. Alkyl groups can be branched or unbranched (i.e., straight-chain). Alkyl groups can also be substituted or unsubstituted (preferably unsubstituted). For example, alkyl groups can be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfoxo, sulfonate, carboxylate, or thiol, as described herein. A "lower alkyl" group is an alkyl group containing 1 to 6 (e.g., 1 to 4) carbon atoms.
[0209] As used herein, the term "alkenyl" refers to an aliphatic group containing at least one carbon-carbon double bond and is intended to include both "unsubstituted alkenyl" and "substituted alkenyl," the latter of which refers to an alkenyl moiety having substituents replacing a hydrogen on one or more carbon atoms of the alkenyl group. Such substituents may be on one or more carbons included or not included in one or more double bonds. Furthermore, such substituents include all of those contemplated for alkyl groups, as described below, except where prohibited by stability. For example, alkenyl groups that may be substituted with one or more alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups are contemplated. Exemplary alkenyl groups include, but are not limited to, vinyl (-CH=CH), allyl (-CHCH=CH), cyclopentenyl (-CH), and 5-hexenyl (-CHCHCHCHCH=CH).
[0210] An "alkylene" group refers to a divalent alkyl radical, which may be branched or unbranched (i.e., straight-chain). Any of the monovalent alkyl groups described above may be converted to an alkylene by abstraction of a second hydrogen atom from the alkyl. Representative alkylenes include C 2-4 Alkylene and C 2-3 Examples of alkylene groups include alkylene. Representative alkylene groups include, but are not limited to, -CH(CH)-, -C(CH)-, -CHCH-, -CHCH(CH)-, -CHC(CH)-, -CHCHCH-, -CHCHCHCH-, and the like. Alkylene groups can also be substituted or unsubstituted. For example, alkylene groups can be substituted with one or more groups, including, but not limited to, alkyl, aryl, heteroaryl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfoxo, sulfonate, sulfonamide, urea, amide, carbamate, ester, carboxylate, or thiol, as described herein.
[0211] The term "alkenylene" includes divalent, straight or branched, unsaturated, acyclic hydrocarbyl groups having at least one carbon-carbon double bond and, in one embodiment, no carbon-carbon triple bonds. Any of the monovalent alkenyl groups described above can be converted to an alkenylene by abstraction of a second hydrogen atom from the alkenyl. Representative alkenylenes include C 2-6 Examples include alkenylene.
[0212] "C x-y The term "alkyl" when used with a chemical moiety such as alkyl or alkylene is meant to include groups containing x to y carbons in the chain. For example, "C x-y The term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including straight- and branched-chain alkyl and alkylene groups, containing x to y carbon atoms in the chain.
[0213] Incorporation by Reference The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein are incorporated herein by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicant reserves the right to physically incorporate into this application all material and information from such articles, patents, patent applications, or other physical and electronic documents. [Example]
[0214] General information All reagents and solvents were purchased from commercial suppliers and used as received or synthesized according to the cited procedures. All intermediates and final compounds were purified using flash column chromatography on silica gel. NMR spectra were recorded on Bruker or Varian 400 MHz spectrometers, and NMR data were collected in CDCl3 at ambient temperature. Chemical shifts are reported in parts per million (ppm) relative to CDCl3 (7.26). 1 H NMR data are reported as chemical shifts, multiplicities (br = broadband, s = singlet, d = doublet, t = triplet, dd = doublet doublet, dt = triplet doublet, q = quartet, m = multiplet, ddd = doublet doublet doublet, td = doublet triplet, tt = triplet triplet, tdd = doublet doublet triplet, dddd = doublet doublet doublet doublet doublet), coupling constants, and integrals. MS data were recorded on a Waters SQD2 mass spectrometer equipped with an electrospray ionization (ESI) source. The purity of the final compounds was determined by UPLC-MS-ELS using a Waters Acquity H-Class liquid chromatography instrument equipped with an SQD2 mass spectrometer equipped with a photodiode array (PDA) and evaporative light scattering (ELS) detector.
[0215] The pKa of each amine lipid was determined according to the method of Jayaraman et al. (Angewandte Chemie, 2012), adapted as follows. pKa was determined for unformulated amine lipids in ethanol. Lipid stock solutions (2.94 mM) were diluted into sodium phosphate buffers (0.1 M, Boston Bioproducts) of different pHs (pH range 4.5-9.0) to obtain final lipid concentrations of approximately 100 μM. Test samples were supplemented with TNS (6-(p-toluidino)-2-naphthalenesulfonic acid, sodium salt), incubated, and the fluorescence intensity was measured using excitation and emission wavelengths of 321 nm and 448 nm, respectively. Recorded data were normalized, and the respective pKa values were derived from a sigmoidal fit. [Table 1] JPEG2024167309000102.jpg210166JPEG2024167309000103.jpg210166JPEG2024167309000104.jpg210166JPEG20241673090 00105.jpg210166JPEG2024167309000106.jpg210167JPEG2024167309000107.jpg215167JPEG2024167309000108.jpg232167 JPEG2024167309000109.jpg232167JPEG2024167309000110.jpg232167JPEG2024167309000111.jpg232167JPEG20241673090 00112.jpg232167JPEG2024167309000113.jpg251168JPEG2024167309000114.jpg205169JPEG2024167309000115.jpg211169 JPEG2024167309000116.jpg215170JPEG2024167309000117.jpg215170JPEG2024167309000118.jpg215170JPEG20241673090 00119.jpg215170JPEG2024167309000120.jpg215170JPEG2024167309000121.jpg215167JPEG2024167309000122.jpg215167 JPEG2024167309000123.jpg215167JPEG2024167309000124.jpg215167JPEG2024167309000125.jpg215167JPEG20241673090 00126.jpg220167JPEG2024167309000127.jpg220167JPEG2024167309000128.jpg226168JPEG2024167309000129.jpg191167
[0216] Example 1 - Comparative Compound 1 Intermediate 1a: 4-oxohexadecanoic acid [ka] A 0.1 M solution of succinic anhydride (3.0 g, 1.0 equiv.) in THF was cooled to −78° C., followed by the dropwise addition of dodecylmagnesium bromide (1.0 M solution in hexanes, 0.5 equiv.) over 5 min. The reaction was maintained at −78° C. for at least 18 h before being quenched by the addition of water and 1 M HCl. The reaction mixture was concentrated in vacuo, and the resulting aqueous layer was extracted three times with DCM. The combined DCM layers were then extracted twice with 2 M NaOH, and the combined aqueous layers were acidified to pH = 1 using concentrated HCl. The mixture was then extracted three times with DCM. The combined DCM layers were dried over NaSO, filtered, and concentrated in vacuo to give the crude material. The crude material was triturated three times with hexanes, and the resulting precipitate was filtered to give the product as a white solid (1.31 g, 33%). 1 H NMR (400 MHz, CDCl3) δ 2.72 (ddd, J = 7.0, 5.8, 1.1 Hz, 2H), 2.67 - 2.60 (m, 2H), 2.44 (t, J = 7.5 Hz, 2H), 1.59 (q, J = 7.4 Hz, 2H), 1.26 (d, J = 2.7 Hz, 18H), 0.91 - 0.85 (m, 3H).
[0217] Intermediate 1b: 2-oxopropane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of dihydroxyacetone (1.55 g, 1.0 equiv.) in DCM (0.1 M) was added linoleic acid (2.05 equiv.), DMAP (0.2 equiv.), DIPEA (2.4 equiv.), and EDCI (2.4 equiv.). The reaction was stirred at room temperature for at least 18 hours. Upon completion, the mixture was quenched by the addition of water, and the organic layer was washed once with 1 M HCl and once with 5% NaHCO3. The organic layer was then dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to give the product (8.0 g, 75%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.28 (m, 8H), 4.75 (s, 4H), 2.82 - 2.74 (m, 4H), 2.42 (t, J = 7.5 Hz, 4H), 2.05 (q, J = 6.7 Hz, 8H), 1.67 (q, J = 7.4 Hz, 4H), 1.40 - 1.24 (m, 28H), 0.95 - 0.86 (m, 6H).
[0218] Intermediate 1c: 2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl (9Z,12Z)-octadeca-9,12-dienoate [ka] A 4:2:1 solution of Intermediate 1b (8.1 g, 1.0 equiv.) in THF / water / toluene (0.05-0.1 M) was cooled to 0-5 °C, followed by the addition of NaBH (1.7 equiv.). The reaction was stirred for at least 1 h at 0-25 °C. Upon completion, the mixture was quenched by the addition of water and EtOAc, and the mixture was extracted three times with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to give the product (5.9 g, 73%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.26 (m, 8H), 4.23 - 4.10 (m, 4H), 2.81 - 2.73 (m, 4H), 2.42 (d, J = 4.8 Hz, 1H), 2.38 - 2.31 (m, 4H), 2.05 (q, J = 6.7 Hz, 8H), 1.68 - 1.57 (m, 4H), 1.42 - 1.23 (m, 29H), 0.93 - 0.85 (m, 6H).
[0219] Intermediate 1d: 2-((4-oxohexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a 0.2 M solution of intermediate 1c (1.0 equiv.) in DCM was added intermediate 1a (1.0–1.2 equiv.), EtN or DIPEA (1.5–4.5 equiv.), DMAP (0.1–0.2 equiv.), and EDCI (1–2 equiv.). The reaction was stirred at room temperature for at least 12 h and then quenched by the addition of water. The mixture was washed once with 1 M HCl and once with 5% NaHCO3. The organic layer was then dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to give the product as a colorless oil (780 mg, 79%). 1 H NMR (400 MHz, CDCl3) δ 5.45 - 5.28 (m, 8H), 5.24 (tt, J = 5.9, 4.3 Hz, 1H), 4.29 (dd, J = 11.9, 4.3 Hz, 2H), 4.15 (dd, J = 11.9, 5.8 Hz, 2H), 2.84 - 2.74 (m, 4H), 2.71 (t, J = 6.8 Hz, 2H), 2.59 (t, J = 6.3 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.32 (t, J = 7.6 Hz, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.60 (dd, J = 14.7, 7.3 Hz, 6H), 1.44 - 1.20 (m, 49H), 0.88 (td, J = 6.9, 4.3 Hz, 9H).
[0220] Intermediate 1e: 2-((4-oxohexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] A 4:2:1 solution of intermediate 1d (1.43 g, 1.0 equiv.) in THF / water / toluene (0.05-0.1 M) was cooled to 0-5 °C, followed by the addition of NaBH (5.0 equiv.). The reaction was maintained at 0-25 °C for at least 2 h. The reaction was then diluted with water and EtOAc, and the resulting biphasic mixture was extracted three times with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to afford the intermediate alcohol as a colorless oil.
[0221] The resulting alcohol was immediately redissolved in DCM (0.1 M), followed by the addition of pyridine (2-3 equiv.) and 4-nitrophenyl chloroformate (1-1.5 equiv.). The reaction was stirred for at least 1 h at room temperature. The mixture was quenched by the addition of water and extracted three times with DCM. The combined DCM layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to give the product as a colorless oil (910 mg, 54%). 1 H NMR (400 MHz, CDCl3) δ 8.37 - 8.25 (m, 2H), 7.48 - 7.40 (m, 2H), 5.49 - 5.25 (m, 9H), 4.96 - 4.84 (m, 1H), 4.34 (dd, J = 12.0, 4.3 Hz, 2H), 4.18 (dd, J = 11.9, 5.7 Hz, 2H), 2.79 (t, J = 6.4 Hz, 4H), 2.49 (dd, J = 8.4, 6.7 Hz, 2H), 2.33 (tt, J = 7.6, 4.2 Hz, 4H), 2.16 - 1.95 (m, 10H), 1.81 - 1.71 (m, 1H), 1.65 (ddq, J = 15.2, 7.5, 4.8, 4.2 Hz, 6H), 1.50 - 1.13 (m, 50H), 0.90 (td, J = 6.8, 3.7 Hz, 9H).
[0222] Compound 1: 2-((4-(((3-(dimethylamino)propoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 1e (250 mg, 1.0 equiv.) in MeCN (0.1 M) was added pyridine (3.0 equiv.), 3-(dimethylamino)propan-1-ol (1.5–3.0 equiv.), and DMAP (1.0 equiv.). The reaction was stirred at room temperature for at least 2 h. Heptane (0.1 M) was then added to the reaction mixture, and the heptane layer was washed three times with MeCN. The combined MeCN layers were back-extracted three times with heptane, and the combined heptane layers were washed one final time with MeCN. The heptane was then removed in vacuo, and the crude material was purified by column chromatography (MeOH / DCM) to give the product (100 mg, 41%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.22 (m, 9H), 4.72 (tdd, J = 7.5, 5.3, 4.0 Hz, 1H), 4.29 (dd, J = 12.0, 4.4 Hz, 2H), 4.23 - 4.10 (m, 4H), 2.84 - 2.73 (m, 4H), 2.62 - 2.27 (m, 13H), 2.05 (q, J = 6.9 Hz, 8H), 2.01 - 1.84 (m, 4H), 1.68 - 1.50 (m, 7H), 1.43 - 1.21 (m, 50H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1001.2 m / z [M+H].
[0223] Example 2 - Compound 2 Compound 2: 2-((4-(((3-(diethylamino)propoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 2 was synthesized in 64% yield from intermediate 1e and 3-(diethylamino)propan-1-ol using the method used in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.43 - 5.20 (m, 9H), 4.72 (tdd, J = 7.5, 5.3, 4.0 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.23 - 4.10 (m, 4H), 2.81 - 2.73 (m, 4H), 2.57 - 2.36 (m, 8H), 2.31 (td, J = 7.6, 1.3 Hz, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.97 - 1.77 (m, 4H), 1.61 (t, J = 7.4Hz, 6H), 1.40 - 1.21 (m, 49H), 1.01 (t, J = 7.1 Hz, 6H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1029.7 m / z [M+H].
[0224] Example 3 - Compound 3 Compound 3: 2-((4-(((3-(ethyl(methyl)amino)propoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 3 was synthesized in 79% yield from intermediate 1e and 3-((methyl)ethylamino)propan-1-ol using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.49 - 5.20 (m, 9H), 4.77 - 4.67 (m, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.16 (tdd, J = 11.9, 6.2, 2.5 Hz, 4H), 2.77 (t, J = 6.4 Hz, 4H), 2.70 - 2.37 (m, 7H), 2.37 - 2.25 (m, 7H), 2.13 - 1.82 (m, 12H), 1.69 - 1.48 (m, 7H), 1.42 - 1.20 (m, 46H), 1.14 (s, 2H), 0.88 (td, J = 6.8, 3.9 Hz, 7H). MS:1015.7 m / z [M+H].
[0225] Example 4 - Compound 4 Compound 4: 2-((4-(((2-(dimethylamino)ethoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 4 was synthesized in 93% yield from intermediate 1e and 2-dimethylaminoethan-1-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.31 (m, 8H), 5.25 (tt, J = 5.8, 4.3 Hz, 1H), 4.73 (tdd, J = 7.6, 5.5, 4.0 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 4H), 4.14 (ddd, J = 11.9, 5.8, 3.4 Hz, 2H), 2.77 (td, J = 6.0, 1.1 Hz, 4H), 2.70 (d, J = 16.4 Hz, 1H), 2.49 - 2.29 (m, 11H), 2.05 (q, J = 6.8 Hz, 8H), 1.99 - 1.81 (m, 2H), 1.67 - 1.50 (m, 8H), 1.40 - 1.21 (m, 48H), 0.88 (td, J = 7.0, 4.2 Hz, 9H). MS:987.6 m / z [M+H].
[0226] Example 5 - Compound 5 Compound 5: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 5 was synthesized in 54% yield from intermediate 1e and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.45 - 5.21 (m, 9H), 4.72 (tdd, J = 7.3, 5.5, 4.2 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.17 (dddd, J = 15.3, 9.1, 7.3, 3.7 Hz, 4H), 2.77 (td, J = 6.0, 1.1 Hz, 4H), 2.57 (d, J = 8.8 Hz, 6H), 2.40 (dt, J = 8.7, 6.5 Hz, 2H), 2.31 (td, J = 7.6, 1.2 Hz, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.98 - 1.83 (m, 5H), 1.80 (p, J = 3.2 Hz, 4H), 1.68 - 1.50 (m, 7H), 1.41 - 1.18 (m, 48H), 0.96 - 0.81 (m, 9H). MS:1027.6 m / z [M+H].
[0227] Example 6 - Compound 6 Example 6: 2-((4-((((1-ethylpiperidin-4-yl)oxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9′Z,12Z,12′Z)-bis(octadeca-9,12-dienoate) [ka] Compound 6 was synthesized in 53% yield from intermediate 1e and 1-ethylpiperidin-4-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.21 (m, 9H), 4.72 (tdd, J = 7.6, 5.3, 4.0 Hz, 1H), 4.64 (d, J = 5.1 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 4.1 Hz, 2H), 2.84 - 2.70 (m, 6H), 2.51 - 2.36 (m, 4H), 2.31 (td, J = 7.6, 1.4 Hz, 4H), 2.24 (d, J = 23.1 Hz, 2H), 2.11 - 1.93 (m, 11H), 1.92 - 1.73 (m, 4H), 1.70 - 1.52 (m, 8H), 1.43 - 1.21 (m, 48H), 1.09 (t, J = 7.2 Hz, 3H), 0.88 (td, J = 7.0, 4.2 Hz, 9H). MS:1028.2 m / z [M+H].
[0228] Example 7 - Compound 7 Compound 7: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 7 was synthesized in 66% yield from intermediate 1e and N1-ethyl-N1-methylethane-1,2-diamine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.47 - 5.08 (m, 10H), 4.76 (s, 1H), 4.28 (ddd, J = 11.9, 4.4, 1.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.9, 3.3 Hz, 2H), 3.24 (q, J = 6.0 Hz, 2H), 2.82 - 2.74 (m, 4H), 2.53 - 2.26 (m, 10H), 2.21 (s, 3H), 2.05 (q, J = 6.8 Hz, 8H), 1.98 - 1.74 (m, 2H), 1.68 - 1.41 (m, 8H), 1.41 - 1.19 (m, 49H), 1.04 (t, J = 7.2 Hz, 3H), 0.95 - 0.82 (m, 9H). MS:1001.1 m / z [M+H].
[0229] Example 8 - Compound 8 Compound 8: 2-((4-(((3-(dimethylamino)propyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 8 was synthesized in 55% yield from intermediate 1e and N1,N1-dimethylpropane-1,3-diamine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.46 (t, J = 5.8 Hz, 1H), 5.43 - 5.28 (m, 8H), 5.24 (tt, J = 5.8, 4.4 Hz, 1H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 2.2 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 1.6 Hz, 2H), 3.23 (h, J = 6.4 Hz, 2H), 2.82 - 2.73 (m, 4H), 2.48 - 2.20 (m, 14H), 2.05 (q, J = 6.8 Hz, 8H), 1.97 - 1.42 (m, 12H), 1.42 - 1.20 (m, 48H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1000.6 m / z [M+H].
[0230] Example 9 - Compound 9 Compound 9: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 9 was synthesized in 65% yield from intermediate 1e and (1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (400 MHz, chloroform-d) δ 5.45 - 5.28 (m, 8H), 5.25 (ddd, J = 10.2, 5.8, 4.4 Hz, 1H), 5.19 - 5.11 (m, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 11.9, 5.9, 3.0 Hz, 2H), 3.44 - 3.31 (m, 1H), 3.19 - 3.02 (m, 2H), 2.84 - 2.72 (m, 4H), 2.46 - 2.16 (m, 12H), 2.05 (q, J = 6.9 Hz, 8H), 1.97 - 1.66 (m, 6H), 1.66 - 1.42 (m, 8H), 1.42 - 1.20 (m, 49H), 0.88 (td, J = 7.0, 4.2 Hz, 9H). MS:1013.1 m / z [M+H].
[0231] Example 10 - Compound 10 Compound 10: 2-((4-((1,4-dimethylpiperidine-4-carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] A 4:2:1 THF / water / toluene solution (0.05 M) of intermediate 1d (360 mg, 1.0 equiv.) was cooled to 0 °C, followed by the addition of NaBH (5.0 equiv.). The reaction was maintained at 0 °C for 18 h. The reaction was then diluted with water and EtOAc, and the resulting biphasic mixture was extracted three times with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to afford the intermediate alcohol as a colorless oil.
[0232] The resulting crude alcohol was immediately redissolved in DCM (0.1 M), followed by the addition of 1,4-dimethylpiperidine-4-carboxylic acid (1.0 equiv.), DMAP (0.1 equiv.), DIPEA (4.0 equiv.), and EDCI (1.5 equiv.). The reaction was stirred at room temperature. After 16 h, additional 1,4-dimethylpiperidine-4-carboxylic acid (1.0 equiv.), DMAP (0.05 equiv.), DIPEA (2.0 equiv.), and EDCI (1.5 equiv.) were added to the reaction, and the reaction was heated to 40 °C. After an additional 2 h, the reaction was quenched by the addition of water and DCM, and the organic layer was washed once with 1 M HCl, once with 5% NaHCO3, and once with brine. The resulting organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (MeOH / DCM) to give the product as a pink oil (94 mg, 22%). 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.22 (m, 9H), 4.92 (ddd, J = 11.6, 7.5, 4.7 Hz, 1H), 4.30 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 12.0, 2.82 - 2.74 (m, 4H), 2.67 (s, 2H), 2.41 - 2.25 (m, 9H), 2.14 (d, J = 14.2 Hz, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.98 - 1.78 (m, 3H), 1.66 - 1.49 (m, 9H), 1.43 - 1.18 (m, 50H), 0.88 (td, J = 6.9, 4.3 Hz, 9H).
[0233] Example 11 - Compound 11 Compound 11: 2-((4-((4-(diethylamino)butanoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 11 was synthesized in 17% yield from intermediate 1d and 3-(diethylamino)butanoic acid using the method described in Example 10. 1 H NMR (400 MHz, CDCl3) δ 5.46 (t, J = 5.8 Hz, 1H), 5.43 - 5.28 (m, 8H), 5.24 (tt, J = 5.8, 4.4 Hz, 1H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 2.2 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 1.6 Hz, 2H), 3.23 (h, J = 6.4 Hz, 2H), 2.82 - 2.73 (m, 4H), 2.48 - 2.20 (m, 14H), 2.05 (q, J = 6.8 Hz, 8H), 1.97 - 1.42 (m, 12H), 1.42 - 1.20 (m, 48H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1013.9 m / z [M+H].
[0234] Example 12 - Compound 12 Compound 12: 2-((4-(((2-(dimethylamino)ethyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 12 was synthesized in 67% yield from intermediate 1e and N1,N1-dimethylethane-1,2-diamine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.29 (m, 8H), 5.29 - 5.18 (m, 2H), 4.75 (s, 1H), 4.34 - 4.24 (m, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.6 Hz, 2H), 3.25 (q, J = 5.8 Hz, 2H), 2.77 (td, J = 6.2, 1.2 Hz, 4H), 2.47 - 2.35 (m, 4H), 2.35 - 2.28 (m, 4H), 2.24 (s, 6H), 2.05 (q, J = 7.1 Hz, 8H), 1.98 - 1.73 (m, 4H), 1.65 - 1.42 (m, 7H), 1.40 - 1.20 (m, 48H), 0.88 (td, J = 7.0, 4.3 Hz, 9H). MS:987.2 m / z [M+H].
[0235] Example 13 - Compound 13 Compound 13: 2-((4-(((3-(diethylamino)propyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 13 was synthesized in 62% yield from intermediate 1e and N1,N1-diethylpropane-1,3-diamine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.93 (s, 1H), 5.44 - 5.28 (m, 8H), 5.24 (ddd, J = 5.8, 4.5, 1.3 Hz, 1H), 4.74 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 2.7 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 1.2 Hz, 2H), 3.24 (tt, J = 13.2, 6.6 Hz, 2H), 2.81 - 2.71 (m, 4H), 2.57 (d, J = 7.7 Hz, 6H), 2.38 (ddd, J = 8.9, 6.8, 3.2 Hz, 2H), 2.35 - 2.28 (m, 4H), 2.05 (q, J = 6.6 Hz, 8H), 1.94 - 1.85 (m, 2H), 1.79 (dq, J = 14.8, 8.1 Hz, 2H), 1.73 - 1.56 (m, 7H), 1.56 - 1.43 (m, 3H), 1.40 - 1.20 (m, 47H), 1.06 (t, J = 7.1 Hz, 6H), 0.88 (td, J = 7.0, 4.3 Hz, 9H). MS:1029.2 m / z [M+H].
[0236] Example 14 - Compound 14 Compound 14: 2-((4-(((4-(diethylamino)butoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 14 was synthesized in 60% yield from intermediate 1e and N1,N1-dimethylethane-1,2-diamine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.45 - 5.30 (m, 9H), 5.28 (tt, J = 5.8, 4.3 Hz, 1H), 4.78 - 4.69 (m, 1H), 4.31 (dd, J = 11.9, 4.4 Hz, 2H), 4.22 - 4.09 (m, 4H), 2.79 (td, J = 6.1, 1.1 Hz, 4H), 2.63 (q, J = 7.2 Hz, 4H), 2.55 (t, J = 7.6 Hz, 2H), 2.47 - 2.38 (m, 2H), 2.38 - 2.30 (m, 4H), 2.07 (q, J = 7.1 Hz, 8H), 2.02 - 1.85 (m, 2H), 1.76 - 1.51 (m, 11H), 1.45 - 1.21 (m, 49H), 1.08 (t, J = 7.2 Hz, 6H), 0.95 - 0.82 (m, 9H). MS:1044.1 m / z [M+H].
[0237] Example 15 - Compound 15 Compound 15: 2-((4-(((2-(diethylamino)ethyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 15 was synthesized in 75% yield from intermediate 1e and N1,N1-diethylethane-1,2-diamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.29 (m, 9H), 5.25 (ddd, J = 5.8, 4.4, 1.4 Hz, 1H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.4, 1.2 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 3.0 Hz, 2H), 3.23 (q, J = 5.7 Hz, 2H), 2.80 - 2.73 (m, 4H), 2.57 (q, J = 7.0 Hz, 6H), 2.38 (ddd, J = 9.0, 6.6, 4.7Hz, 2H), 2.34 - 2.28 (m, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.90 (h, J = 9.0, 7.9 Hz, 1H), 1.80 (p, J = 7.3, 6.5 Hz, 1H), 1.66 - 1.44 (m, 7H), 1.40 - 1.20 (m, 53H), 1.03 (t, J = 7.1 Hz, 6H), 0.88 (td, J = 6.9, 4.3 Hz, 9H). MS:1014.9 m / z [M+H].
[0238] Example 16 - Compound 16 Compound 16: 2-((4-(((2-(1-methylpyrrolidin-2-yl)ethoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 16 was synthesized in 78% yield from intermediate 1e and 2-(1-methylpyrrolidin-2-yl)ethan-1-ol using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.28 (m, 9H), 5.25 (tt, J = 5.8, 4.3 Hz, 1H), 4.72 (qd, J = 7.6, 4.6 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.26 - 4.09 (m, 4H), 3.14 (t, J = 8.8 Hz, 1H), 2.82 - 2.74 (m, 4H), 2.45 - 2.28 (m, 9H), 2.22 (td, J = 11.5, 10.9, 6.0 Hz, 2H), 2.15 - 1.91 (m, 12H), 1.69 - 1.48 (m, 9H), 1.42 - 1.20 (m, 50H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1027.9 m / z [M+H].
[0239] Example 17 - Compound 17 Intermediate 17a: Hexadecylmagnesium bromide [ka] To a solution of Mg (15.92 g, 2 equiv.) in THF (300 mL) was added I2 (0.01 equiv.), followed by dropwise addition of 1-bromohexadecane (1.0 equiv.) in THF (100 mL) at 80 °C. The mixture was stirred for 6 h at 80 °C. The product was obtained as a brown liquid in quantitative yield and was used immediately in the next step.
[0240] Intermediate 17b: 4-oxoicosanoic acid [ka] A 1.2 M solution of succinic anhydride (54 g, 1.0 equiv.) in THF was cooled to −78° C., followed by the addition of Intermediate 17a. The reaction was maintained at −78° C. for 12 h, then poured into saturated NH4Cl and extracted three times with EtOAc. The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. Purification by column chromatography afforded the product as a white solid (4 g, 2%). 1H NMR (400 MHz, CDCl3) δ 4.11 (t, J = 6.7 Hz, 1H), 2.80 - 2.62 (m, 4H), 2.46 (t, J = 7.5 Hz, 1H), 1.63 (dq, J = 14.7, 7.1 Hz, 2H), 1.49 - 1.20 (m, 27H), 0.90 (t, J = 6.7 Hz, 3H).
[0241] Intermediate 17c: 2-((4-oxoicosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 17c was synthesized in 53% yield from intermediate 17b and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.43 - 5.21 (m, 9H), 4.29 (dt, J = 11.9, 4.1 Hz, 2H), 4.14 (dd, J = 11.9, 5.9 Hz, 2H), 4.06 (t, J = 6.8 Hz, 1H), 2.73 (dt, J = 22.5, 6.5 Hz, 6H), 2.67 - 2.54 (m, 4H), 2.42 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 4H), 2.04 (q, J = 6.9 Hz, 9H), 1.61 (q, J = 7.9, 7.3 Hz, 8H), 1.42 - 1.15 (m, 55H), 0.88 (td, J = 6.7, 4.0 Hz, 9H).
[0242] Intermediate 17d: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)icosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 17d was synthesized in 29% yield from intermediate 17c using the method used for intermediate 1e. 1 H NMR (400 MHz, CDCl3) δ 8.33 - 8.24 (m, 2H), 7.43 - 7.34 (m, 2H), 5.45 - 5.23 (m, 8H), 4.92 - 4.82 (m, 1H), 4.31 (dd, J = 12.0, 4.3 Hz, 2H), 4.20 - 4.09 (m, 2H), 2.76 (t, J = 6.3 Hz, 4H), 2.47 (dd, J = 8.3, 6.7 Hz, 2H), 2.30 (td, J = 7.6, 4.2 Hz, 4H), 2.04 (q, J = 7.2 Hz, 9H), 1.61 (ddt, J = 11.5, 7.4, 3.7 Hz, 4H), 1.43 - 1.22 (m, 49H), 0.88 (td, J = 6.9, 3.8 Hz, 9H).
[0243] Compound 17: 2-((4-(((3-(dimethylamino)propoxy)carbonyl)oxy)icosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 17 was synthesized in 74% yield from intermediate 17d and 3-(dimethylamino)propan-1-ol using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.22 (m, 10H), 4.72 (tdd, J = 7.5, 5.4, 4.0 Hz, 1H), 4.36 - 4.25 (m, 2H), 4.23 - 4.08 (m, 4H), 2.82 - 2.71 (m, 4H), 2.50 - 2.28 (m, 9H), 2.25 (s, 6H), 2.09 - 1.97 (m, 9H), 1.91 - 1.80 (m, 3H), 1.70 - 1.47 (m, 7H), 1.40 - 1.20 (m, 57H), 0.96 - 0.82 (m, 9H). MS: 1058.1 m / z [M+H].
[0244] Example 18 - Compound 18 Compound 18: 2-((4-(((3-(ethyl(methyl)amino)propoxy)carbonyl)oxy)icosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 18 was synthesized in 77% yield from intermediate 17d and 3-((methyl)ethylamino)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.45 - 5.22 (m, 10H), 4.72 (qd, J = 7.7, 4.7 Hz, 1H), 4.29 (dd, J = 12.0, 4.4 Hz, 2H), 4.20 - 4.10 (m, 4H), 2.83 - 2.73 (m, 4H), 2.51 - 2.36 (m, 6H), 2.35 - 2.28 (m, 4H), 2.24 (s, 3H), 2.10 - 1.99 (m, 9H), 1.91 - 1.82 (m, 3H), 1.66 - 1.52 (m, 6H), 1.42 - 1.19 (m, 60H), 1.06 (t, J = 7.1 Hz, 3H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1072.3 m / z [M+H].
[0245] Example 19 - Compound 19 Compound 19: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)icosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 19 was synthesized in 67% yield from intermediate 17d and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.44 - 5.22 (m, 9H), 4.72 (tt, J = 7.5, 4.5 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.24 - 4.10 (m, 4H), 2.83 - 2.72 (m, 4H), 2.57 (d, J = 8.3 Hz, 6H), 2.40 (dt, J = 8.6, 6.7 Hz, 2H), 2.31 (td, J = 7.6, 1.2 Hz, 4H), 2.04 (dd, J = 8.5, 5.3 Hz, 8H), 2.00 - 1.86 (m, 4H), 1.86 - 1.78 (m, 4H), 1.53 (ddt, J = 14.1, 8.3, 4.7 Hz, 7H), 1.44 - 1.20 (m, 56H), 0.88 (td, J = 6.9, 4.2 Hz, 9H). MS:1084.2 m / z [M+H].
[0246] Example 20 - Compound 20 Compound 20: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)icosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 20 was synthesized in 73% yield from intermediate 17d and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.44 - 5.17 (m, 10H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.4, 1.3 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.4 Hz, 2H), 3.25 (d, J = 6.2 Hz, 2H), 2.81 - 2.73 (m, 4H), 2.50 - 2.36 (m, 6H), 2.36 - 2.28 (m, 4H), 2.22 (s, 3H), 2.05 (q, J = 6.8 Hz, 8H), 1.94 - 1.71 (m, 4H), 1.66 - 1.20 (m, 63H), 1.05 (t, J = 7.1 Hz, 3H), 0.88 (td, J = 6.9, 4.2 Hz, 9H). MS:1056.6 m / z [M+H].
[0247] Example 21 - Compound 21 Compound 21: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)icosanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 21 was synthesized in 85% yield from intermediate 17d and (1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.30 (m, 8H), 5.29 - 5.18 (m, 2H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.21 - 4.07 (m, 2H), 3.46 - 3.30 (m, 1H), 3.11 (ddt, J = 22.3, 8.9, 4.3 Hz, 2H), 2.80 - 2.72 (m, 4H), 2.45 - 2.15 (m, 12H), 2.04 (dd, J = 8.5, 5.3 Hz, 9H), 1.96 - 1.77 (m, 4H), 1.71 (tq, J = 8.4, 5.1, 4.0 Hz, 2H), 1.65 - 1.45 (m, 8H), 1.39 - 1.20 (m, 60H), 0.88 (td, J = 6.9, 4.4 Hz, 9H). MS:1068.8 m / z [M+H].
[0248] Example 22 - Compound 22 Intermediate 22a: (Z)-9-(non-2-en-1-yloxy)-9-oxononanoic acid [ka] To a solution of nonanedioic acid (25 g, 1.3 equiv.) in THF (100 mL) at 0° C., oxalyl chloride (1.0 equiv.) was added dropwise over 1 minute. DMF (0.1 equiv.) was then added dropwise over 1 minute. The reaction mixture was stirred at 0° C. for 10 minutes, followed by 10 minutes at room temperature. The reaction was then cooled back to 0° C., after which cis-2-nonen-1-ol (1.0 equiv.) in THF (100 mL) was added. The reaction was stirred at 0° C. for 5 minutes, followed by 16 hours at room temperature. Upon completion, the reaction was concentrated in vacuo, slurried with DCM, and filtered. The filtrate was concentrated and purified by column chromatography (80 g, MeOH / DCM) to give the product as a pale yellow oil (15 g, 47%), which was used directly in the subsequent step.
[0249] Intermediate 22b: 9,9'-di((Z)-non-2-en-1-yl)O'1,O1-(2-oxopropane-1,3-diyl)di(nonanedioate) [ka] Intermediate 22b was synthesized in 73% yield by combining dihydroxyacetone with intermediate 22a using the method used for intermediate 1b.
[0250] Intermediate 22c: O'1,O1-(2-hydroxypropane-1,3-diyl)9,9'-di((Z)-non-2-en-1-yl)di(nonanedioate) [ka] Intermediate 22c was synthesized in 71% yield from intermediate 22b using the method used for intermediate 1c except the reaction was complete after 45 minutes. 1 H NMR (400 MHz, CDCl3) δ 5.64 (dtt, J = 11.0, 7.3, 1.3 Hz, 2H), 5.52 (dtt, J = 10.9, 6.8, 1.5 Hz, 2H), 4.67 - 4.58 (m, 4H), 4.23 - 4.05 (m, 5H), 2.51 (d, J = 4.6 Hz, 1H), 2.32 (dt, J = 18.1, 7.6 Hz, 8H), 2.15 - 2.00 (m, 4H), 1.61 (td, J = 10.0, 2.7 Hz, 8H), 1.42 - 1.20 (m, 28H), 0.93 - 0.83 (m, 6H).
[0251] Intermediate 22d: 9,9'-di((Z)-non-2-en-1-yl)O'1,O1-(2-((4-oxohexadecanoyl)oxy)propane-1,3-diyl)di(nonanedioate) [ka] Intermediate 22d was synthesized in 38% yield from intermediate 22c and intermediate 1a using the method used for intermediate 1d.1 H NMR (400 MHz, CDCl3) δ 5.66 (dtt, J = 11.0, 7.3, 1.3 Hz, 2H), 5.54 (dtt, J = 11.0, 6.9, 1.5 Hz, 2H), 5.26 (tt, J = 5.9, 4.3 Hz, 1H), 4.64 (dd, J = 6.9, 1.3 Hz, 4H), 4.31 (dd, J = 11.9, 4.3 Hz, 2H), 4.17 (dd, J = 11.9, 5.9 Hz, 2H), 2.74 (t, J = 6.7 Hz, 2H), 2.68 - 2.56 (m, 2H), 2.45 (t, J = 7.5 Hz, 2H), 2.33 (td, J = 7.6, 6.0 Hz, 8H), 2.19 - 2.07 (m, 4H), 1.70 - 1.57 (m, 12H), 1.43 - 1.23 (m, 46H), 0.98 - 0.84 (m, 9H).
[0252] Intermediate 22e: O'1,O1-(2-((4-(((4-nitrophenoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl)9,9'-di((Z)-non-2-en-1-yl)di(nonanedioate) [ka] Intermediate 22e was synthesized in 51% yield from intermediate 22d using the method used for intermediate 1e. 1H NMR (400 MHz, CDCl3) δ 8.38 - 8.31 (m, 1H), 8.31 - 8.24 (m, 2H), 7.54 - 7.47 (m, 1H), 7.44 - 7.36 (m, 2H), 5.64 (dtt, J = 11.0, 7.3, 1.3 Hz, 2H), 5.51 (dtt, J = 11.0, 6.8, 1.5 Hz, 2H), 5.26 (tt, J = 5.8, 4.3 Hz, 1H), 4.86 (ddd, J = 11.8, 7.5, 4.8 Hz, 1H), 4.65 - 4.57 (m, 4H), 4.36 - 4.25 (m, 2H), 4.21 - 4.10 (m, 2H), 2.50 - 2.44 (m, 2H), 2.30 (td, J = 7.5, 4.5 Hz, 8H), 2.13 - 2.05 (m, 4H), 1.62 (d, J = 37.2 Hz, 9H), 1.46 - 1.18 (m, 49H), 0.94 - 0.80 (m, 9H).
[0253] Compound 22: O'1,O1-(2-((4-(((3-(dimethylamino)propoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl)9,9'-di((Z)-non-2-en-1-yl)di(nonanedioate) [ka] Compound 22 was synthesized in 54% yield from intermediate 22e and 3-(dimethylamino)propan-1-ol using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.71 - 5.58 (m, 2H), 5.52 (dtt, J = 10.9, 6.8, 1.5 Hz, 2H), 5.25 (tt, J = 5.7, 4.4 Hz, 1H), 4.72 (ddd, J = 11.7, 7.4, 4.5 Hz, 1H), 4.62 (dd, J = 6.8, 1.3 Hz, 4H), 4.34 - 4.25 (m, 2H), 4.25 - 4.08 (m, 4H), 2.39 (ddd, J = 12.9, 8.4, 6.4 Hz, 4H), 2.34 - 2.21 (m, 13H), 2.09 (tdd, J = 7.4, 5.7, 1.5 Hz, 4H), 2.02 - 1.67 (m, 7H), 1.69 - 1.51 (m, 11H), 1.42 - 1.19 (m, 45H), 0.97 - 0.78 (m, 8H). MS:1065.7 m / z [M+H].
[0254] Example 23 - Compound 23 Compound 23: O'1,O1-(2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl)9,9'-di((Z)-non-2-en-1-yl)di(nonanedioate) [ka] Compound 23 was synthesized in 59% yield from intermediate 22e and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.72 - 5.59 (m, 2H), 5.52 (dtt, J = 11.0, 6.8, 1.5 Hz, 2H), 5.36 - 5.18 (m, 2H), 4.75 (s, 1H), 4.62 (dd, J = 6.9, 1.2 Hz, 4H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 3.5 Hz, 2H), 3.35 - 3.20 (m, 2H), 2.56 - 2.43 (m, 4H), 2.38 (ddd, J = 8.7, 6.6, 4.1 Hz, 2H), 2.34 - 2.19 (m, 11H), 2.10 (qd, J = 7.4, 1.5 Hz, 4H), 1.96 - 1.72 (m, 3H), 1.63 (d, J = 6.9 Hz, 11H), 1.41 - 1.18 (m, 48H), 1.07 (t, J = 7.1 Hz, 3H), 0.93 - 0.81 (m, 9H). MS:1065.2 m / z [M+H].
[0255] Example 24 - Compound 24 Compound 24: O'1,O1-(2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl)9,9'-di((Z)-non-2-en-1-yl)di(nonanedioate) [ka] Compound 24 was synthesized from intermediate 22e and (1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.71 - 5.59 (m, 2H), 5.52 (dtt, J = 10.9, 6.8, 1.5 Hz, 2H), 5.24 (ddd, J = 8.8, 5.8, 4.4 Hz, 2H), 4.76 (s, 1H), 4.62 (dd, J = 6.9, 1.3 Hz, 4H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 3.2 Hz, 2H), 3.39 (q, J = 11.2, 10.1 Hz, 1H), 3.10 (t, J = 14.0 Hz, 2H), 2.50 - 2.20 (m, 15H), 2.10 (qd, J = 7.4, 1.5 Hz, 4H), 1.97 - 1.67 (m, 6H), 1.61 (d, J = 7.3 Hz, 12H), 1.41 - 1.18 (m, 47H), 0.97 - 0.79 (m, 9H). MS:1076.7 m / z [M+H].
[0256] Example 25 - Compound 25 Intermediate 25a: 5-oxoheptadecanoic acid [ka] Intermediate 25a was synthesized in 64% yield from glutaric anhydride and dodecylmagnesium bromide solution using the method used for intermediate 1a. 1 H NMR (400 MHz, CDCl3) δ 2.75 (t, J = 6.7 Hz, 1H), 2.49 (t, J = 7.2 Hz, 2H), 2.44 - 2.35 (m, 4H), 1.90 (p, J = 7.2 Hz, 2H), 1.56 (t, J = 7.3 Hz, 2H), 1.26 (d, J = 4.0 Hz, 19H), 0.88 (t, J = 6.7 Hz, 3H).
[0257] Intermediate 25b: 2-((5-oxoheptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 25b was synthesized in 55% yield from intermediate 25a and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.45 - 5.19 (m, 9H), 4.30 (dd, J = 11.9, 4.3 Hz, 2H), 4.12 (dd, J = 11.9, 5.8 Hz, 2H), 2.76 (t, J = 6.4 Hz, 4H), 2.46 (t, J = 7.2 Hz, 2H), 2.42 - 2.24 (m, 8H), 2.04 (q, J = 6.8 Hz, 8H), 1.88 (p, J = 7.2 Hz, 2H), 1.57 (dp, J = 21.3, 7.2 Hz, 6H), 1.43 - 1.18 (m, 41H), 0.87 (td, J = 6.8, 4.1 Hz, 8H).
[0258] Intermediate 25c: 2-((5-(((4-nitrophenoxy)carbonyl)oxy)heptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 25c was synthesized in 23% yield from intermediate 25b using the method used for intermediate 1e. 1H NMR (400 MHz, CDCl3) δ 8.31 - 8.24 (m, 2H), 7.42 - 7.35 (m, 2H), 5.44 - 5.19 (m, 9H), 4.83 (q, J = 5.7 Hz, 1H), 4.31 (ddd, J = 12.0, 4.4, 2.9 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 2.1 Hz, 2H), 2.76 (t, J = 6.3 Hz, 4H), 2.34 (dt, J = 30.7, 7.0 Hz, 6H), 2.04 (q, J = 6.9 Hz, 8H), 1.80 - 1.52 (m, 14H), 1.29 (dd, J = 19.3, 12.3 Hz, 44H), 0.88 (td, J = 6.8, 3.7 Hz, 9H).
[0259] Compound 25: 2-((5-(((3-(dimethylamino)propoxy)carbonyl)oxy)heptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 25 was synthesized in 94% yield from intermediate 25c and 3-(dimethylamino)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.19 (m, 9H), 4.74 - 4.65 (m, 1H), 4.29 (ddd, J = 11.9, 4.4, 1.7 Hz, 2H), 4.25 - 4.07 (m, 4H), 2.82 - 2.72 (m, 4H), 2.39 - 2.28 (m, 8H), 2.22 (s, 6H), 2.05 (q, J = 6.8 Hz, 8H), 1.84 (dq, J = 8.2, 6.7 Hz, 2H), 1.73 - 1.50 (m, 14H), 1.41 - 1.18 (m, 50H), 0.88 (td, J = 7.0, 4.2 Hz, 9H). MS:1016.11 m / z [M+H].
[0260] Example 26 - Compound 26 Compound 26: 2-((5-(((3-(ethyl(methyl)amino)propoxy)carbonyl)oxy)heptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 26 was synthesized in 84% yield from intermediate 25c and 3-((methyl)ethylamino)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.20 (m, 10H), 4.69 (dq, J = 7.5, 5.5 Hz, 1H), 4.29 (ddd, J = 11.9, 4.4, 1.6 Hz, 2H), 4.25 - 4.10 (m, 4H), 2.83 - 2.72 (m, 4H), 2.45 - 2.38 (m, 4H), 2.37 - 2.28 (m, 6H), 2.21 (s, 3H), 2.05 (q, J = 6.8 Hz, 8H), 1.88 - 1.79 (m, 2H), 1.74 - 1.52 (m, 13H), 1.44 - 1.22 (m, 51H), 1.04 (t, J = 7.2 Hz, 3H), 0.88 (td, J = 6.9, 4.1 Hz, 9H). MS:1030.1 m / z [M+H].
[0261] Example 27 - Compound 27 Compound 27: 2-((5-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)heptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 27 was synthesized in 79% yield from intermediate 25c and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.44 - 5.21 (m, 10H), 4.69 (dt, J = 7.1, 5.3 Hz, 1H), 4.29 (ddd, J = 11.9, 4.3, 1.6 Hz, 2H), 4.25 - 4.10 (m, 4H), 2.81 - 2.73 (m, 4H), 2.52 (dd, J = 14.8, 7.1 Hz, 6H), 2.33 (dt, J = 13.4, 7.2 Hz, 6H), 2.05 (q, J = 6.8 Hz, 8H), 1.89 (dq, J = 10.8, 6.8Hz, 2H), 1.82 - 1.74 (m, J = 3.8, 3.3 Hz, 4H), 1.71 - 1.53 (m, 13H), 1.40 - 1.21 (m, 49H), 0.88 (td, J = 6.9, 4.2 Hz, 9H). MS:1041.8 m / z [M+H].
[0262] Example 28 - Compound 28 Compound 28: 2-((5-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)heptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 28 was synthesized in 87% yield from intermediate 25c and N1-ethyl-N1-methylethane-1,2-diamine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.21 (m, 10H), 5.12 (s, 1H), 4.80 - 4.65 (m, 1H), 4.29 (dt, J = 11.9, 4.5 Hz, 2H), 4.19 - 4.09 (m, 2H), 3.24 (d, J = 4.8 Hz, 2H), 2.83 - 2.72 (m, 4H), 2.44 (dt, J = 14.6, 6.6 Hz, 4H), 2.38 - 2.27 (m, 6H), 2.20 (s, 3H), 2.04 (dd, J = 7.8, 5.7Hz, 8H), 1.74 - 1.42 (m, 15H), 1.42 - 1.19 (m, 50H), 1.04 (t, J = 7.1 Hz, 3H), 0.88 (td, J = 7.0, 4.4 Hz, 9H). MS:1014.1 m / z [M+H].
[0263] Example 29 - Compound 29 Compound 29: 2-((5-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)heptadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 29 was synthesized in 93% yield from intermediate 25c and (1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.21 (m, 11H), 5.08 (d, J = 8.8 Hz, 1H), 4.74 (s, 1H), 4.29 (dt, J = 11.9, 4.6 Hz, 2H), 4.13 (ddd, J = 11.9, 5.8, 4.5 Hz, 2H), 3.39 (q, J = 11.3, 10.6 Hz, 1H), 3.08 (d, J = 25.9 Hz, 2H), 2.82 - 2.73 (m, 4H), 2.39 - 2.18 (m, 12H), 2.05 (q, J = 6.8Hz, 9H), 1.91 - 1.82 (m, 1H), 1.62 (dddd, J = 27.4, 20.2, 13.2, 6.7 Hz, 18H), 1.42 - 1.20 (m, 52H), 0.88 (td, J = 6.9, 4.4 Hz, 9H). MS:1026.8 m / z [M+H].
[0264] Example 30 - Compound 30 Intermediate 30a: 3-hydroxypropane-1,2-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of glycerol (1.59 g, 1.0 equiv.) in DCM (0.1 M) were added linoleic acid (2.05 equiv.), DMAP (0.2 equiv.), DIPEA (2.4 equiv.), EDCI (2.4 equiv.), and 1 mL of DMF in succession. The reaction was stirred at room temperature for 65 h. Upon completion, the mixture was quenched by the addition of water, and the organic layer was washed once with 1 M HCl and once with 5% NaHCO3. The organic layer was then dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to give the product as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.28 (m, 8H), 5.13 - 5.04 (m, 1H), 4.32 (dd, J = 11.9, 4.6 Hz, 1H), 4.23 (dd, J = 11.9, 5.6 Hz, 1H), 3.73 (ddd, J = 6.5, 5.0, 1.3 Hz, 2H), 2.82 - 2.73 (m, 4H), 2.33 (dt, J = 8.8, 7.5 Hz, 4H), 2.03 (dq, J = 13.1, 6.6 Hz, 9H), 1.69 - 1.57 (m, 4H), 1.44 - 1.23 (m, 29H), 0.96 - 0.83 (m, 6H).
[0265] Intermediate 30b: 3-((4-oxohexadecanoyl)oxy)propane-1,2-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 30b was synthesized in 66% yield from intermediate 30a and intermediate 1a using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.43 - 5.26 (m, 9H), 4.29 (ddd, J = 11.8, 4.3, 2.1 Hz, 2H), 4.15 (ddd, J = 11.9, 7.7, 6.0 Hz, 2H), 2.82 - 2.74 (m, 4H), 2.71 (td, J = 6.3, 5.6, 2.4 Hz, 2H), 2.62 - 2.55 (m, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.31 (td, J = 7.6, 5.4 Hz, 4H), 2.05 (q, J = 6.9Hz, 8H), 1.66 - 1.54 (m, 8H), 1.41 - 1.19 (m, 47H), 0.88 (td, J = 7.0, 4.4 Hz, 9H).
[0266] Intermediate 30c: 3-((4-(((4-nitrophenoxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,2-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 30c was synthesized in 40% yield from intermediate 30b using the method used for intermediate 1e.
[0267] Compound 30: 9-Dodecyl-2-methyl-7,12-dioxo-6,8,13-trioxa-2-azahexadecane-15,16-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 30 was synthesized in 84% yield from intermediate 30c and 3-((methyl)ethylamino)propan-1-ol using the method used in Example 1. 1 H NMR (500 MHz, CDCl3) δ 5.44 - 5.20 (m, 8H), 4.76 - 4.67 (m, 1H), 4.29 (ddd, J = 11.9, 4.3, 1.7 Hz, 2H), 4.22 - 4.11 (m, 4H), 2.77 (t, J = 6.7 Hz, 4H), 2.45 - 2.28 (m, 8H), 2.22 (s, 6H), 2.05 (q, J = 6.9 Hz, 8H), 2.00 - 1.79 (m, 4H), 1.69 - 1.51 (m, 6H), 1.40 - 1.17 (m, 48H), 0.88 (td, J = 6.9, 4.8Hz, 8H). MS:1002.2 m / z [M+H].
[0268] Example 31 - Compound 31 Intermediate 31a: 4-oxododecanoic acid [ka] Intermediate 31a was synthesized in 9% yield from succinic anhydride and octylmagnesium bromide solution using the method used for intermediate 1a. 1 H NMR (400 MHz, CDCl3) δ 2.71 (t, J = 6.4 Hz, 2H), 2.62 (t, J = 6.7 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 1.57 (p, J = 7.1 Hz, 2H), 1.26 (d, J = 3.6 Hz, 10H), 0.87 (t, J = 6.7 Hz, 3H).
[0269] Intermediate 31b: 2-((4-oxododecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 31b was synthesized in 38% yield from intermediates 31a and 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.47 - 5.19 (m, 8H), 4.28 (dd, J = 11.9, 4.3 Hz, 2H), 4.15 (dd, J = 11.9, 5.9 Hz, 2H), 2.77 (t, J = 6.4 Hz, 4H), 2.71 (t, J = 6.5 Hz, 2H), 2.59 (t, J = 6.5 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.32 (t, J = 7.6 Hz, 4H), 2.04 (q, J = 6.9 Hz, 8H), 1.67 - 1.53 (m, 6H), 1.40 - 1.20 (m, 37H), 0.88 (td, J = 6.8, 5.0 Hz, 9H).
[0270] Intermediate 31c: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 31c was synthesized in 68% yield using the method used for intermediate 1e. 1 H NMR (400 MHz, CDCl3) δ 8.26 - 8.16 (m, 2H), 7.40 - 7.30 (m, 2H), 5.39 - 5.05 (m, 9H), 4.80 (tdd, J = 7.5, 5.4, 4.0 Hz, 1H), 4.49 - 4.04 (m, 4H), 2.77 - 2.63 (m, 4H), 2.45 - 2.18 (m, 6H), 2.08 - 1.85 (m, 10H), 1.74 - 1.46 (m, 6H), 1.41 - 1.11 (m, 40H), 0.81 (td, J = 6.9, 2.4 Hz, 9H).
[0271] Compound 31: 2-((4-(((3-(dimethylamino)propoxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 31 was synthesized in 71% yield from intermediate 31c and 3-(dimethylamino)propan-1-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.22 (m, 9H), 4.72 (tdd, J = 7.4, 5.3, 4.0 Hz, 1H), 4.34 - 4.26 (m, 2H), 4.23 - 4.10 (m, 4H), 2.82 - 2.72 (m, 4H), 2.45 - 2.36 (m, 4H), 2.31 (ddd, J = 8.0, 7.1, 1.2 Hz, 4H), 2.25 (s, 6H), 2.05 (q, J = 6.6 Hz, 8H), 1.99 - 1.91 (m, 1H), 1.91 - 1.82 (m, 3H), 1.67 - 1.53 (m, 6H), 1.40 - 1.21 (m, 41H), 0.94 - 0.82 (m, 9H). MS:945.6 m / z [M+H].
[0272] Example 32 - Compound 32 Compound 32: 2-((4-(((3-(diethylamino)propoxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 32 was synthesized in 71% yield from intermediate 31c and 3-(diethylamino)propan-1-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.28 (m, 9H), 5.25 (ddd, J = 5.8, 4.4, 1.5 Hz, 1H), 4.72 (tdd, J = 7.6, 5.4, 4.0 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.25 - 4.08 (m, 5H), 2.77 (td, J = 6.1, 1.1 Hz, 4H), 2.64 - 2.53 (m, 6H), 2.40 (dt, J = 8.7, 6.8 Hz, 2H), 2.31 (ddd, J = 8.0, 7.2, 1.1Hz, 4H), 2.10 - 2.01 (m, 10H), 1.95 (dddd, J = 11.1, 9.2, 6.9, 3.5 Hz, 1H), 1.91 - 1.81 (m, 3H), 1.69 - 1.49 (m, 7H), 1.39 - 1.20 (m, 42H), 1.05 (t, J = 7.2 Hz, 6H), 0.88 (td, J = 7.0, 4.9 Hz, 9H). MS:974.0 m / z [M+H].
[0273] Example 33 - Compound 33 Compound 33: 2-((4-(((3-(ethyl(methyl)amino)propoxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 33 was synthesized in 79% yield from intermediate 31c and 3-((methyl)ethylamino)propan-1-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.45 - 5.21 (m, 10H), 4.72 (tdd, J = 9.5, 6.7, 4.1 Hz, 1H), 4.38 - 4.25 (m, 2H), 4.25 - 4.10 (m, 4H), 2.77 (td, J = 6.2, 1.1 Hz, 4H), 2.51 - 2.38 (m, 6H), 2.37 - 2.27 (m, 5H), 2.24 (d, J = 2.4 Hz, 3H), 2.05 (q, J = 7.1 Hz, 8H), 1.97 - 1.83 (m, 4H), 1.70 - 1.50 (m, 7H), 1.39 - 1.21 (m, 41H), 1.06 (t, J = 7.2 Hz, 3H), 0.94 - 0.84 (m, 9H). 960.1 m / z [M+H].
[0274] Example 34 - Compound 34 Compound 34: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 34 was synthesized in 59% yield from intermediate 31c and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.13 (m, 10H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.4, 1.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.3 Hz, 2H), 3.25 (q, J = 5.7 Hz, 2H), 2.83 - 2.73 (m, 4H), 2.53 - 2.35 (m, 6H), 2.35 - 2.27 (m, 4H), 2.21 (d, J = 3.3 Hz, 3H), 2.05 (q, J = 6.8 Hz, 8H), 1.96 - 1.74 (m, 944.7 m / z [M+H].
[0275] Example 35 - Compound 35 Compound 35: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 35 was synthesized in 71% yield from intermediate 31c and (1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.21 (m, 10H), 4.86 - 4.66 (m, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 3.1 Hz, 2H), 3.48 - 3.35 (m, 1H), 3.22 - 3.00 (m, 2H), 2.83 - 2.71 (m, 4H), 2.47 - 2.19 (m, 12H), 2.04 (q, J = 6.9 Hz, 8H), 1.96 - 1.67 (m, 6H), 1.67 - 1.42 (m, 8H), 1.41 - 1.19 (m, 41H), 0.95 - 0.84 (m, 9H). 956.5 m / z [M+H].
[0276] Example 36 - Compound 36 Compound 36: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 36 was synthesized in 34% yield from intermediate 31c and 3-(pyrrolidin-1-yl)propan-1-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.22 (m, 9H), 4.72 (tdd, J = 7.4, 5.4, 4.0 Hz, 1H), 4.29 (dd, J = 11.9, 4.3 Hz, 2H), 4.25 - 4.08 (m, 4H), 2.82 - 2.72 (m, 4H), 2.67 (t, J = 7.6 Hz, 5H), 2.47 - 2.27 (m, 6H), 2.09 - 1.91 (m, 11H), 1.91 - 1.80 (m, 4H), 1.68 - 1.47 (m, 7H), 1.47 - 1.19 (m, 42H), 0.88 (td, J = 7.0, 4.8 Hz, 9H). 971.3 m / z [M+H].
[0277] Example 37 - Compound 37 Compound 37: 2-((4-(((2-(ethyl(methyl)amino)ethyl)(methyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 37 was synthesized in 67% yield from intermediate 31c and N1-ethyl-N1,N2-dimethylethane-1,2-diamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.18 (m, 8H), 4.78 (s, 1H), 4.28 (dt, J = 11.9, 4.3 Hz, 2H), 4.14 (dd, J = 11.9, 5.8 Hz, 2H), 3.44 - 3.24 (m, 2H), 2.91 (d, J = 8.1 Hz, 3H), 2.81 - 2.71 (m, 4H), 2.60 - 2.21 (m, 12H), 2.05 (q, J = 6.9 Hz, 7H), 1.98 - 1.46 (m, 14H), 1.43 - 1.19 (m, 37H), 1.14 - 1.00 (m, 3H), 0.88 (td, J = 7.0, 5.3 Hz, 8H). 958.6 m / z [M+H].
[0278] Example 38 - Compound 38 Compound 38: 2-((4-(((2-(dimethylamino)ethyl)(methyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 38 was synthesized in 83% yield from intermediate 31c and N1,N1,N2-trimethylethane-1,2-diamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.19 (m, 8H), 4.78 (s, 1H), 4.28 (dt, J = 11.9, 4.1 Hz, 2H), 4.14 (dd, J = 11.9, 5.8 Hz, 2H), 3.37 (d, J = 23.8 Hz, 2H), 2.91 (d, J = 6.8 Hz, 3H), 2.82 - 2.72 (m, 4H), 2.54 - 2.21 (m, 13H), 2.04 (q, J = 6.7 Hz, 7H), 1.95 - 1.44 (m, 14H), 1.42 - 1.21 (m, 37H), 0.88 (td, J = 7.0, 5.3 Hz, 8H). 944.5 m / z [M+H].
[0279] Example 39 - Compound 39 Intermediate 39a: Decylmagnesium bromide [ka] To a solution of Mg (10.99 g, 2 equiv.) and I2 (0.001 equiv.) in THF (250 mL) was added 1-bromodecane (1.0 equiv.) dropwise over 2 h at 80 °C. After the addition, the mixture was stirred at this temperature for 2 h. The crude product, decylmagnesium bromide, was obtained as a dark brown solution and was used immediately in the next step without further purification.
[0280] Intermediate 39b: 4-oxotetradecanoic acid [ka] A 1.1 M solution of succinic anhydride (45 g, 1.0 equiv.) in THF was cooled to −78° C., followed by the addition of Intermediate 39a. The reaction was maintained at −78° C. for 2 h and then stirred at 15° C. for 16 h. The reaction was then quenched by the addition of saturated NH4Cl, diluted with HO, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. Purification by column chromatography afforded the product as a white solid (7.8 g, 7%). 1H NMR (400 MHz, CDCl3) δ 2.74 (dd, J = 6.9, 5.2 Hz, 2H), 2.70 - 2.63 (m, 2H), 2.46 (t, J = 7.5 Hz, 2H), 1.67 - 1.54 (m, 2H), 1.29 (d, J = 5.2 Hz, 14H), 0.90 (t, J = 6.8 Hz, 3H).
[0281] Intermediate 39c: 2-((4-oxotetradecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 39c was prepared from intermediate 39b and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.42 - 5.18 (m, 9H), 4.28 (dd, J = 11.9, 4.3 Hz, 2H), 4.14 (dd, J = 11.9, 5.9 Hz, 2H), 2.74 (dt, J = 22.1, 6.8 Hz, 6H), 2.66 - 2.56 (m, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 4H), 2.04 (q, J = 6.8 Hz, 8H), 1.59 (tq, J = 14.2, 7.5 Hz, 7H), 1.41 - 1.18 (m, 44H), 0.88 (td, J = 6.9, 4.6 Hz, 9H).
[0282] Intermediate 39d: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)tetradecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 39c in MeOH (0.13 M) was slowly added NaBH4 (2.5 equiv.) at 5 °C. The mixture was stirred at this temperature for 2 h. The reaction mixture was quenched by adding HO and then extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give a colorless oil, which was immediately reconstituted in DCM (1 M) followed by the addition of 4-nitrophenyl chloroformate (1.5 equiv.) and pyridine (2 equiv.) at 0 °C. The mixture was stirred at 20 °C for 12 h, after which the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give intermediate 39d in 31% yield. 1 H NMR (400 MHz, CDCl3) δ 8.33 - 8.22 (m, 2H), 7.46 - 7.33 (m, 2H), 5.43 - 5.23 (m, 9H), 4.31 (dd, J = 12.0, 4.3 Hz, 2H), 4.15 (dd, J = 12.0, 5.8 Hz, 2H), 2.76 (t, J = 6.3 Hz, 4H), 2.47 (t, J = 7.5 Hz, 2H), 2.30 (td, J = 7.6, 4.2 Hz, 4H), 2.04 (q, J = 7.3 Hz, 10H), 1.67 (dt, J = 47.7, 6.1Hz, 7H), 1.30 (tq, J = 14.3, 4.9, 3.0 Hz, 53H), 0.88 (td, J = 6.8, 3.5 Hz, 10H).
[0283] Compound 39: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)tetradecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 39 was synthesized in 78% yield from intermediate 39d and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1.1 H NMR (400 MHz, CDCl3) δ 5.49 - 5.17 (m, 9H), 4.75 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.9, 3.3 Hz, 2H), 3.26 (q, J = 6.0 Hz, 2H), 2.77 (t, J = 6.4 Hz, 4H), 2.52 - 2.27 (m, 10H), 2.23 (s, 3H), 2.05 (q, J = 6.8 Hz, 8H), 1.95 - 1.42 (m, 14H), 1.42 - 1.18 (m, 40H), 1.05 (t, J = 7.1 Hz, 3H), 0.88 (td, J = 6.8, 4.5 Hz, 7H). 972.9 m / z [M+H].
[0284] Example 40 - Compound 40 Intermediate 40a: 4-hydroxydecanoic acid [ka] To a solution of 5-hexyltotetrahydrofuran-2-one (15 g, 1.0 equiv.) in EtOH (240 mL) and HO (80 mL) was added NaOH (2.0 equiv.). The reaction was stirred at 25 °C for 12 h. The mixture was concentrated to remove EtOH. The pH was then adjusted to 5 with 1 N aqueous HCl and extracted three times with EtOAc. The combined organic phases were washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / hexanes) to give the product as a white solid (48%).
[0285] Intermediate 40b: 4-oxodecanoic acid [ka] To a solution of NaH2PO4 (17 equiv.) and Na2HPO4 (2.4 equiv.) in HO (1000 mL) was added Intermediate 40a (10 g, 1.0 equiv.). Next, NaClO (200 mL, 6-8% Cl) was added to the solution. The reaction mixture was stirred at 25 °C for 12 h. Next, H3PO4 (200 mL, 85%) and silica gel (300 g) were added to the mixture. The mixture was dried under reduced pressure and washed three times with EtOAc. The organic layer was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography (EtOH / hexane) to give the product as a white solid (80%). 1 H NMR (400 MHz, CDCl3) δ 2.70 (dd, J = 7.0, 5.3 Hz, 2H), 2.63 - 2.58 (m, 2H), 2.43 (t, J = 7.5 Hz, 2H), 1.58 (q, J = 7.4 Hz, 2H), 1.33 - 1.19 (m, 6H), 0.90 - 0.83 (m, 3H).
[0286] Intermediate 40c: 2-((4-oxodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 40c was synthesized from intermediate 40b and intermediate 1c using the method used in Example 1 in 40% yield. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.28 (m, 8H), 5.24 (tt, J = 5.9, 4.3 Hz, 1H), 4.28 (dd, J = 11.9, 4.3 Hz, 2H), 4.14 (dd, J = 11.9, 5.9 Hz, 2H), 2.73 (dt, J = 22.4, 6.7 Hz, 7H), 2.58 (t, J = 6.5 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 4H), 2.04 (q, J = 6.9 Hz, 8H), 1.59 (q, J = 6.7 Hz, 7H), 1.40 - 1.22 (m, 35H), 0.88 (td, J = 6.8, 4.0 Hz, 9H).
[0287] Intermediate 40d: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 40d was synthesized in 31% yield from intermediate 40c using the method used for intermediate 1e. 1 H NMR (400 MHz, CDCl3) δ 8.37 - 8.27 (m, 2H), 7.43 (dd, J = 9.1, 5.9 Hz, 2H), 5.45 - 5.24 (m, 9H), 4.34 (dd, J = 12.0, 4.3 Hz, 2H), 4.18 (dd, J = 11.9, 6.0 Hz, 2H), 2.79 (t, J = 6.3 Hz, 4H), 2.49 (t, J = 7.5 Hz, 2H), 2.41 - 2.30 (m, 4H), 2.07 (q, J = 6.9 Hz, 9H), 1.83 - 1.58 (m, 7H), 1.48 - 1.12 (m, 37H), 1.00 - 0.82 (m, 9H).
[0288] Compound 40: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 40 was synthesized in 53% yield from intermediate 40d and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.44 - 5.19 (m, 9H), 4.76 (s, 1H), 4.32 - 4.22 (m, 2H), 4.15 (ddd, J = 11.9, 5.9, 3.4 Hz, 2H), 3.26 (s, 2H), 2.77 (t, J = 6.5 Hz, 4H), 2.57 - 2.36 (m, 6H), 2.36 - 2.27 (m, 4H), 2.23 (s, 3H), 2.05 (q, J = 6.6 Hz, 8H), 1.98 - 1.42 (m, 15H), 1.41 - 1.19 (m, 35H), 1.06 (t, J = 7.2 Hz, 3H), 0.88 (td, J = 9.7, 8.2, 4.2 Hz, 9H). MS:916.7 m / z [M+H].
[0289] Example 41 - Compound 41 Intermediate 41a: 4-cyclohexyl-4-oxobutanoic acid [ka] To a solution of succinic anhydride (30 g, 1.0 equiv.) in EtO (300 mL) was added CuI (0.1 equiv.). The mixture was cooled to -20 °C. Then, cyclohexylmagnesium bromide (1.0 equiv.) was added to the mixture. The reaction was warmed to 25 °C and stirred for 14 h. The reaction was quenched by the addition of 1 M aqueous HCl and stirred for 15 min. The reaction was then filtered, and the filtrate was extracted three times with DCM. The combined organic layers were dried over NaSO, filtered, and concentrated. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a pale pink solid (13%). 1 H NMR (400 MHz, CDCl3) δ 10.09 (s, 1H), 2.66 (dt, J = 55.4, 6.5 Hz, 4H), 2.35 (td, J = 10.8, 9.3, 5.2 Hz, 1H), 1.75 (ddd, J = 43.2, 36.6, 11.9 Hz, 5H), 1.46 - 1.09 (m, 5H).
[0290] Intermediate 41b: 2-((4-cyclohexyl-4-oxobutanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 41b was synthesized from intermediate 41a and intermediate 1c using the method used in Example 1 in 34% yield. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.28 (m, 8H), 5.24 (ddd, J = 10.2, 5.6, 4.2 Hz, 1H), 4.28 (dt, J = 11.9, 4.6 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 2.3 Hz, 2H), 2.81 - 2.70 (m, 6H), 2.64 - 2.54 (m, 3H), 2.38 - 2.27 (m, 5H), 2.04 (q, J = 6.8 Hz, 8H), 1.89 - 1.55 (m, 11H), 1.40 - 1.20 (m, 34H), 0.88 (t, J = 6.8 Hz, 6H).
[0291] Intermediate 41c: 2-((4-cyclohexyl-4-(((4-nitrophenoxy)carbonyl)oxy)butanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 41c was synthesized from intermediate 41b using the method used in Example 1 in 14% yield. 1 H NMR (400 MHz, CDCl3) δ 8.33 - 8.21 (m, 2H), 7.45 - 7.34 (m, 2H), 5.44 - 5.13 (m, 9H), 4.70 (ddd, J = 9.3, 6.1, 3.4 Hz, 1H), 4.50 (dd, J = 12.3, 3.9 Hz, 1H), 4.35 - 4.10 (m, 4H), 2.76 (t, J = 6.4 Hz, 4H), 2.50 - 2.40 (m, 2H), 2.38 - 2.22 (m, 4H), 2.04 (q, J = 6.9 Hz, 10H), 1.85 - 1.52 (m, 10H), 1.49 - 1.00 (m, 31H), 0.88 (t, J = 6.8 Hz, 6H).
[0292] Compound 41: 2-((4-cyclohexyl-4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)butanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 41 was synthesized in 60% yield from intermediate 41d and N1-ethyl-N1-methylethane-1,2-diamine using the method used for intermediate 1e. 1 H NMR (400 MHz, CDCl3) δ 5.45 - 5.09 (m, 9H), 4.60 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 1.6 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 2.9 Hz, 2H), 3.25 (s, 2H), 2.77 (t, J = 6.5 Hz, 4H), 2.54 - 2.15 (m, 12H), 2.05 (q, J = 6.7 Hz, 8H), 1.99 - 0.95 (m, 50H), 0.93 - 0.80 (m, 6H). MS:914.5 m / z [M+H].
[0293] Example 42 - Compound 42 Intermediate 42a: 4-hydroxyoctanoic acid [ka] Intermediate 42a was synthesized in 53% yield from 5-butyltetrahydrofuran-2-one using the method used for intermediate 39b.
[0294] Intermediate 42b: 4-oxooctanoic acid [ka] Intermediate 42b was synthesized in 61% yield from intermediate 42a using the method used for intermediate 38b. 1H NMR (400 MHz, CDCl3) δ 2.65 (ddd, J = 7.0, 5.8, 1.1 Hz, 2H), 2.56 (ddd, J = 7.1, 6.0, 1.2 Hz, 2H), 2.38 (t, J = 7.5 Hz, 2H), 1.56 - 1.44 (m, 2H), 1.30 - 1.17 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H).
[0295] Intermediate 42c: 2-((4-oxooctanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 42c was synthesized from intermediate 42b and intermediate 1c using the method used in Example 1 in 29% yield. 1 H NMR (400 MHz, CDCl3) δ 5.35 (tq, J = 18.2, 9.4, 7.6 Hz, 8H), 5.24 (t, J = 5.3 Hz, 1H), 4.28 (dd, J = 12.0, 3.9 Hz, 2H), 4.14 (dd, J = 12.1, 5.8 Hz, 2H), 2.74 (dt, J = 20.9, 6.7 Hz, 6H), 2.59 (d, J = 6.6 Hz, 2H), 2.43 (t, J = 7.6 Hz, 2H), 2.31 (t, J = 7.7 Hz, 4H), 2.04 (q, J = 7.0 Hz, 8H), 1.60 (t, J = 7.5 Hz, 8H), 1.31 (d, J = 14.1 Hz, 29H), 0.88 (t, J = 6.9 Hz, 9H).
[0296] Intermediate 42d: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)octanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 42d was synthesized in 51% yield from intermediate 40c using the method used for intermediate 1e. 1 H NMR (400 MHz, CDCl3) δ 8.28 (dd, J = 7.8, 4.7 Hz, 2H), 7.47 - 7.36 (m, 2H), 5.32 (dp, J = 19.8, 9.2 Hz, 8H), 5.17 (s, 1H), 4.87 (d, J = 7.3 Hz, 1H), 4.49 (d, J = 12.2 Hz, 1H), 4.36 - 4.09 (m, 4H), 2.75 (d, J = 6.7 Hz, 4H), 2.49 (dt, J = 23.8, 7.9 Hz, 2H), 2.42 - 2.14 (m, 5H), 2.03 (q, J = 7.2 Hz, 10H), 1.73 (s, 1H), 1.61 (dd, J = 23.8, 11.9 Hz, 6H), 1.31 (d, J = 14.4 Hz, 30H), 0.89 (tt, J = 9.5, 7.0, 2.7 Hz, 9H).
[0297] Compound 42: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)octanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 42 was synthesized in 93% yield from intermediate 42d and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.10 (m, 11H), 4.76 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 1.3 Hz, 2H), 4.15 (ddd, J = 11.8, 5.8, 3.3 Hz, 2H), 3.25 (s, 2H), 2.77 (t, J = 6.5 Hz, 4H), 2.39 (ddd, J = 8.7, 6.6, 4.3 Hz, 6H), 2.35 - 2.28 (m, 4H), 2.22 (s, 3H), 2.05 (q, J = 6.7 Hz, 8H), 1.96 - 1.74 (m, 3H), 1.61 (s, 11H), 1.42 - 1.22 (m, 34H), 1.10 - 0.99 (m, 3H), 0.95 - 0.83 (m, 9H).
[0298] Example 43 - Compound 43 Intermediate 43a: Sodium 4-hydroxybutanoate [ka] To a mixture of tetrahydrofuran-2-one (10 g, 1.0 equiv.) in HO (100 mL) was added NaOH (4.0 equiv.), and the mixture was degassed and purged with N three times. The mixture was stirred under N atmosphere at 25 °C for 24 h. The reaction mixture was then concentrated under reduced pressure to give the crude residue (12 g, crude) as a colorless oil, which was used in the next step without further purification.
[0299] Intermediate 43b: Benzyl 4-hydroxybutanoate [ka] To a mixture of Intermediate 43a (12 g, 1.0 equiv.) in acetone (100 mL) was added TBAB (0.05 equiv.) and benzyl bromide (1.2 equiv.), and the mixture was degassed and purged with N2 three times. The mixture was stirred at 60 °C under N2 atmosphere for 12 h. The reaction mixture was then concentrated under reduced pressure, and the resulting residue was diluted with EtOAc and washed with 1N NaH SThe organic layer was washed once each with O, NaHCO, and H O. The organic layer was dried over Na SO, filtered, concentrated, and the crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a colorless oil (43%).
[0300] Intermediate 43c: Benzyl 4-(((4-nitrophenoxy)carbonyl)oxy)butanoate [ka] To a mixture of intermediate 43b (5 g, 1.0 equiv.) in DCM (150 mL) was added 4-nitrophenyl chloroformate (1.0 equiv.), and the mixture was degassed and purged with N2 three times. After cooling the reaction to 0 °C, pyridine (2.0 equiv.) was added. The reaction was stirred at 25 °C under a N2 atmosphere for 5 h. The reaction mixture was then concentrated under reduced pressure, diluted with hexane, and filtered. The filtrate was washed 10 times with HO, and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The crude material was purified by column chromatography to give the product as a yellow oil (32%).
[0301] Intermediate 43d: Benzyl 4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)butanoate [ka] To a mixture of Intermediate 43c (3 g, 1.0 equiv.) in MeCN (50 mL) was added N1-ethyl-N1-methylethane-1,2-diamine (2.5 equiv.), pyridine (3.0 equiv.), and DMAP (1.0 equiv.). The mixture was degassed and purged with N2 three times, and the mixture was stirred at 70 °C under N2 for 12 h. The reaction mixture was then concentrated under reduced pressure, and the crude residue was purified by column chromatography to give the product as a yellow oil (56%). 1H NMR (400 MHz, CDCl3) δ 7.33 - 7.23 (m, 4H), 5.24 (d, J = 12.8 Hz, 1H), 5.05 (s, 2H), 4.04 (dt, J = 12.9, 6.7 Hz, 2H), 3.19 (q, J = 5.8 Hz, 2H), 3.00 (s, 1H), 2.39 (dt, J = 10.4, 6.6 Hz, 6H), 2.13 (s, 3H), 1.89 (p, J = 6.9 Hz, 2H), 0.98 (t, J = 7.1 Hz, 3H).
[0302] Intermediate 43e: 4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)butanoic acid [ka] To a mixture of intermediate 43d (1.5 g, 1.0 equiv.) in MeOH (30 mL) was added Pd / C (10 wt%, 0.05 equiv.), and the mixture was degassed and purged with H three times. The reaction mixture was stirred under an atmosphere of H at 25 °C for 1 h, after which the filtrate was concentrated to give a crude residue, which was used in the next step without further purification. 1 H NMR (400 MHz, CD3OD) δ 4.11 (t, J = 6.3 Hz, 2H), 3.49 (t, J = 6.0 Hz, 2H), 3.29 - 3.21 (m, 5H), 2.89 (s, 3H), 2.38 (t, J = 7.2 Hz, 2H), 1.92 (p, J = 6.7 Hz, 2H), 1.34 (t, J = 7.3 Hz, 3H).
[0303] Compound 43: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)butanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 43 was synthesized in 45% yield from intermediate 43d and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.43 - 5.22 (m, 9H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.18 - 4.06 (m, 4H), 3.25 (q, J = 5.8 Hz, 2H), 2.76 (t, J = 6.4 Hz, 4H), 2.43 (dt, J = 10.5, 7.3 Hz, 6H), 2.31 (t, J = 7.6 Hz, 4H), 2.20 (s, 3H), 2.04 (q, J = 6.9 Hz, 8H), 1.95 (q, J = 6.9 Hz, 2H), 1.59 (d, J = 7.1 Hz, 7H), 1.40 - 1.22 (m, 26H), 1.04 (t, J = 7.1 Hz, 3H), 0.88 (t, J = 6.8 Hz, 6H).
[0304] Example 44 - Compound 44 Compound 44: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 44 was synthesized in 35% yield from intermediate 40d and (1-methylpyrrolidin-2-yl)methanamine using the method used for intermediate 1e. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.20 (m, 9H), 5.16 (s, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.0 Hz, 2H), 3.39 (s, 1H), 3.10 (d, J = 27.2 Hz, 2H), 2.81 - 2.73 (m, 4H), 2.43 - 2.18 (m, 11H), 2.05 (q, J = 6.7 Hz, 8H), 1.96 - 1.42 (m, 17H), 1.30 (dqt, J = 12.8, 8.8, 5.4 Hz, 36H), 0.92 - 0.83 (m, 9H). MS:928.9 m / z [M+H].
[0305] Example 45 - Compound 45 Compound 45: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 45 was synthesized in 52% yield from intermediate 40d and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.21 (m, 9H), 4.72 (ddd, J = 11.3, 8.8, 5.7 Hz, 1H), 4.29 (dd, J = 11.9, 4.3 Hz, 2H), 4.25 - 4.10 (m, 4H), 2.81 - 2.74 (m, 4H), 2.59 (s, 5H), 2.40 (dt, J = 8.6, 6.4 Hz, 2H), 2.36 - 2.27 (m, 4H), 2.05 (q, J = 6.7 Hz, 8H), 1.98 - 1.78 (m, 9H), 1.67 - 1.51 (m, 7H), 1.41 - 1.21 (m, 36H), 0.88 (td, J = 7.0, 5.0 Hz, 9H). MS:943.8 m / z [M+H].
[0306] Example 46 - Compound 46 Compound 46: 2-((4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 46 was synthesized in 53% yield from intermediate 1e and 2-(pyrrolidin-1-yl)ethan-1-amine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.55 (s, 1H), 5.46 - 5.21 (m, 9H), 4.75 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.6 Hz, 2H), 3.35 (d, J = 6.0 Hz, 2H), 2.81 - 2.60 (m, 9H), 2.39 (ddd, J = 8.6, 6.7, 3.8 Hz, 2H), 2.31 (t, J = 7.6 Hz, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.84 (s, 7H), 1.66 - 1.19 (m, 55H), 0.88 (td, J = 7.0, 4.3 Hz, 9H). MS:1012.5 m / z [M+H].
[0307] Example 47 - Compound 47 Compound 47: 2-((4-((((1-methylpiperidin-4-yl)oxy)carbonyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 1e (250 mg, 1.0 equiv.) in MeCN (0.1 M) was added pyridine (3.0 equiv.), 1-methylpiperidin-4-ol (1.5 equiv.), and DMAP (1.0 equiv.). The reaction was stirred for 18 hours at room temperature. An additional portion of 1-methylpiperidin-4-ol (3.0 equiv.) was added, and the mixture was heated to 50° C. After 2 hours, an additional portion of DMAP (1.0 equiv.) was added, and the reaction was maintained for an additional 2 hours. Upon completion, heptane (0.1 M) was then added to the reaction mixture, and the heptane layer was washed three times with MeCN. The combined MeCN layers were back-extracted three times with heptane, and the combined heptane layers were washed one final time with MeCN. The heptane was then removed in vacuo, and the crude material was purified by column chromatography (MeOH / DCM) to afford the product (62 mg, 32%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.20 (m, 9H), 4.77 - 4.60 (m, 2H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 3.6 Hz, 2H), 2.83 - 2.66 (m, 6H), 2.46 - 2.26 (m, 11H), 2.08 - 1.71 (m, 18H), 1.71 - 1.47 (m, 8H), 1.40 - 1.21 (m, 47H), 0.88 (td, J = 7.0, 4.2 Hz, 9H). MS: 1013.7 m / z [M+H].
[0308] Example 48 - Compound 48 Compound 48: 2-((4-(((3-(bis(2-hydroxyethyl)amino)propyl)carbamoyl)oxy)hexadecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 1e (250 mg, 1.0 equiv.) in MeCN (0.1 M) was added pyridine (3.0 equiv.) and 2-[(3-aminopropyl)(2-hydroxyethyl)amino]ethan-1-ol (1.5 equiv.). The reaction was stirred at room temperature for 2 hours. Upon completion, heptane (0.1 M) was then added to the reaction mixture, and the heptane layer was washed three times with MeCN. The combined MeCN layers were back-extracted three times with heptane, and the combined heptane layers were washed one final time with MeCN. The heptane was then removed in vacuo, and the crude material was purified by column chromatography (MeOH / DCM) to afford the product (97 mg, 48%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.20 (m, 9H), 4.76 (s, 1H), 4.29 (ddd, J = 11.9, 4.6, 1.8 Hz, 2H), 4.16 (dd, J = 11.9, 5.8 Hz, 2H), 3.72 (t, J = 5.0 Hz, 4H), 3.35 - 3.22 (m, 2H), 2.98 - 2.46 (m, 14H), 2.41 - 2.28 (m, 6H), 2.09 - 1.86 (m, 9H), 1.80 (dd, J = 14.2, 7.2 Hz, 3H), 1.67 - 1.42 (m, 7H), 1.42 - 1.18 (m, 46H), 0.88 (td, J = 7.0, 4.3 Hz, 9H). MS:1060.6 m / z [M+H].
[0309] Example 49 - Comparative Compound 49 Compound 49: 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl(9Z,12Z)-octadeca-9,12-dienoate [ka] Compound 49 was synthesized according to the method described in WO 2015 / 095340 A1 (Example 13). 1H NMR (CDCl3, 400 MHz) δ 5.35 (m, 4H), 4.48 (t, J = 5.6 Hz, 1H), 4.17 (m, 8H), 3.56 (m, 2H), 3.40 (m, 2H), 2.77 (t, J = 6.6 Hz, 2H), 2.55 (q, J = 7.2 Hz, 6H), 2.40 (m, 3H), 2.30 (t, J = 7.6 Hz, 2H), 2.05 (q, J = 6.8 Hz, 4H), 1.92 (m, 2H), 1.84 (m, 2H), 1.57 (m, 6H), 1.30 (m, 34H), 1.03 (t, J = 7.2 Hz, 6H), 0.88 (m, 9H) ppm; MS:853 m / z [M+H].
[0310] Example 50 - Compound 50 Compound 50: 2-((4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 50 was synthesized in 36% yield from intermediate 40d and 2-(pyrrolidin-1-yl)ethan-1-amine using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.49 - 5.29 (m, 8H), 5.27 - 5.20 (m, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.8 Hz, 2H), 3.35 (s, 2H), 2.83 - 2.44 (m, 10H), 2.39 (ddd, J = 8.4, 6.7, 3.3 Hz, 2H), 2.36 - 2.25 (m, 4H), 2.05 (q, J = 6.8 Hz, 8H), 1.98 - 1.43 (m, 15H), 1.42 - 1.20 (m, 33H), 0.89 (td, J = 6.1, 5.4, 0.9 Hz, 9H). MS:928.6 m / z [M+H].
[0311] Example 51 - Compound 51 Compound 51: 2-((4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 51 was synthesized in 27% yield from intermediate 31c and 2-(pyrrolidin-1-yl)ethan-1-amine using the method described in Example 1.1 H NMR (400 MHz, CDCl3) δ 5.55 (s, 1H), 5.44 - 5.28 (m, 8H), 5.28 - 5.22 (m, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 3.9 Hz, 2H), 3.37 (s, 2H), 2.83 - 2.51 (m, 10H), 2.39 (ddd, J = 8.4, 6.8, 3.1 Hz, 2H), 2.35 - 2.27 (m, 4H), 2.05 (q, J = 6.7 Hz, 8H), 1.97 - 1.41 (m, 17H), 1.41 - 1.20 (m, 40H), 0.94 - 0.84 (m, 9H). MS:957.0 m / z [M+H].
[0312] Example 52 - Compound 52 Intermediate 52a: Benzyl 3-hydroxyundecanoate [ka] To a solution of Zn (22.99 g, 1.0 equiv.) and nonanal (25 g, 1.0 equiv.) in THF (150 mL) at 66 °C under N2 was added dropwise. 2-Bromobenzyl acetate (50.00 g, 1.24 equiv.) was then slowly and carefully added dropwise to the reaction mixture. Upon complete addition of 2-bromobenzyl acetate, the mixture was cooled and stirred at 20 °C for 2 h. The reaction mixture was then concentrated under reduced pressure to remove THF, and the resulting residue was diluted with water and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure and purified by column chromatography to give the product (25 g, 49%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 7.33 - 7.24 (m, 5H), 5.09 (s, 2H), 3.95 (tt, J = 7.7, 3.8 Hz, 1H), 2.75 (d, J = 3.9 Hz, 1H), 2.56 - 2.35 (m, 2H), 1.54 - 1.11 (m, 18H), 0.81 (t, J = 6.7 Hz, 3H).
[0313] Intermediate 52b: Benzyl 3-(((4-nitrophenoxy)carbonyl)oxy)undecanoate [ka] To a solution of intermediate 52a (25 g, 1.0 equiv.) in DCM (250 mL) was added (4-nitrophenyl)carbonochloridate (17.23 g, 1.0 equiv.) and pyridine (13.80 mL, 2.0 equiv.) under a N atmosphere. The mixture was stirred at 20 °C for 2 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove DCM, and the resulting residue was diluted with water and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure and purified by column chromatography to give the product as a colorless oil (12 g, 31%). 1 H NMR (400 MHz, CDCl3) δ 8.31 - 8.01 (m, 4H), 7.28 (s, 5H), 5.22 - 5.14 (m, 2H), 5.13 - 5.01 (m, 4H), 2.68 (dd, J = 14.8, 6.4 Hz, 3H), 1.75 - 1.64 (m, 2H), 1.30 - 1.19 (m, 18H), 0.80 (t, J = 6.6 Hz, 3H).
[0314] Intermediate 52c: Benzyl 3-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)undecanoate [ka] To a solution of Intermediate 52b (14 g, 1.0 equiv.) and N'-ethyl-N'-methyl-ethane-1,2-diamine (6.25 g, 2.0 equiv.) in MeCN (400 mL) was added pyridine (7.41 mL, 3.0 equiv.) and DMAP (3.74 g, 1.0 equiv.). The mixture was stirred at 20 °C for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove MeCN, and the resulting residue was diluted with water and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure and purified by column chromatography to give the product (6 g, 47%) as a colorless oil.1 H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 5.11 (s, 4H), 3.21 (h, J = 6.8 Hz, 2H), 2.62 (td, J = 14.4, 13.6, 6.4 Hz, 2H), 2.50 - 2.39 (m, 4H), 1.59 (h, J = 8.2 Hz, 2H), 1.25 (d, J = 16.1 Hz, 14H), 1.03 (t, J = 7.2 Hz, 3H), 0.86 (t, J = 6.7 Hz, 3H).
[0315] Intermediate 52d: 3-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)undecanoic acid [ka] To a solution of intermediate 52c (6 g, 1.0 equiv.) in MeOH (60 mL) was added Pd / C (2 g, 10% w / w). The mixture was stirred under H at 20° C. for 2 hours. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a brown oil. 1 H NMR (400 MHz, CDCl3) δ 12.76 (s, 1H), 6.28 (t, J = 5.8 Hz, 1H), 5.01 (p, J = 6.1, 5.6 Hz, 1H), 3.30 (qq, J = 13.8, 6.0 Hz, 2H), 2.70 (hd, J = 12.1, 11.0, 5.4 Hz, 3H), 2.37 (d, J = 14.1 Hz, 4H), 1.51 (ddq, J = 21.6, 14.2, 6.7 Hz, 2H), 1.34 - 1.14 (m, 11H), 1.10 (t, J = 7.1 Hz, 3H), 0.80 (t, J = 6.7 Hz, 3H).
[0316] Compound 52: 2-((3-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of Intermediate 52d (1.0–1.1 equiv.) and Intermediate 1c (1.0–1.1 equiv.) in DCM (0.1–0.25 equiv.) were added DMAP (0.25 equiv.), DIPEA (3.5 equiv.), and EDCI (1.5 equiv.) sequentially. The reaction was stirred at 23 °C for at least 16 h. Additional DMAP (0.25 equiv.) was added to the reaction, and the reaction was stirred at 23 °C for an additional 6 h. The reaction was then quenched by the addition of water and washed once with 1 M HCl and once with 5% NaHCO3. The organic layer was dried over Na2SO4, filtered, and concentrated. Purification by column chromatography afforded the product as a colorless oil (28%). 1 H NMR (400 MHz, CDCl3) δ 5.53 - 5.28 (m, 8H), 5.24 (s, 1H), 5.08 (s, 1H), 4.28 (ddd, J = 15.9, 11.9, 4.5 Hz, 2H), 4.15 (dt, J = 13.4, 6.8 Hz, 2H), 2.77 (t, J = 6.5 Hz, 4H), 2.59 (tt, J = 15.9, 9.0 Hz, 6H), 2.37 - 2.14 (m, 6H), 2.05 (q, J = 6.8 Hz, 7H), 1.59 (d, J = 14.2 Hz, 12H), 1.46 - 0.97 (m, 42H), 0.96 - 0.81 (m, 9H). MS:930.8 m / z [M+H].
[0317] Example 53 - Compound 53 Intermediate 53a: 2-(hydroxymethyl)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of linoleic acid (20 g, 1.0 equiv.) and 2-(hydroxymethyl)propane-1,3-diol (7.57 g, 1.0 equiv.) in DCM (200 mL) was added EDCI (13.67 g, 1.0 equiv.), DMAP (1.39 g, 0.16 equiv.), and DIPEA (37.27 mL, 3.0 equiv.). The mixture was stirred at 20 °C for 2 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove DCM, and the resulting residue was diluted with water and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na SO , filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to afford the product (6.3 g, 11%) as a colorless oil. 1 H NMR (400 MHz, CD3OD) δ 5.44 - 5.30 (m, 8H), 4.17 (qd, J = 11.1, 6.0 Hz, 4H), 3.63 (d, J = 6.0 Hz, 2H), 2.80 (t, J = 6.1 Hz, 4H), 2.35 (t, J = 7.4 Hz, 4H), 2.21 (h, J = 6.0 Hz, 1H), 2.14 - 2.03 (m, 8H), 1.64 (p, J = 7.4 Hz, 4H), 1.46 - 1.28 (m, 27H), 0.93 (t, J = 6.7 Hz, 6H).
[0318] Compound 53: 2-(11-methyl-5-octyl-3,7-dioxo-2,6-dioxa-8,11-diazatridecyl)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 53 was synthesized in 45% yield from intermediate 52d and intermediate 53a using the method used for compound 52. 1H NMR (400 MHz, CDCl3) δ 5.48 - 5.24 (m, 8H), 5.07 (t, J = 6.5 Hz, 1H), 4.20 - 4.07 (m, 6H), 2.77 (t, J = 6.5 Hz, 4H), 2.62 - 2.46 (m, 4H), 2.45 - 2.37 (m, 2H), 2.34 - 2.15 (m, 6H), 2.05 (q, J = 6.8 Hz, 8H), 1.43 - 0.97 (m, 43H), 0.95 - 0.83 (m, 9H). MS:944.8 m / z [M+H].
[0319] Example 54 - Compound 54 Intermediate 54a: Benzyl 4-hydroxydodecanoate [ka] To a solution of 5-octyltetrahydrofuran-2-one (20 g, 1.0 equiv.) in water (200–250 mL) was added NaOH (1.1 equiv.). The mixture was stirred at 20°C under a N2 atmosphere for 24 h. The reaction mixture was then concentrated under reduced pressure to remove the aqueous solvent. The resulting crude material was reconstituted in acetone (200 mL), followed by the addition of TBAB (0.05 equiv.) and BnBr (1.2–1.5 equiv.). The mixture was heated to 60°C and stirred under a N2 atmosphere for 12 h. Upon completion, the mixture was concentrated under reduced pressure, and the resulting residue was poured into saturated NaHCO3 solution. The product was extracted three times with EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to afford the product (20 g, 39%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.45 - 7.29 (m, 5H), 5.12 (s, 2H), 3.65 - 3.57 (m, 1H), 2.51 (td, J = 7.2, 2.7 Hz, 2H), 1.86 (dtd, J = 14.6, 7.4, 3.5 Hz, 1H), 1.71 (ddd, J = 14.2, 8.6, 7.1 Hz, 1H), 1.61 (d, J = 5.0 Hz, 1H), 1.52 - 1.17 (m, 17H), 0.88 (t, J = 6.7 Hz, 3H).
[0320] Intermediate 54b: Benzyl 4-(((4-nitrophenoxy)carbonyl)oxy)dodecanoate [ka] To a solution of intermediate 54a (10 g, 1.0 equiv.) in DCM (80–100 mL) was added (4-nitrophenyl)carbonochloridate (1.5 equiv.). The reaction was degassed and purged with N2 three times and cooled to 0 °C before adding pyridine (2.0 equiv.). The reaction mixture was stirred at 20 °C under a N2 atmosphere for 5 h. Upon completion, the mixture was concentrated under reduced pressure, and the resulting residue was reconstituted in hexane and filtered. The resulting filtrate was washed three times with water, and the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to afford the product (9 g, 29%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.27 (dd, J = 9.8, 7.8 Hz, 2H), 7.50 - 7.30 (m, 8H), 5.12 (d, J = 8.3 Hz, 2H), 4.87 (ddt, J = 12.2, 7.3, 4.1 Hz, 1H), 2.50 (t, J = 7.5 Hz, 2H), 2.16 - 2.06 (m, 1H), 1.99 (dq, J = 14.8, 7.5 Hz, 1H), 1.73 (ddd, J = 14.0, 12.0, 7.0 Hz, 1H), 1.63 (tt, J = 8.6, 4.5 Hz, 1H), 1.45 - 1.19 (m, 12H), 0.94 - 0.84 (m, 3H).
[0321] Intermediate 54c: Benzyl 4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoate [ka] To a solution of intermediate 54b (9 g, 1.0 equiv.) in MeCN (45–90 mL) was added N′-ethyl-N′-methyl-ethane-1,2-diamine (1.5–2.5 equiv.), pyridine (3–4 equiv.), and DMAP (2.33 g, 1.0 equiv.), and the resulting mixture was degassed and purged with N₂ three times. The reaction was heated to 70 °C and stirred under a N₂ atmosphere for 2 h. Upon completion, the mixture was concentrated to remove the solvent, and the resulting residue was diluted with EtOAc and washed three times with saturated NaHCO₃ and three times with water. The organic layer was then dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a pale yellow oil (5 g, 60%). 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.22 (m, 5H), 5.04 (s, 2H), 4.69 (s, 1H), 3.16 (q, J = 6.0 Hz, 2H), 2.45 - 2.27 (m, 6H), 2.13 (s, 3H), 1.95 - 1.71 (m, 2H), 1.40 (d, J = 7.3 Hz, 2H), 1.34 - 1.09 (m, 13H), 0.96 (t, J = 7.1 Hz, 3H), 0.80 (t, J = 6.7 Hz, 3H).
[0322] Intermediate 54d: 4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoic acid [ka] To a solution of intermediate 54c (6 g, 1.0 equiv.) in MeOH (60 mL) was added Pd / C (1.8 g, 10% w / w). The mixture was stirred under H at 20 °C for 5 h. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a brown oil (3.2 g, 67%). 1 H NMR (400 MHz, CD3OD) δ 4.76 (dp, J = 8.1, 4.1 Hz, 1H), 3.65 (dt, J = 14.0, 7.0 Hz, 1H), 3.28 - 3.10 (m, 4H), 3.07 (ddd, J = 11.3, 7.5, 2.1 Hz, 1H), 2.79 (s, 3H), 2.27 (ddd, J = 14.0, 8.2, 4.4 Hz, 1H), 2.20 - 1.99 (m, 2H), 1.86 - 1.74 (m, 1H), 1.71 - 1.56 (m, 1H), 1.48 (dq, J = 13.7, 7.6, 6.8 Hz, 1H), 1.31 (dd, J = 14.1, 7.0 Hz, 14H), 0.94 - 0.83 (m, 3H).
[0323] Compound 54: 2-(12-methyl-6-octyl-3,8-dioxo-2,7-dioxa-9,12-diazatetradecyl)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 54 was synthesized in 47% yield from intermediate 54d and intermediate 53a using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.44 - 5.26 (m, 8H), 4.75 (s, 1H), 4.12 (d, J = 6.0 Hz, 6H), 2.77 (t, J = 6.5 Hz, 4H), 2.55 - 2.34 (m, 6H), 2.34 - 2.19 (m, 6H), 2.05 (q, J = 6.8 Hz, 8H), 1.97 - 1.70 (m, 4H), 1.61 (t, J = 7.2 Hz, 10H), 1.41 - 1.00 (m, 43H), 0.94 - 0.82 (m, 9H). MS:959.1 m / z [M+H].
[0324] Example 55 - Compound 55 Intermediate 55a: Benzyl 5-hydroxytridecanoate [ka] Intermediate 55a was prepared in 25% yield from 6-octyltetrahydropyran-2-one using the method used for intermediate 54a. 1 H NMR (400 MHz, CDCl3) δ 7.34 (qt, J = 9.5, 4.5 Hz, 5H), 5.11 (s, 2H), 3.57 (s, 1H), 2.39 (t, J = 7.3 Hz, 2H), 1.85 - 1.65 (m, 2H), 1.60 - 1.11 (m, 18H), 0.98 - 0.80 (m, 3H).
[0325] Intermediate 55b: Benzyl 5-(((4-nitrophenoxy)carbonyl)oxy)tridecanoate [ka] Intermediate 55b was prepared in 37% yield from intermediate 55a using the method used for intermediate 54b. 1 H NMR (400 MHz, CDCl3) δ 8.32 - 8.24 (m, 3H), 7.39 (dddd, J = 20.3, 9.9, 5.7, 1.9 Hz, 8H), 5.12 (s, 2H), 4.87 - 4.75 (m, 1H), 2.41 (t, J = 6.8 Hz, 2H), 1.69 (dddt, J = 33.5, 23.3, 14.2, 6.0 Hz, 6H), 1.51 - 1.01 (m, 13H), 0.87 (t, J = 6.6 Hz, 3H).
[0326] Intermediate 55c: Benzyl 5-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)tridecanoate [ka] Intermediate 55c was prepared in 53% yield from intermediate 55b using the method used for intermediate 54c. 1 H NMR (400 MHz, CDCl3) δ 7.41 - 7.18 (m, 5H), 5.04 (s, 2H), 4.65 (p, J = 6.5 Hz, 1H), 3.19 (q, J = 6.4, 5.9 Hz, 2H), 2.49 - 2.23 (m, 6H), 2.16 (d, J = 29.0 Hz, 3H), 1.69 - 1.54 (m, J = 6.7 Hz, 2H), 1.44 (tt, J = 13.6, 7.1 Hz, 4H), 1.37 - 1.05 (m, 14H), 0.98 (t, J = 7.1 Hz, 3H), 0.80 (t, J = 6.6 Hz, 3H).
[0327] Intermediate 55d: 5-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)tridecanoic acid [ka] To a solution of intermediate 55c (2.2 g, 1.0 equiv.) in THF (20 mL) was added Pd / C (2.5 g, 10% w / w). The mixture was stirred under H at 20 °C for 5 h. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a brown oil (1 g, 58%). 1 H NMR (400 MHz, CDCl3) δ 12.81 (s, 1H), 5.93 - 5.72 (m, 1H), 4.61 (q, J = 7.1 Hz, 1H), 3.68 - 3.47 (m, 1H), 3.29 - 3.04 (m, 1H), 2.76 (tt, J = 17.2, 9.1 Hz, 3H), 2.40 (s, 3H), 2.34 - 2.06 (m, 2H), 1.85 - 0.87 (m, 22H), 0.80 (t, J = 6.4 Hz, 3H).
[0328] Compound 55: 2-(13-methyl-7-octyl-3,9-dioxo-2,8-dioxa-10,13-diazapentadecyl)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 55 was prepared in 58% yield from intermediate 53a and intermediate 55d using the method used for compound 52. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.27 (m, 8H), 4.73 (s, 1H), 4.12 (d, J = 6.0 Hz, 6H), 3.32 (s, 2H), 2.81 - 2.73 (m, 4H), 2.49 (d, J = 45.9 Hz, 4H), 2.43 - 2.22 (m, 10H), 2.05 (q, J = 6.8 Hz, 8H), 1.75 - 1.42 (m, 13H), 1.42 - 1.21 (m, 40H), 1.11 (s, 3H), 0.95 - 0.82 (m, 9H). MS:972.8 m / z [M+H].
[0329] Example 56 - Compound 56 Intermediate 56a: 9-(decyloxy)-9-oxononanoic acid [ka] To a mixture of nonanedioic acid (90 g, 1.0 equiv.) in THF (300–900 mL) at 0°C, DMF (0.1–0.2 equiv.) and (COCl) (1.0 equiv.) were added dropwise. The mixture was degassed and purged with N three times, and then the mixture was stirred at 20°C under a N atmosphere for 2 h. Decane-1-ol (1.0 equiv.) was added dropwise to the reaction mixture at 0°C and stirred at 20°C under a N atmosphere for 2 h. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the resulting solution was poured into water and extracted three times with EtOAc. The combined organic layers were washed with brine, then dried over NaSO, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a white solid (20 g, 6%). 1 H NMR (400 MHz, CDCl3) δ 4.05 (t, J = 6.7 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.62 (q, J = 7.3 Hz, 6H), 1.41 - 1.15 (m, 19H), 0.88 (t, J = 6.7 Hz, 3H).
[0330] Intermediate 56b: 9,9'-Didecyl O'1,O1-(2-oxopropane-1,3-diyl)di(nonanedioate) [ka] To a mixture of 1,3-dihydroxypropan-2-one (1.37 g, 0.5 equiv.), EDCI (1.0 equiv.), and DMAP (1.0 equiv.) in DCM (100–200 mL) was added Intermediate 56a (1.0 equiv.) in portions at 0°C, and the mixture was degassed and purged with N2 three times. The mixture was stirred under N2 atmosphere at 20°C for 5 h. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the resulting solution was poured into water and extracted three times with EtOAc. The combined organic layers were washed with brine, then dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a white solid (10 g, 46%). 1 H NMR (400 MHz, CDCl3) δ 4.74 (d, J = 2.1 Hz, 4H), 4.05 (t, J = 6.8 Hz, 4H), 2.41 (t, J = 7.5 Hz, 4H), 2.28 (t, J = 7.5 Hz, 4H), 1.62 (d, J = 8.8 Hz, 12H), 1.39 - 1.19 (m, 39H), 0.87 (t, J = 6.7 Hz, 6H).
[0331] Intermediate 56c: 9,9'-Didecyl O'1,O1-(2-hydroxypropane-1,3-diyl)di(nonanedioate) [ka] To a solution of intermediate 56b (13.4 g, 1.0 equiv.) in THF / toluene / water (4:1:2, 0.4 M) at 0 °C under N was added NaBH (1.5 equiv.). The mixture was stirred at 15–20 °C under N for 5 h. Upon completion, the reaction mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were washed with brine, then dried over NaSO, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a white solid (5.1 g, 38%). 1 H NMR (400 MHz, CDCl3) δ 4.15 - 4.03 (m, 5H), 3.98 (t, J = 6.8 Hz, 4H), 2.44 (d, J = 4.8 Hz, 1H), 2.25 (dt, J = 24.2, 7.5 Hz, 8H), 1.55 (q, J = 7.1 Hz, 12H), 1.22 (d, J = 22.7 Hz, 38H), 0.81 (t, J = 6.7 Hz, 6H).
[0332] Compound 56: 9,9'-Didecyl O'1,O1-(2-((3-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl)di(nonanedioate) [ka] Compound 56 was prepared in 36% yield from intermediate 52d and intermediate 56c using the method used for compound 52. 1H NMR (400 MHz, CDCl3) δ 5.24 (t, J = 5.2 Hz, 1H), 5.13 - 5.04 (m, 1H), 4.28 (ddd, J = 14.5, 11.9, 4.5 Hz, 2H), 4.14 (ddd, J = 11.9, 8.3, 5.8 Hz, 2H), 4.05 (t, J = 6.8 Hz, 4H), 3.31 (s, 2H), 2.58 (qd, J = 15.3, 6.4 Hz, 6H), 2.30 (dt, J = 10.3, 7.6 Hz, 10H), 1.61 (dd, J = 10.1, 4.1 Hz, 16H), 1.29 (dt, J = 17.6, 3.3 Hz, 54H), 0.88 (td, J = 6.9, 1.9 Hz, 9H). MS:1027.2 m / z [M+H].
[0333] Example 57 - Compound 57 Compound 57: 9,9'-Didecyl O'1,O1-(2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl)di(nonanedioate) [ka] Compound 57 was prepared in 55% yield from intermediate 54d and intermediate 56c using the method used for compound 52. 1H NMR (400 MHz, CDCl3) δ 5.28 - 5.21 (m, 1H), 4.76 (s, 1H), 4.28 (ddd, J = 11.8, 4.4, 1.2 Hz, 2H), 4.15 (ddd, J = 11.9, 5.9, 4.6 Hz, 2H), 4.05 (t, J = 6.8 Hz, 4H), 3.29 (s, 2H), 2.38 (ddd, J = 8.6, 6.9, 2.7 Hz, 5H), 2.35 - 2.12 (m, 10H), 1.98 - 1.73 (m, 3H), 1.68 - 1.37 (m, 17H), 1.29 (dt, J = 19.5, 4.1 Hz, 54H), 0.88 (td, J = 6.9, 1.9 Hz, 9H). MS:1040.8 m / z [M+H].
[0334] Example 58 - Compound 58 Compound 58: 9,9'-Didecyl O'1,O1-(2-((5-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)tridecanoyl)oxy)propane-1,3-diyl)di(nonanedioate)) [ka] Compound 58 was prepared in 60% yield from intermediate 55d and intermediate 56c using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.27 - 5.20 (m, 1H), 4.73 (s, 1H), 4.28 (ddd, J = 11.9, 4.4, 2.8 Hz, 2H), 4.13 (ddd, J = 11.9, 5.9, 2.6 Hz, 2H), 4.05 (t, J = 6.7 Hz, 4H), 3.31 (s, 2H), 2.39 - 2.09 (m, 12H), 1.62 (dq, J = 13.8, 7.2, 6.5 Hz, 22H), 1.41 - 0.99 (m, 54H), 0.88 (td, J = 6.9, 2.0 Hz, 9H). MS: 1055.0 m / z [M+H].
[0335] Example 59 - Compound 59 Intermediate 59a: 9-oxo-9-(undecyloxy)nonanoic acid [ka] Intermediate 59a was prepared in 41% yield from nonanedioic acid and undecan-1-ol using the method used for intermediate 56a. 1 H NMR (400 MHz, CDCl3) δ 4.05 (t, J = 6.7 Hz, 2H), 2.31 (dt, J = 22.6, 7.5 Hz, 4H), 1.62 (q, J = 7.1 Hz, 6H), 1.40 - 1.18 (m, 23H), 0.87 (t, J = 6.7 Hz, 3H).
[0336] Intermediate 59b: O'1,O1-(2-oxopropane-1,3-diyl)9,9'-diundecyl di(nonanedioate) [ka] Intermediate 59b was prepared in 23% yield from 1,3-dihydroxypropan-2-one and intermediate 59a using the method used for intermediate 56b. 1 H NMR (400 MHz, CDCl3) δ 3.98 (t, J = 6.7 Hz, 2H), 2.35 (t, J = 7.5 Hz, 2H), 2.22 (t, J = 7.5 Hz, 2H), 1.57 (dt, J = 18.6, 6.9 Hz, 6H), 1.36 - 1.12 (m, 23H), 0.89 - 0.76 (m, 3H).
[0337] Intermediate 59c: O'1,O1-(2-hydroxypropane-1,3-diyl)9,9'-diundecyl di(nonanedioate) [ka] Intermediate 59c was prepared in 47% yield from intermediate 59b using the method used for intermediate 56c. 1H NMR (400 MHz, CDCl3) δ 4.23 - 4.00 (m, 9H), 2.52 (d, J = 4.7 Hz, 1H), 2.31 (dt, J = 24.2, 7.5 Hz, 8H), 1.62 (q, J = 7.0 Hz, 13H), 1.29 (d, J = 23.9 Hz, 43H), 0.88 (t, J = 6.7 Hz, 6H).
[0338] Compound 59: O'1,O1-(2-((3-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl)9,9'-diundecyl di(nonanedioate) [ka] Compound 59 was prepared in 35% yield from intermediate 52d and intermediate 59c using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.23 (s, 1H), 5.08 (d, J = 6.5 Hz, 1H), 4.28 (ddd, J = 15.0, 11.9, 4.5 Hz, 2H), 4.14 (dt, J = 13.1, 6.7 Hz, 2H), 4.05 (t, J = 6.8 Hz, 4H), 2.58 (qd, J = 15.4, 6.6 Hz, 4H), 2.30 (dt, J = 10.4, 7.5 Hz, 10H), 1.60 (q, J = 7.7, 6.9 Hz, 20H), 1.43 - 0.97 (m, 58H), 0.88 (td, J = 6.9, 1.9 Hz, 9H). MS:1054.9 m / z [M+H].
[0339] Example 60 - Compound 60 Compound 60: O'1,O1-(2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl)9,9'-diundecyl di(nonanedioate) [ka] Compound 60 was prepared in 79% yield from intermediate 54d and intermediate 59c using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.25 (p, J = 5.1 Hz, 1H), 4.76 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 2.7 Hz, 2H), 4.15 (dt, J = 11.7, 5.6 Hz, 2H), 4.05 (t, J = 6.8 Hz, 4H), 2.38 (t, J = 7.5 Hz, 5H), 2.35 - 2.11 (m, 10H), 1.98 - 1.41 (m, 23H), 1.41 - 0.96 (m, 57H), 0.88 (td, J = 6.9, 1.8 Hz, 9H). MS: 1068.9 m / z [M+H].
[0340] Example 61 - Compound 61 Compound 61: O'1,O1-(2-((5-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)tridecanoyl)oxy)propane-1,3-diyl)9,9'-diundecyl di(nonanedioate) [ka] Compound 61 was prepared in 61% yield from intermediate 55d and intermediate 59c using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.29 - 5.20 (m, 1H), 4.72 (d, J = 7.4 Hz, 1H), 4.28 (ddd, J = 11.9, 4.4, 2.3 Hz, 2H), 4.14 (ddd, J = 11.9, 5.9, 2.0 Hz, 2H), 4.05 (t, J = 6.8 Hz, 4H), 2.82 - 2.13 (m, 15H), 1.82 - 1.39 (m, 21H), 1.39 - 0.97 (m, 56H), 0.88 (td, J = 6.9, 1.9 Hz, 9H). MS:1083.0 m / z [M+H].
[0341] Example 62 - Compound 62 Intermediate 62a: 1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-one [ka] To a mixture of 1,3-dihydroxypropan-2-one (50 g, 1.0 equiv.), imidazole (37.79 g, 1.0 equiv.) in THF (40 mL) at 0° C., TBSCl (83.66 g, 1.0 equiv.) was added, and the mixture was stirred for 2 h at 20° C. under a N atmosphere. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue, which was purified by column chromatography (EtOAc / hexanes) to give the product as a colorless oil (15 g, 13%).
[0342] Intermediate 62b: 1-(3-((tert-butyldimethylsilyl)oxy)-2-oxopropyl)9-undecyl nonanedioate [ka] To a mixture of intermediate 62a (10 g, 1.0 equiv.), EDCI (9.38 g, 1.0 equiv.), and DMAP (5.98 g, 1.0 equiv.) in DCM (300 mL) at 0 °C, intermediate 59a (16.76 g, 1.0 equiv.) was added, and the mixture was stirred at 20 °C under a N atmosphere for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove DCM, and the resulting residue was diluted with water. The crude material was extracted three times with EtOAc, and the combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to afford the product (11 g, 43%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.84 (s, 2H), 4.16 (s, 2H), 3.95 (t, J = 6.8 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H), 2.18 (t, J = 7.5 Hz, 2H), 1.61 - 1.48 (m, 6H), 1.30 - 1.12 (m, 22H), 0.82 (s, 9H), 0.78 (t, J = 6.8 Hz, 3H).
[0343] Intermediate 62c: 1-(3-hydroxy-2-oxopropyl)9-undecyl nonanedioate [ka] To a mixture of Intermediate 62b (11 g, 1.0 equiv.) in THF (50 mL) was added HF·pyridine (3.75 mL, 8.0 equiv.). The mixture was stirred at 20 °C under a N atmosphere for 5 h. Upon completion, the reaction mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product as a white solid (6 g, 70%). 1 H NMR (400 MHz, CDCl3) δ 4.70 (s, 2H), 4.30 (s, 2H), 3.98 (t, J = 6.8 Hz, 2H), 2.95 (s, 1H), 2.36 (t, J = 7.5 Hz, 2H), 2.22 (t, J = 7.6 Hz, 2H), 1.57 (dt, J = 20.3, 7.1 Hz, 6H), 1.37 - 1.10 (m, 22H), 0.81 (t, J = 6.7 Hz, 3H).
[0344] Intermediate 62d: 1-(3-(((9Z,12Z)-octadeca-9,12-dienoyl)oxy)-2-oxopropyl)9-undecyl nonanedioate [ka] To a solution of intermediate 62c (6 g, 1.0 equiv.) in DCM (100 mL) at 0 °C was added EDCI (1.0 equiv.) and DMAP (1.0 equiv.). The solution was degassed and purged with N2 three times, after which linoleic acid (4 mL, 1.0 equiv.) was added. The mixture was stirred at 20 °C under a N2 atmosphere for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove DCM, and the resulting residue was diluted with water. The crude material was extracted three times with EtOAc, and the combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product (7.5 g, 55%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 4.70 (s, 2H), 4.30 (s, 2H), 3.98 (t, J = 6.8 Hz, 2H), 2.95 (s, 1H), 2.36 (t, J = 7.5 Hz, 2H), 2.22 (t, J = 7.6 Hz, 2H), 1.57 (dt, J = 20.3, 7.1 Hz, 6H), 1.37 - 1.10 (m, 22H), 0.81 (t, J = 6.7 Hz, 3H).
[0345] Intermediate 62e: 1-(2-hydroxy-3-(((9Z,12Z)-octadeca-9,12-dienoyl)oxy)propyl)9-undecyl nonanedioate [ka] To a solution of intermediate 62d (7 g, 1.0 equiv.) in THF / toluene / water (4:1:2, 0.04 M) at 0 °C, NaBH (5 equiv.) was added, and the mixture was stirred at 20 °C under a N atmosphere for 5 h. Upon completion, the mixture was quenched with saturated NH Cl at 5 °C and extracted three times with EtOAc. The combined organic layers were washed twice with brine, dried over Na SO , filtered, and concentrated to give a residue. The crude residue was purified by column chromatography (EtOAc / hexanes) to give the product (6 g, 85%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.25 (m, 4H), 4.25 - 3.90 (m, 8H), 2.76 (t, J = 6.4 Hz, 2H), 2.55 (s, 1H), 2.30 (dt, J = 24.5, 7.6 Hz, 6H), 2.03 (q, J = 6.8 Hz, 4H), 1.61 (q, J = 7.0 Hz, 8H), 1.48 - 1.06 (m, 35H), 0.87 (td, J = 6.8, 3.8 Hz, 6H).
[0346] Compound 62: 1-(3-methyl-13-((((9Z,12Z)-octadeca-9,12-dienoyl)oxy)methyl)-9-octyl-7,11-dioxo-8,12-dioxa-3,6-diazatetradecan-14-yl)9-undecyl nonanedioate [ka] Compound 62 was prepared in 36% yield from intermediate 52d and intermediate 62e using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.47 - 5.28 (m, 4H), 5.23 (t, J = 5.2 Hz, 1H), 5.14 - 5.04 (m, 1H), 4.28 (ddd, J = 15.3, 11.9, 4.6 Hz, 2H), 4.14 (ddd, J = 11.8, 7.5, 5.8 Hz, 2H), 4.05 (t, J = 6.8 Hz, 2H), 3.38 (s, 2H), 2.77 (t, J = 6.5 Hz, 2H), 2.58 (qd, J = 15.2, 6.3 Hz, 5H), 2.37 - 2.22 (m, 7H), 2.05 (q, J = 6.7 Hz, 4H), 1.62 (d, J = 6.8 Hz, 14H), 1.48 - 0.97 (m, 50H), 0.97 - 0.79 (m, 9H). MS:992.3 m / z [M+H].
[0347] Example 63 - Compound 63 Compound 63: 1-(3-methyl-14-((((9Z,12Z)-octadeca-9,12-dienoyl)oxy)methyl)-9-octyl-7,12-dioxo-8,13-dioxa-3,6-diazapentadecan-15-yl)9-undecyl nonanedioate [ka] Compound 63 was prepared in 79% yield from intermediate 54d and intermediate 62e using the method used for compound 52. 1 H NMR (400 MHz, CDCl3) δ 5.44 - 5.28 (m, 4H), 5.25 (ddd, J = 5.8, 4.5, 1.4 Hz, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 4.2 Hz, 2H), 4.05 (t, J = 6.8 Hz, 2H), 3.31 (s, 2H), 2.77 (t, J = 6.7 Hz, 2H), 2.70 - 2.12 (m, 15H), 2.05 (q, J = 6.9 Hz, 4H), 1.97 - 1.72 (m, 3H), 1.61 (h, J = 6.5 Hz, 12H), 1.40 - 1.19 (m, 47H), 1.11 (s, 3H), 0.96 - 0.81 (m, 9H). MS:1006.9 m / z [M+H].
[0348] Example 64 - Compound 64 Compound 64: 1-(3-methyl-15-((((9Z,12Z)-octadeca-9,12-dienoyl)oxy)methyl)-9-octyl-7,13-dioxo-8,14-dioxa-3,6-diazahexadecan-16-yl)9-undecyl nonanedioate [ka] Compound 64 was prepared in 79% yield from intermediate 55d and intermediate 62e using the method used for compound 52. 1H NMR (400 MHz, CDCl3) δ 5.48 - 5.28 (m, 4H), 5.24 (h, J = 4.2, 4.4 Hz, 1H), 4.73 (s, 1H), 4.29 (ddd, J = 11.9, 4.4, 3.3 Hz, 2H), 4.14 (ddd, J = 11.9, 5.9, 3.1 Hz, 2H), 4.05 (t, J = 6.8 Hz, 2H), 3.31 (s, 2H), 2.77 (t, J = 6.5 Hz, 2H), 2.67 - 2.11 (m, 14H), 2.05 (q, J = 6.8 Hz, 4H), 1.73 - 1.41 (m, 17H), 1.41 - 0.95 (m, 50H), 0.94 - 0.82 (m, 9H). MS:1021.0 m / z [M+H].
[0349] Example 65 - Compound 65 Compound 65: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)tetradecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 65 was prepared in 75% yield from intermediate 39d and 1-(1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.45 - 5.28 (m, 8H), 5.25 (ddd, J = 10.2, 5.7, 4.4 Hz, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.20 - 4.11 (m, 2H), 3.45 (s, 1H), 3.21 (s, 2H), 2.82 - 2.74 (m, 4H), 2.46 - 2.24 (m, 9H), 2.05 (q, J = 6.8 Hz, 8H), 2.01 - 1.42 (m, 16H), 1.41 - 1.20 (m, 45H), 0.88 (td, J = 7.0, 4.7 Hz, 9H). MS:984.9 m / z [M+H].
[0350] Example 66 - Compound 66 Compound 66: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)tetradecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 66 was prepared in 65% yield from intermediate 39d and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.57 - 5.21 (m, 9H), 4.72 (dt, J = 12.2, 5.2 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.24 - 4.07 (m, 4H), 2.82 - 2.74 (m, 4H), 2.60 (d, J = 102.7 Hz, 5H), 2.45 - 2.38 (m, 2H), 2.38 - 2.26 (m, 4H), 2.13 - 1.73 (m, 16H), 1.73 - 1.43 (m, 9H), 1.41 - 1.16 (m, 42H), 1.04 - 0.74 (m, 9H). MS:999.4 m / z [M+H].
[0351] Example 67 - Compound 67 Compound 67: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)octanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 67 was prepared in 50% yield from intermediate 42d and 1-(1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.42 - 5.08 (m, 9H), 4.77 (s, 1H), 4.28 (ddd, J = 11.8, 4.5, 1.8 Hz, 2H), 4.20 - 4.12 (m, 2H), 3.48 (s, 1H), 3.33 (s, 2H), 2.77 (td, J = 6.1, 1.2 Hz, 4H), 2.63 - 2.23 (m, 11H), 2.05 (q, J = 6.8 Hz, 9H), 1.98 - 1.42 (m, 14H), 1.42 - 1.22 (m, 32H), 0.96 - 0.81 (m, 9H). MS: 900.0 m / z [M+H].
[0352] Example 68 - Compound 68 Compound 68: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)octanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 68 was prepared in 43% yield from intermediate 42d and 3-(pyrrolidin-1-yl)propan-1-ol using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.04 (m, 9H), 4.72 (tt, J = 7.4, 5.1 Hz, 1H), 4.40 - 4.10 (m, 6H), 2.81 - 2.74 (m, 4H), 2.54 (d, J = 58.1 Hz, 5H), 2.40 (ddd, J = 8.4, 6.8, 4.4 Hz, 2H), 2.36 - 2.27 (m, 4H), 2.11 - 1.73 (m, 16H), 1.73 - 1.43 (m, 8H), 1.43 - 1.21 (m, 31H), 0.99 - 0.77 (m, 9H). MS: 915.7 m / z [M+H].
[0353] Example 69 - Compound 69 Intermediate 69a: 4-oxononanoic acid [ka] To a mixture of 5-pentyltetrahydrofuran-2-one (50 g, 1.0 equiv.) in 3:1 EtOH / HO (500 mL) was added NaOH (2.0 equiv.) in one portion under N at 15° C. The mixture was stirred at 15° C. for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure and the resulting residue was extracted twice with DCM. The combined organic layers were dried over NaSO and concentrated to give the crude residue.
[0354] The crude residue was then reconstituted in DCM (1 L) and then DMP (3 equiv.) was added in one portion at 15° C. under N. The mixture was stirred at 15° C. for 4 h. Upon completion, the reaction was concentrated under reduced pressure and the solution was adjusted to pH=3 with 1 M HCl. The slurry was filtered and washed with HO. The resulting filter cake was dissolved in EtOAc, dried over NaSO, filtered, and concentrated to give the product as a white solid (22 g, 45%). 1H NMR (400 MHz, CDCl3) δ 2.72 (dd, J = 7.0, 5.4 Hz, 2H), 2.63 (ddd, J = 7.2, 5.9, 1.2 Hz, 2H), 2.44 (t, J = 7.4 Hz, 2H), 1.64 - 1.54 (m, 2H), 1.36 - 1.20 (m, 4H), 0.89 (t, J = 6.9 Hz, 3H).
[0355] Intermediate 69b: 2-((4-oxononanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 69b was synthesized in 74% yield from intermediate 69a and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.46 - 5.16 (m, 9H), 4.29 (dd, J = 11.9, 4.3 Hz, 2H), 4.14 (dt, J = 11.8, 6.0 Hz, 2H), 2.74 (dt, J = 21.5, 6.5 Hz, 6H), 2.59 (t, J = 6.6 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.32 (t, J = 7.6 Hz, 4H), 2.04 (dd, J = 8.6, 5.3 Hz, 8H), 1.60 (ddd, J = 14.2, 8.4, 4.8 Hz, 6H), 1.50 - 1.06 (m, 32H), 0.89 (t, J = 6.8 Hz, 9H).
[0356] Intermediate 69c: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)nonanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 69b (10 g, 1.0 equiv.) in THF (300 mL), toluene (150 mL), and HO (75 mL) was added NaBH (5.0 equiv.) at 5 °C. The mixture was stirred at 15 °C under a N atmosphere for 3 h. Upon completion, NaSO was added to the reaction mixture at 0 °C, and the resulting mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford the alcohol intermediate as a colorless oil.
[0357] The intermediate was immediately reconstituted in DCM (80 mL), followed by the addition of pyridine (1.67 equiv.) and (4-nitrophenyl)carbonochloridate (2 equiv.) at 0° C. The mixture was stirred at 0° C. under N atmosphere for 5 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue which was further purified by column chromatography to give the product as a colorless oil (4.05 g, 33%). 1 H NMR (400 MHz, CDCl3) δ 8.26 - 8.19 (m, 2H), 7.40 - 7.28 (m, 2H), 5.43 - 5.11 (m, 9H), 4.80 (tt, J = 7.5, 4.4 Hz, 1H), 4.25 (dd, J = 11.9, 4.3 Hz, 2H), 4.09 (dd, J = 11.9, 5.8 Hz, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.40 (t, J = 7.4 Hz, 2H), 2.33 - 2.16 (m, 4H), 1.97 (q, J = 6.8 Hz, 10H), 1.67 (ddt, J = 13.4, 9.9, 4.7 Hz, 1H), 1.55 (dtd, J = 15.7, 8.4, 7.4, 4.8 Hz, 5H), 1.43 - 1.16 (m, 36H), 0.83 (q, J = 6.8 Hz, 9H).
[0358] Compound 69: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)nonanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 69 was prepared in 77% yield from intermediate 69c and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1. 1 H NMR (500 MHz, CDCl3) δ 5.35 (pt, J = 8.8, 4.4 Hz, 8H), 5.25 (p, J = 5.1 Hz, 1H), 4.76 (dt, J = 12.3, 6.7 Hz, 1H), 4.28 (dd, J = 11.9, 4.5 Hz, 2H), 4.15 (dh, J = 11.4, 5.9 Hz, 2H), 3.31 (s, 2H), 2.77 (t, J = 6.8 Hz, 4H), 2.62 - 2.45 (m, 4H), 2.38 (dt, J = 9.0, 6.2 Hz, 2H), 2.30 (q, J = 13.0, 10.4 Hz, 8H), 2.05 (q, J = 7.0 Hz, 9H), 1.91 (tt, J = 9.5, 4.5 Hz, 1H), 1.81 (dt, J = 14.7, 7.8 Hz, 1H), 1.65 - 1.43 (m, 7H), 1.40 - 1.17 (m, 36H), 1.09 (q, J = 8.8, 8.2 Hz, 3H), 0.88 (q, J = 6.5 Hz, 9H). MS:902.6 m / z [M+H].
[0359] Example 70 - Compound 70 Compound 70: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)nonanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 70 was prepared in 62% yield from intermediate 69c and 1-(1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1. 1H NMR (500 MHz, CDCl3) δ 5.45 - 5.29 (m, 8H), 5.25 (p, J = 5.2 Hz, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.5 Hz, 2H), 4.15 (dq, J = 11.7, 5.8 Hz, 2H), 3.46 (d, J = 25.9 Hz, 1H), 3.19 (s, 2H), 2.77 (t, J = 6.8 Hz, 4H), 2.34 (dt, J = 31.1, 8.3 Hz, 12H), 2.05 (q, J = 7.0 Hz, 8H), 1.99 - 1.42 (m, 16H), 1.42 - 1.19 (m, 35H), 0.88 (q, J = 6.8 Hz, 9H). MS:914.4 m / z [M+H].
[0360] Example 71 - Compound 71 Compound 71: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)nonanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 71 was prepared in 78% yield from intermediate 69c and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1H NMR (500 MHz, chloroform-d) δ 5.50 - 5.28 (m, 8H), 5.25 (p, J = 5.1 Hz, 1H), 4.72 (tt, J = 7.8, 4.5 Hz, 1H), 4.36 - 4.26 (m, 2H), 4.23 - 4.11 (m, 4H), 2.77 (t, J = 6.7 Hz, 4H), 2.41 (dt, J = 15.0, 9.0 Hz, 2H), 2.31 (t, J = 7.5 Hz, 5H), 2.05 (q, J = 6.9 Hz, 8H), 2.00 - 1.75 (m, 9H), 1.72 - 1.48 (m, 8H), 1.43 - 1.20 (m, 35H), 1.00 - 0.75 (m, 9H). MS:929.4 m / z [M+H].
[0361] Example 72 - Compound 72 Compound 72: 2-((4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)nonanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 72 was prepared in 72% yield from intermediate 69c and 2-(pyrrolidin-1-yl)ethan-1-amine using the method used in Example 1. 1H NMR (500 MHz, CDCl3) δ 5.49 (s, 1H), 5.34 (dtt, J = 18.0, 6.9, 3.9 Hz, 8H), 5.25 (p, J = 5.1 Hz, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (dt, J = 11.6, 5.4 Hz, 2H), 3.40 - 3.27 (m, 2H), 2.80 - 2.50 (m, 11H), 2.45 - 2.35 (m, 2H), 2.31 (t, J = 7.6 Hz, 5H), 2.05 (q, J = 7.0 Hz, 9H), 1.97 - 1.67 (m, 8H), 1.60 (q, J = 7.3 Hz, 8H), 1.33 (d, J = 26.5 Hz, 36H), 0.88 (q, J = 6.5 Hz, 9H). MS:914.7 m / z [M+H].
[0362] Example 73 - Compound 73 Intermediate 73a: 4-oxoundecanoic acid [ka] To a solution of 5-heptyltetrahydrofuran-2-one (20 g, 1.0 equiv.) in 2:1 EtOH / HO (400 mL) was added NaOH (1.1 equiv.). The mixture was degassed and purged with N three times, after which the mixture was stirred under a N atmosphere at 20 °C for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove the solvent, and 1 N HCl was added to the resulting residue until the pH was 3. The resulting slurry was filtered, and the filter cake was concentrated under reduced pressure to provide a residue.
[0363] The resulting residue was reconstituted in DCM (200 mL), followed by the addition of DMP (3 equiv.). The mixture was stirred at 20° C. for 5 hours. Upon completion, the mixture was concentrated under reduced pressure, and the resulting residue was diluted with HO and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over NaSO, filtered, and concentrated. The crude material was purified by column chromatography to afford the product as a white solid (10 g, 46%).1 H NMR (400 MHz, CDCl3) δ 2.65 (dd, J = 7.0, 5.3 Hz, 2H), 2.56 (t, J = 6.8 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H), 1.51 (q, J = 7.2 Hz, 2H), 1.27 - 1.13 (m, 8H), 0.86 - 0.76 (m, 3H).
[0364] Intermediate 73b: 2-((4-oxoundecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 73b was synthesized in 42% yield from intermediate 73a and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.28 (dddd, J = 12.3, 10.7, 8.7, 5.5 Hz, 8H), 5.21 - 5.15 (m, 1H), 4.22 (dd, J = 11.9, 4.3 Hz, 2H), 4.13 - 4.05 (m, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.64 (t, J = 6.5 Hz, 2H), 2.52 (t, J = 6.5 Hz, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.25 (t, J = 7.6 Hz, 4H), 2.02 - 1.95 (m, 8H), 1.53 (h, J = 7.0 Hz, 6H), 1.33 - 1.16 (m, 37H), 0.81 (td, J = 6.8, 4.7 Hz, 9H).
[0365] Intermediate 73c: 2-((4-(((4-nitrophenoxy)carbonyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 73b (25 g, 1.0 equiv.) in THF (500 mL), toluene (125 mL), and HO (250 mL) at 0 °C under N was added NaBH (5.0 equiv.). The mixture was stirred at 5 °C under N for 1 h. Upon completion, the residue was poured into saturated NH Cl solution and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na SO , filtered, and concentrated in vacuo. The residue was purified by column chromatography to give the intermediate alcohol as a colorless residue.
[0366] The intermediate was immediately reconstituted in DCM (100 mL), followed by the addition of pyridine (2 equiv.) and (4-nitrophenyl)carbonochloridate (2 equiv.) at 0 °C. The mixture was stirred at 20 °C under a N atmosphere for 5 h, after which the reaction mixture was concentrated under reduced pressure. The resulting residue was diluted with hexane and filtered. The filtrate was washed three times with water and once with brine, then dried over NaSO, filtered, and concentrated. Purification by column chromatography afforded the product as a colorless oil (5.2 g, 40%). 1H NMR (400 MHz, chloroform-d) δ 8.28 (d, J = 8.8 Hz, 2H), 7.41 (dd, J = 8.6, 6.1 Hz, 2H), 5.33 (tdd, J = 23.5, 11.3, 6.1 Hz, 9H), 4.87 (tt, J = 7.7, 4.6 Hz, 1H), 4.32 (dd, J = 12.0, 4.4 Hz, 2H), 4.16 (dd, J = 12.0, 5.8 Hz, 2H), 2.77 (t, J = 6.4 Hz, 4H), 2.47 (t, J = 7.5 Hz, 2H), 2.39 - 2.25 (m, 4H), 2.04 (q, J = 6.9 Hz, 10H), 1.79 - 1.55 (m, 7H), 1.48 - 1.15 (m, 36H), 0.89 (t, J = 6.7 Hz, 9H).
[0367] Compound 73: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 73 was prepared in 53% yield from intermediate 73c and (2-aminoethyl)(ethyl)methylamine using the method used in Example 1. 1 H NMR (500 MHz, CDCl3) δ 5.47 - 5.27 (m, 8H), 5.24 (q, J = 5.1 Hz, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (dt, J = 11.6, 5.4 Hz, 2H), 3.31 (s, 2H), 2.77 (t, J = 6.7 Hz, 4H), 2.61 - 2.35 (m, 6H), 2.31 (t, J = 7.6 Hz, 7H), 2.05 (q, J = 7.0 Hz, 8H), 1.90 (q, J = 11.5, 9.0 Hz, 1H), 1.81 (dt, J = 14.5, 7.6 Hz, 1H), 1.65 - 1.41 (m, 9H), 1.39 - 1.19 (m, 38H), 1.10 (s, 3H), 0.88 (q, J = 7.0 Hz, 9H). MS:930.3 m / z [M+H].
[0368] Example 74 - Compound 74 Compound 74: 2-((4-((((1-methylpyrrolidin-2-yl)methyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 74 was prepared in 55% yield from intermediate 73c and 1-(1-methylpyrrolidin-2-yl)methanamine using the method used in Example 1.1 H NMR (500 MHz, CDCl3) δ 5.34 (dtt, J = 18.0, 6.9, 3.8 Hz, 8H), 5.25 (p, J = 5.2 Hz, 1H), 4.81 - 4.72 (m, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (dt, J = 11.7, 5.2 Hz, 2H), 3.43 (s, 1H), 3.17 (s, 2H), 2.77 (t, J = 6.8 Hz, 4H), 2.34 (dt, J = 31.2, 8.3 Hz, 11H), 2.05 (q, J = 7.0 Hz, 8H), 1.99 - 1.43 (m, 16H), 1.43 - 1.13 (m, 39H), 0.88 (q, J = 7.7, 7.2 Hz, 9H). MS:942.8 m / z [M+H].
[0369] Example 75 - Compound 75 Compound 75: 2-((4-(((3-(pyrrolidin-1-yl)propoxy)carbonyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 75 was prepared in 73% yield from intermediate 73c and 3-(pyrrolidin-1-yl)propan-1-ol using the method described in Example 1. 1H NMR (500 MHz, CDCl3) δ 5.46 - 5.28 (m, 8H), 5.25 (p, J = 5.1 Hz, 1H), 4.72 (tt, J = 7.8, 4.5 Hz, 1H), 4.29 (dd, J = 11.9, 4.4 Hz, 2H), 4.22 - 4.11 (m, 4H), 2.77 (t, J = 6.8 Hz, 4H), 2.45 - 2.37 (m, 2H), 2.31 (t, J = 7.5 Hz, 4H), 2.05 (q, J = 7.0 Hz, 8H), 2.01 - 1.91 (m, 3H), 1.91 - 1.78 (m, 5H), 1.67 - 1.50 (m, 9H), 1.39 - 1.22 (m, 39H), 0.88 (q, J = 6.6 Hz, 9H). MS:957.4 m / z [M+H].
[0370] Example 76 - Compound 76 Compound 76: 2-((4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 76 was prepared from intermediate 73c and 2-(pyrrolidin-1-yl)ethan-1-amine using the method used in Example 1 in 81% yield. 1H NMR (500 MHz, CDCl3) δ 5.56 (s, 1H), 5.46 - 5.28 (m, 8H), 5.25 (p, J = 5.2 Hz, 1H), 4.76 (s, 1H), 4.28 (dd, J = 11.9, 4.4 Hz, 2H), 4.15 (dt, J = 11.7, 5.5 Hz, 2H), 3.43 - 3.31 (m, 2H), 2.77 (t, J = 6.7 Hz, 11H), 2.45 - 2.35 (m, 2H), 2.31 (t, J = 7.6 Hz, 4H), 2.05 (q, J = 7.0Hz, 8H), 1.97 - 1.74 (m, 7H), 1.69 - 1.43 (m, 8H), 1.43 - 1.09 (m, 39H), 0.88 (q, J = 7.0 Hz, 9H). MS:943.2 m / z [M+H].
[0371] Example 77 - Compound 77 Compound 77: 2-((4-(((2-(azetidin-1-yl)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 77 was prepared from intermediate 40d and 2-(azetidin-1-yl)ethan-1-amine using the method described in Example 1 in 36% yield. 1H NMR (400 MHz, CDCl3) δ 5.45 - 5.29 (m, 8H), 5.25 (h, J = 4.6, 4.1 Hz, 1H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 1.9 Hz, 2H), 4.15 (ddt, J = 11.9, 5.8, 3.6 Hz, 2H), 3.74 - 3.54 (m, 3H), 3.48 - 3.38 (m, 1H), 3.31 (d, J = 6.3 Hz, 1H), 2.86 (s, 1H), 2.81 - 2.73 (m, 4H), 2.41 - 2.26 (m, 7H), 2.05 (q, J = 6.8 Hz, 8H), 1.97 - 1.87 (m, 2H), 1.87 - 1.77 (m, 2H), 1.60 (d, J = 7.2 Hz, 8H), 1.44 - 1.15 (m, 37H), 0.96 - 0.84 (m, 9H). MS:914.7 m / z [M+H].
[0372] Example 78 - Compound 78 Compound 78: 2-((4-(((2-(piperidin-1-yl)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 78 was prepared in 60% yield from intermediate 40d and 2-(piperidin-1-yl)ethan-1-amine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.47 - 5.28 (m, 8H), 5.25 (h, J = 4.8 Hz, 1H), 4.76 (s, 1H), 4.28 (ddd, J = 11.9, 4.4, 1.3 Hz, 2H), 4.15 (dt, J = 11.8, 5.7 Hz, 2H), 3.42 (s, 2H), 2.80 - 2.72 (m, 4H), 2.44 (d, J = 6.7 Hz, 2H), 2.39 (ddd, J = 8.6, 6.9, 2.5 Hz, 2H), 2.36 - 2.27 (m, 5H), 2.05 (q, J = 6.9 Hz, 8H), 1.95 - 1.41 (m, 18H), 1.41 - 1.20 (m, 37H), 0.96 - 0.81 (m, 9H). MS:942.4 m / z [M+H].
[0373] Example 79 - Compound 79 Compound 79: 2-((4-(((2-methyl-1-(pyrrolidin-1-yl)propan-2-yl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 79 was prepared in 48% yield from intermediate 40d and 2-methyl-1-(pyrrolidin-1-yl)propan-2-amine using the method described in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.21 (m, 9H), 4.72 (s, 1H), 4.28 (ddt, J = 11.9, 4.4, 2.2 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 4.6 Hz, 2H), 2.86 - 2.49 (m, 8H), 2.39 (td, J = 8.2, 7.4, 2.2 Hz, 1H), 2.31 (td, J = 7.6, 1.8 Hz, 4H), 2.05 (q, J = 6.8 Hz, 8H), 2.00 - 1.45 (m, 17H), 1.45 - 1.03 (m, 41H), 0.98 - 0.77 (m, 9H). MS:956.5 m / z [M+H].
[0374] Example 80 - Compound 80 Intermediate 80a: (5-methylhexyl)magnesium bromide [ka] To a solution of Mg (1.63 g, 1.2 equiv.) and I2 (0.1 equiv.) in THF (100 mL) was added 1-bromo-5-methyl-hexane (1.0 equiv.) at 15 °C. The mixture was stirred at 40 °C under a N2 atmosphere for 2 h. No further workup was performed. The reaction mixture was used directly in the next step. Bromo(5-methylhexyl)magnesium was obtained as a gray THF solution.
[0375] Intermediate 80b: Ethyl 9-methyl-4-oxodecanoate [ka] To a solution of ethyl 4-chloro-4-oxobutanoate (16 g, 1.0 equiv.) in THF (150 mL) was added CuI (1.0 equiv.) and Intermediate 80a (2.0 equiv.) at −78° C. The mixture was stirred at −78° C. under a N atmosphere for 2 hours. Upon completion, the reaction mixture was quenched with water and extracted three times with EtOAc. The combined organic layers were washed twice with brine, dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The crude residue was purified by column chromatography to give the product as a colorless oil (10 g, 45% yield). 1 H NMR (400 MHz, CDCl3) δ 4.06 (q, J = 7.1 Hz, 2H), 2.64 (t, J = 6.6 Hz, 2H), 2.50 (t, J = 6.8 Hz, 2H), 2.38 (t, J = 7.5 Hz, 2H), 1.55 - 1.45 (m, 3H), 1.28 - 1.15 (m, 6H), 1.15 - 1.06 (m, 2H), 0.79 (d, J = 6.6 Hz, 6H).
[0376] Intermediate 80c: 9-methyl-4-oxodecanoic acid [ka] To a solution of intermediate 80b (10 g, 1.0 equiv.) in EtOH (100 mL) was added KOH (3.0 equiv.) at 20° C. The mixture was stirred at 50° C. under a N atmosphere for 12 h. The reaction was then concentrated to remove EtOH, and the pH was adjusted to 5.5 with HCl (1 M). The resulting mixture was diluted with water and extracted twice with EtOAc. The combined organic layers were washed twice with brine, dried over NaSO, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography to give the product as a white solid (4.4 g, 50%). 1H NMR (400 MHz, CDCl3) δ 2.71 (t, J = 6.8 Hz, 2H), 2.63 (ddd, J = 7.0, 5.8, 1.1 Hz, 2H), 2.44 (t, J = 7.5 Hz, 2H), 1.53 (dq, J = 19.8, 7.0, 6.6 Hz, 3H), 1.31 - 1.24 (m, 2H), 1.16 (dt, J = 8.6, 6.7 Hz, 2H), 0.85 (d, J = 6.6 Hz, 6H).
[0377] Intermediate 80d: 2-((9-methyl-4-oxodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 80d was synthesized in 40% yield from intermediate 80c and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.45 - 5.28 (m, 8H), 5.24 (p, J = 5.1 Hz, 1H), 4.28 (dd, J = 11.9, 4.3 Hz, 2H), 4.14 (dd, J = 11.9, 5.9 Hz, 2H), 2.76 (t, J = 6.4 Hz, 4H), 2.71 (t, J = 6.5 Hz, 2H), 2.59 (t, J = 6.5 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.6 Hz, 4H), 2.04 (q, J = 6.8 Hz, 8H), 1.67 - 1.50 (m, 8H), 1.39 - 1.21 (m, 29H), 1.22 - 1.12 (m, 3H), 0.93 - 0.82 (m, 12H).
[0378] Intermediate 80e: 2-((9-methyl-4-(((4-nitrophenoxy)carbonyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 80d (1.5 g, 1.0 equiv.) in THF (30 mL), toluene (15 mL), and HO (7.5 mL) was added NaBH (5.0 equiv.) at 0 °C. The mixture was stirred at 5 °C for 5 h. Upon complete reduction, the reaction mixture was partitioned between THF and HO, and the resulting organic phase was separated, dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the intermediate alcohol as a yellow oil.
[0379] The resulting intermediate was immediately reconstituted in DCM (10 mL), followed by the addition of pyridine (2.0 equiv.) and (4-nitrophenyl)carbonochloridate (2.0 equiv.) at 0° C. The mixture was stirred at 0° C. for 5 h. The reaction mixture was then filtered and concentrated under reduced pressure to give the crude residue, which was purified by column chromatography to give the product as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.25 - 8.18 (m, 2H), 7.38 - 7.28 (m, 2H), 5.39 - 5.15 (m, 9H), 4.80 (tt, J = 7.1, 4.3 Hz, 1H), 4.25 (dd, J = 12.0, 4.3 Hz, 2H), 4.13 - 4.04 (m, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.40 (dd, J = 8.3, 6.6 Hz, 2H), 2.33 - 2.19 (m, 4H), 2.05 - 1.85 (m, 10H), 1.67 (ddt, J = 14.6, 9.4, 4.8 Hz, 1H), 1.52 (dddq, J = 32.6, 26.2, 13.2, 6.6, 6.1 Hz, 8H), 1.37 - 1.17 (m, 30H), 1.11 (dt, J = 9.0, 6.5 Hz, 2H), 0.94 - 0.66 (m, 12H).
[0380] Compound 80: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)-9-methyldecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 80 was prepared in 68% yield from intermediate 80e and (2-aminoethyl)(ethyl)methylamine using the method used in Example 1. 1H NMR (400 MHz, CDCl3) δ 5.43 - 5.22 (m, 9H), 4.76 (s, 1H), 4.28 (ddd, J = 12.0, 4.5, 1.5 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 4.7 Hz, 2H), 3.37 (s, 3H), 2.77 (td, J = 6.0, 1.3 Hz, 4H), 2.39 (ddd, J = 8.4, 6.9, 2.4 Hz, 2H), 2.35 - 2.28 (m, 5H), 2.05 (q, J = 6.8 Hz, 8H), 1.86 (ddt, J = 37.3, 14.4, 7.1 Hz, 3H), 1.77 - 1.38 (m, 12H), 1.39 - 1.19 (m, 34H), 1.15 (d, J = 6.7 Hz, 3H), 0.94 - 0.79 (m, 12H). MS:929.9 m / z [M+H].
[0381] Example 81 - Compound 81 Intermediate 81a: 1-Bromo-6-methylheptane [ka] To a solution of PPh3 (66.97 g, 1.33 equiv.) in DCM (300 mL) was added Br2 (1.33 equiv.) at 0 °C. Then, 6-methylheptan-1-ol (1.0 equiv.) was added in one portion. The mixture was stirred at 0 °C under a N2 atmosphere for 2 h. Upon completion, the reaction mixture was diluted with HO and the organic phase was separated. The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. Pentane was added, and the precipitated triphenylphosphine oxide was removed by filtration. The organic layer was concentrated under reduced pressure to give a residue that was purified by column chromatography to give the product as a yellow oil (30 g, 81%). 1H NMR (400 MHz, CDCl3) δ 3.41 (td, J = 6.9, 1.1 Hz, 2H), 1.91 - 1.79 (m, 2H), 1.59 - 1.49 (m, 1H), 1.45 - 1.35 (m, 2H), 1.34 - 1.25 (m, 3H), 1.21 - 1.12 (m, 2H), 0.86 (dd, J = 6.6, 1.1 Hz, 6H).
[0382] Intermediate 81b: (6-methylheptyl)magnesium bromide [ka] To a solution of Mg (4.53 g, 1.2 equiv.) and I2 (0.1 equiv.) in THF (300 mL) was added Intermediate 81a (1.0 equiv.) at 15 °C. The mixture was stirred at 40 °C under a N2 atmosphere for 2 h. No further workup was performed. The reaction mixture was used directly in the next step. Bromo(6-methylheptyl)magnesium was obtained as a gray THF solution.
[0383] Intermediate 81c: Ethyl 10-methyl-4-oxoundecanoate [ka] To a solution of ethyl 4-chloro-4-oxobutanoate (25 g, 1.0 equiv.) and CuI (1.0 equiv.) in THF (200 mL) was added Intermediate 81b (1.0 equiv.) at −78° C. The mixture was stirred at −78° C. under a N atmosphere for 5 hours. The reaction mixture was then diluted with water and extracted three times with EtOAc. The combined organic layer was separated, washed twice with brine, dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a yellow oil (10 g, 27%). 1H NMR (400 MHz, CDCl3) δ 4.06 (q, J = 7.1 Hz, 2H), 2.64 (t, J = 6.6 Hz, 2H), 2.50 (t, J = 6.7 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H), 1.51 (q, J = 7.5 Hz, 2H), 1.43 (dq, J = 13.2, 6.6 Hz, 1H), 1.26 - 1.15 (m, 7H), 1.14 - 1.04 (m, 2H), 0.79 (d, J = 6.6 Hz, 6H).
[0384] Intermediate 81d: 10-methyl-4-oxoundecanoic acid [ka] A mixture of intermediate 81c (10 g, 1.0 equiv.) and KOH (3.0 equiv.) in EtOH (50 mL) was degassed and purged with N three times, and then the mixture was stirred at 50 °C under a N atmosphere for 12 h. The mixture was concentrated to remove EtOH and then adjusted to pH 5.5 with HCl (1 M). The reaction mixture was then diluted with water and extracted three times with EtOAc. The combined organic layers were separated, washed twice with brine, dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a white solid (4 g, 45%). 1 H NMR (400 MHz, CDCl3) δ 2.65 (t, J = 6.1 Hz, 2H), 2.56 (ddd, J = 7.1, 5.9, 1.2 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H), 1.51 (q, J = 7.3 Hz, 2H), 1.42 (dt, J = 13.2, 6.6 Hz, 1H), 1.20 (tt, J = 4.9, 2.5 Hz, 4H), 1.14 - 1.05 (m, 2H), 0.79 (d, J = 6.6 Hz, 6H).
[0385] Intermediate 81e: 2-((10-methyl-4-oxoundecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Intermediate 81e was synthesized in 40% yield from intermediate 81d and intermediate 1c using the method used for intermediate 1d. 1 H NMR (400 MHz, CDCl3) δ 5.39 - 5.20 (m, 8H), 5.17 (ddd, J = 10.1, 5.8, 4.3 Hz, 1H), 4.21 (dd, J = 11.9, 4.3 Hz, 2H), 4.07 (dd, J = 11.9, 5.9 Hz, 2H), 2.69 (t, J = 6.4 Hz, 4H), 2.64 (t, J = 6.5 Hz, 2H), 2.52 (t, J = 6.5 Hz, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.24 (t, J = 7.5 Hz, 4H), 1.97 (q, J = 6.8 Hz, 8H), 1.66 - 1.46 (m, 7H), 1.33 - 1.13 (m, 35H), 1.08 (q, J = 6.9 Hz, 2H), 0.84 - 0.77 (m, 12H).
[0386] Intermediate 81f: 2-((10-methyl-4-(((4-nitrophenoxy)carbonyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 81e (6 g, 1.0 equiv.) in THF (120 mL), toluene (30 mL), and HO (60 mL) was added NaBH (5.0 equiv.) at 0 °C. The mixture was stirred at 5 °C for 5 h. Upon complete reduction, the reaction mixture was partitioned between THF and HO, and the resulting organic phase was separated, dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the intermediate alcohol as a yellow oil.
[0387] The resulting intermediate was immediately reconstituted in DCM (10 mL), followed by the addition of pyridine (2.0 equiv.) and (4-nitrophenyl)carbonochloridate (2.0 equiv.) at 0° C. The mixture was stirred at 0° C. for 1 h. The reaction mixture was then filtered and concentrated under reduced pressure to give the crude residue, which was purified by column chromatography to give the product as a yellow oil (4.3 g, 59%). 1H NMR (400 MHz, CDCl3) δ 8.27 - 8.16 (m, 2H), 7.37 - 7.29 (m, 2H), 5.43 - 5.12 (m, 9H), 4.80 (s, 1H), 4.25 (dd, J = 11.9, 4.4 Hz, 2H), 4.14 - 4.06 (m, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.40 (t, J = 7.5 Hz, 2H), 2.24 (td, J = 7.5, 4.1 Hz, 4H), 2.05 - 1.88 (m, 9H), 1.71 - 1.62 (m, 1H), 1.62 - 1.47 (m, 6H), 1.45 - 0.97 (m, 35H), 0.89 - 0.66 (m, 12H).
[0388] Compound 81: 2-((4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)-10-methylundecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 81 was prepared in 85% yield from intermediate 81f and (2-aminoethyl)(ethyl)methylamine using the method used in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.42 - 5.21 (m, 9H), 4.76 (s, 1H), 4.33 - 4.23 (m, 2H), 4.15 (dt, J = 11.8, 5.7 Hz, 2H), 3.38 (d, J = 40.4 Hz, 3H), 2.77 (t, J = 6.5 Hz, 4H), 2.38 (t, J = 7.7 Hz, 2H), 2.32 (td, J = 7.6, 1.1 Hz, 5H), 2.05 (q, J = 6.7 Hz, 8H), 1.96 - 1.78 (m, 3H), 1.68 - 1.43 (m, 12H), 1.43 - 1.20 (m, 36H), 1.14 (d, J = 6.6 Hz, 3H), 0.93 - 0.80 (m, 12H). MS:944.5 m / z [M+H].
[0389] Example 82 - Compound 82 Compound 82: 2-((9-methyl-4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 82 was prepared from intermediate 80e and 2-(pyrrolidin-1-yl)ethan-1-amine using the method described in Example 1 in 86% yield. 1H NMR (400 MHz, CDCl3) δ 5.87 (s, 1H), 5.43 - 5.23 (m, 9H), 4.76 (s, 1H), 4.28 (ddd, J = 12.0, 4.5, 2.6 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 4.6 Hz, 2H), 3.52 - 3.42 (m, 2H), 2.94 (s, 5H), 2.82 - 2.75 (m, 4H), 2.39 (ddd, J = 8.4, 6.9, 2.0 Hz, 2H), 2.36 - 2.29 (m, 4H), 2.05 (q, J = 6.8 Hz, 8H), 2.01 - 1.76 (m, 7H), 1.67 - 1.45 (m, 8H), 1.40 - 1.21 (m, 33H), 1.15 (s, 2H), 0.93 - 0.81 (m, 12H). MS:942.3 m / z [M+H].
[0390] Example 83 - Compound 83 Compound 83: 2-((10-methyl-4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)undecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 83 was prepared from intermediate 81f and 2-(pyrrolidin-1-yl)ethan-1-amine using the method used in Example 1 in 87% yield. 1H NMR (400 MHz, CDCl3) δ 5.99 (s, 1H), 5.45 - 5.19 (m, 9H), 4.76 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 3.2 Hz, 2H), 4.15 (ddd, J = 11.9, 5.8, 4.7 Hz, 2H), 3.50 (d, J = 6.3 Hz, 2H), 2.99 (s, 5H), 2.81 - 2.73 (m, 4H), 2.39 (ddd, J = 8.2, 6.9, 1.8 Hz, 2H), 2.35 - 2.28 (m, 4H), 2.05 (q, J = 6.8 Hz, 8H), 2.02 - 1.77 (m, 7H), 1.66 - 1.43 (m, 8H), 1.41 - 1.20 (m, 35H), 1.14 (d, J = 6.7 Hz, 2H), 0.95 - 0.81 (m, 12H). MS:956.5 m / z [M+H].
[0391] Example 84 - Compound 84 Compound 84: 2-((4-(((1-methylazetidin-3-yl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 84 was prepared in 87% yield from intermediate 40d and 1-methylazetidin-3-amine using the method used in Example 1. 1H NMR (500 MHz, CDCl3) δ 5.44 - 5.28 (m, 8H), 5.23 (p, J = 5.2 Hz, 1H), 4.77 (d, J = 7.0 Hz, 1H), 4.46 (s, 1H), 4.28 (dt, J = 10.9, 5.2 Hz, 2H), 4.16 (ddd, J = 8.7, 5.6, 2.8 Hz, 2H), 3.99 (s, 2H), 3.81 (s, 2H), 2.77 (t, J = 6.7 Hz, 4H), 2.65 (s, 2H), 2.40 - 2.29 (m, 6H), 2.05 (q, J = 7.0 Hz, 8H), 1.93 (dtd, J = 15.1, 7.6, 3.8 Hz, 1H), 1.83 (q, J = 7.4 Hz, 1H), 1.66 - 1.44 (m, 7H), 1.40 - 1.17 (m, 37H), 0.88 (q, J = 7.0 Hz, 9H). MS:900.4 m / z [M+H].
[0392] Example 85 - Compound 85 Intermediate 85a: Benzyl 4-hydroxyoctanoate [ka] To a solution of 5-butyltetrahydrofuran-2-one (20 g, 1.0 equiv.) in HO (50 mL) was added NaOH (5.63 g, 1.0 equiv.). The mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove the HO.
[0393] The resulting residue was reconstituted in DMF (100 mL), and then BnBr (14.08 g, 1.0 equiv.) was added. The mixture was stirred at 25° C. for 2 hours. The reaction mixture was then concentrated under reduced pressure to remove DMF. The residue was diluted with HO (150 mL), extracted three times with EtOAc, dried over NaSO, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a yellow oil (15 g, 43%).
[0394] Intermediate 85b: Benzyl 4-(((4-nitrophenoxy)carbonyl)oxy)octanoate [ka] To a mixture of intermediate 85a (15 g, 1.0 equiv.) in DCM (150 mL) was added (4-nitrophenyl)carbonochloridate (32.21 g, 5.0 equiv.) under N2, and then pyridine (5.16 mL, 2.0 equiv.) was added to the mixture. The reaction mixture was stirred at 20 °C under N2 atmosphere for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with hexane and filtered. The filtrate was washed three times with H2O. The organic layer was washed once with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product as a colorless oil (12 g, 48%). 1 H NMR (400 MHz, CDCl3) δ 8.31 - 8.17 (m, 2H), 7.42 - 7.30 (m, 6H), 5.13 (s, 2H), 4.87 (qd, J = 7.6, 4.8 Hz, 1H), 2.50 (t, J = 7.4 Hz, 2H), 2.11 (dtd, J = 15.3, 7.8, 4.0 Hz, 1H), 2.00 (dt, J = 14.7, 7.6 Hz, 1H), 1.82 - 1.69 (m, 1H), 1.63 (ddt, J = 14.3, 8.5, 5.0 Hz, 1H), 1.45 - 1.27 (m, 4H), 1.01 - 0.83 (m, 3H).
[0395] Intermediate 85c: Benzyl 4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)octanoate [ka] To a solution of intermediate 85b (4 g, 2.0 equiv.) and 2-pyrrolidin-1-ylethanamine (550 mg, 1.0 equiv.) in MeCN (20 mL) was added DMAP (59 mg, 0.1 equiv.) followed by pyridine (1.17 mL, 3.0 equiv.) at 0° C. The mixture was stirred at 20° C. under a N atmosphere for 12 hours. The reaction mixture was concentrated under reduced pressure to remove MeCN (20 mL). The residue was diluted with HO and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product (1.8 g, 48%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.32 - 7.23 (m, 5H), 5.03 (d, J = 10.2 Hz, 3H), 4.69 (s, 1H), 3.23 (dq, J = 18.7, 5.9 Hz, 3H), 2.70 (s, 2H), 2.60 - 2.40 (m, 7H), 2.34 (td, J = 8.3, 7.6, 2.7 Hz, 2H), 1.87 (d, J = 10.5 Hz, 1H), 1.70 (t, J = 3.8 Hz, 6H), 1.44 (d, J = 24.4 Hz, 2H), 1.22 (q, J = 11.9 Hz, 4H), 0.80 (t, J = 4.2 Hz, 3H).
[0396] Compound 85: 2-((4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)octanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 85c (1.8 g, 1.0 equiv.) in THF (9 mL) was added Pd / C (0.5 g, 10% w / w) under an Ar atmosphere. After purging the mixture with H three times, the mixture was stirred under an H atmosphere (15 Psi) at 20 °C for 5 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to remove THF.
[0397] The resulting crude material was dissolved in DCM (10 mL), and then DMAP (65 mg, 0.16 equiv.), DIPEA (1.74 mL, 3.0 equiv.), and EDCI (638 mg, 1.0 equiv.) were added. Intermediate 1c (2.05 g, 1.0 equiv.) was then added at 0° C. The mixture was stirred at 20° C. under a N atmosphere for 16 hours. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was diluted with H2O and extracted twice with EtOAc. The combined organic layers were concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product as a colorless oil (1.1 g, 50%). 1 H NMR (400 MHz, CDCl3) δ 5.39 - 5.21 (m, 7H), 5.18 (p, J = 5.0 Hz, 1H), 5.09 (s, 1H), 4.76 - 4.65 (m, 1H), 4.22 (dd, J = 12.0, 4.4 Hz, 2H), 4.08 (ddd, J = 11.9, 5.9, 3.4 Hz, 2H), 3.21 (q, J = 5.9 Hz, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.51 (t, J = 6.1 Hz, 2H), 2.43 (d, J = 5.8 Hz, 4H), 2.32 (ddd, J = 8.9, 6.6, 3.9 Hz, 2H), 2.25 (t, J = 7.6 Hz, 4H), 1.98 (q, J = 6.9 Hz, 7H), 1.91 - 1.66 (m, 6H), 1.63 - 1.35 (m, 8H), 1.25 (tq, J = 7.2, 4.6, 3.6 Hz, 30H), 0.82 (t, J = 6.7 Hz, 9H). MS:900.4 m / z [M+H].
[0398] Example 86 - Compound 86 Intermediate 86a: Ethyl 1-nonanoylcyclopropane-1-carboxylate [ka] To a solution of diethyl cyclopropane-1,1-carboxylate (15 g, 1.0 equiv.) in THF (200 mL) was added a solution of bromo(octyl)magnesium (2 M, 40.28 mL, 1.0 equiv.) dropwise at −78° C. under N2. The reaction mixture was stirred at −78° C. under N2 for 5 h. The reaction mixture was poured into aqueous NH4Cl. The aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated in vacuo. The residue, along with another batch, was purified by column chromatography to give the product (20 g, 48%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 4.13 (q, J = 7.1 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H), 1.57 - 1.49 (m, 2H), 1.35 (s, 4H), 1.21 (dd, J = 8.7, 5.5 Hz, 16H), 0.81 (t, J = 6.9 Hz, 6H).
[0399] Intermediate 86b: 1-nonanoylcyclopropane-1-carboxylic acid [ka] To a solution of intermediate 86a (10 g, 1.0 equiv.) in EtOH (60 mL) and HO (30 mL) was added NaOH (2.36 g, 1.5 equiv.) and LiOH (1.41 g, 1.5 equiv.) under N. The mixture was then stirred at 20 °C under N for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The pH of the residue was adjusted to 3 by adding 2 N HCl. The mixture was then stirred at 20 °C under N for 1 h. The mixture was extracted three times with EtOAc. The combined organic phases were washed with brine, dried over anhydrous NaSO, filtered, and the filtrate was concentrated in vacuo. The product was collected as a colorless oil (5 g, 28%). 1H NMR (400 MHz, CDCl3) δ 2.25 (t, J = 7.3 Hz, 2H), 1.96 (q, J = 4.4 Hz, 2H), 1.71 (q, J = 4.4 Hz, 2H), 1.64 - 1.55 (m, 2H), 1.26 (d, J = 3.7 Hz, 11H), 0.87 (t, J = 6.8 Hz, 3H).
[0400] Intermediate 86c: 2-((1-nonanoylcyclopropane-1-carbonyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of Intermediate 86b (6 g, 1.0 equiv.), Intermediate 1C (16.36 g, 1.0 equiv.), EDCI (6.10 g, 1.5 equiv.), and DMAP (324 mg, 0.1 equiv.) in DCM (60 mL) was added EtN (5.54 mL, 1.5 equiv.) at 0 °C. The mixture was stirred at 20 °C under a N atmosphere for 12 hours. It was then poured into water and extracted three times with EtOAc. The combined organic phase was washed with brine, dried over anhydrous NaSO, filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by column chromatography to give the product as a colorless oil (8 g, 37%). 1 H NMR (400 MHz, CDCl3) δ 5.28 (dtt, J = 15.4, 10.8, 5.8 Hz, 8H), 4.26 (dd, J = 12.1, 4.1 Hz, 2H), 4.08 (dd, J = 12.0, 6.1 Hz, 2H), 2.76 (t, J = 7.4 Hz, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.24 (t, J = 7.6 Hz, 4H), 1.98 (q, J = 6.9 Hz, 8H), 1.54 (p, J = 7.0 Hz, 9H), 1.43 - 1.33 (m, 4H), 1.33 - 1.15 (m, 40H), 0.85 - 0.79 (m, 9H).
[0401] Intermediate 86d: 2-((1-(1-hydroxynonyl)cyclopropane-1-carbonyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] A 4:2:1 solution of Intermediate 86c (8 g, 1.0 equiv.) in THF / water / toluene (0.05-0.1 M) was cooled to 0-5 °C, followed by the addition of NaBH (5.0 equiv.). The reaction was maintained at 0-25 °C for at least 2 h. The reaction was then diluted with water and EtOAc, and the resulting biphasic mixture was extracted three times with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (EtOAc / hexanes) to give the product (4 g, 50%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 5.33 (tdq, J = 20.3, 10.0, 5.6, 4.9 Hz, 9H), 4.28 (dt, J = 12.0, 4.0 Hz, 2H), 4.15 (ddd, J = 12.1, 8.0, 6.0 Hz, 2H), 3.18 - 3.12 (m, 1H), 2.77 (t, J = 6.4 Hz, 4H), 2.68 (s, 1H), 2.31 (t, J = 7.6 Hz, 4H), 2.05 (q, J = 6.9 Hz, 8H), 1.68 - 1.48 (m, 9H), 1.40 - 1.16 (m, 43H), 0.98 (ddd, J = 10.7, 6.7, 4.1 Hz, 1H), 0.93 - 0.84 (m, 9H), 0.81 (ddd, J = 9.7, 6.8, 4.2 Hz, 1H).
[0402] Intermediate 86e: 2-((1-(1-(((4-nitrophenoxy)carbonyl)oxy)nonyl)cyclopropane-1-carbonyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 86d (4 g, 1.0 equiv.) in DCM (40 mL) was added (4-nitrophenyl)carbonochloridate (1.95 g, 2.0 equiv.) and pyridine (781 uL, 2.0 equiv.) at 0 °C. The reaction mixture was then stirred at 20 °C under a N atmosphere for 5 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was reconstituted in petroleum ether and filtered. The filtrate was washed with H O. The combined organic layers were washed with brine, dried over anhydrous Na SO , filtered, and the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product (2.8 g, 59%) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 8.25 - 8.16 (m, 2H), 7.36 - 7.26 (m, 2H), 5.27 (tdd, J = 17.5, 8.5, 4.0 Hz, 9H), 4.84 (dd, J = 9.1, 4.4 Hz, 1H), 4.24 (dt, J = 11.9, 3.8 Hz, 2H), 4.08 (dd, J = 11.8, 5.8 Hz, 2H), 2.70 (t, J = 6.3 Hz, 4H), 2.23 (t, J = 7.6 Hz, 4H), 2.02 - 1.93 (m, 8H), 1.82 (qd, J = 9.4, 4.9 Hz, 1H), 1.69 (ddt, J = 14.4, 10.0, 5.1 Hz, 1H), 1.53 (t, J = 7.2 Hz, 5H), 1.35 - 1.16 (m, 41H), 1.07 - 1.01 (m, 1H), 0.95 - 0.89 (m, 1H), 0.81 (td, J = 6.8, 3.8 Hz, 9H).
[0403] Compound 86: 2-((1-(1-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)nonyl)cyclopropane-1-carbonyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 86 was synthesized in 90% yield from intermediate 86e and N1-ethyl-N1-methylethane-1,2-diamine using the method used in Example 1. 1 H NMR (400 MHz, CDCl3) δ 5.53 - 5.22 (m, 9H), 4.75 (dd, J = 8.7, 4.5 Hz, 1H), 4.29 (ddd, J = 22.5, 11.8, 4.3 Hz, 2H), 4.14 (dd, J = 11.9, 5.9 Hz, 2H), 3.30 (s, 2H), 2.77 (t, J = 6.5 Hz, 4H), 2.54 (d, J = 13.7 Hz, 4H), 2.38 - 2.21 (m, 7H), 2.05 (q, J = 6.7 Hz, 8H), 1.60 (t, J = 7.4Hz, 4H), 1.40 - 1.17 (m, 40H), 1.12 - 1.00 (m, 4H), 0.91 - 0.85 (m, 9H). MS:956.1 m / z [M+H].
[0404] Example 87 - Compound 87 Intermediate 87a: 5-hydroxy-1-methyl-5-octylpyrrolidin-2-one [ka] To a solution of 1-methylpyrrolidine-2,5-dione (20 g, 1.0 equiv.) in THF (150 mL) was added (octyl)magnesium (1 M, 265 mL, 1.5 equiv.) dropwise at 15° C. under N. The mixture was stirred at 15° C. under N for 12 h. The reaction mixture was quenched by adding NH.sub.4Cl at 0° C. The residue was then diluted with HO and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product as a white solid (20 g, 50%). 1H NMR (400 MHz, CDCl3) δ 3.75 (s, 1H), 2.68 (s, 3H), 2.43 (ddd, J = 16.4, 10.0, 6.4 Hz, 1H), 2.24 (ddd, J = 16.7, 10.0, 4.5 Hz, 1H), 2.13 (ddd, J = 13.6, 10.0, 6.4 Hz, 1H), 1.93 (ddd, J = 14.0, 10.0, 4.7 Hz, 1H), 1.73 (td, J = 13.4, 3.7 Hz, 1H), 1.65 - 1.53 (m, 1H), 1.35 - 1.07 (m, 12H), 0.88 - 0.76 (m, 3H).
[0405] Intermediate 87b: 4-hydroxy-N-methyldodecanamide [ka] To a solution of intermediate 87a (15 g, 1.0 equiv.) in MeOH (150 mL) was added NaBH (4.99 g, 2.0 equiv.) in portions. The mixture was stirred at 15° C. for 1 hour. The reaction mixture was quenched by adding NH Cl at 0° C., then diluted with HO and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a white solid (8 g, 53%). 1 H NMR (400 MHz, CDCl3) δ 5.93 (s, 1H), 3.60 - 3.50 (m, 1H), 3.11 (s, 1H), 2.73 (d, J = 4.8 Hz, 3H), 2.36 - 2.20 (m, 2H), 1.78 (dddd, J = 14.3, 7.7, 6.5, 3.1 Hz, 1H), 1.58 (ddt, J = 13.8, 8.9, 6.7 Hz, 1H), 1.46 - 1.09 (m, 14H), 0.87 - 0.77 (m, 3H).
[0406] Intermediate 87c: (R)-4-hydroxy-N-methyldodecanamide [ka] To a solution of intermediate 87b (1.0 equiv.) in EtO (0.2-1 M) was added Novozym 435 (0.89 equiv.) and vinyl acetate (2.0 equiv.). The mixture was stirred at 40 °C for 96 h. The reaction mixture was concentrated under reduced pressure to give a residue that was purified by column chromatography. The material collected from the column was subjected to the above reaction conditions three more times to give (R)-88c as a yellow solid (24% yield). 1 H NMR (400 MHz, CDCl3) δ 5.57 (s, 1H), 3.54 (tt, J = 7.7, 3.6 Hz, 1H), 2.74 (d, J = 4.8 Hz, 3H), 2.64 (d, J = 4.6 Hz, 1H), 2.28 (td, J = 6.9, 3.2 Hz, 2H), 1.79 (dtd, J = 14.3, 7.0, 3.1 Hz, 1H), 1.60 (ddd, J = 14.3, 8.8, 6.8 Hz, 2H), 1.47 - 1.12 (m, 14H), 0.87 - 0.74 (m, 3H).
[0407] Intermediate 87d: (R)-5-octyldihydrofuran-2(3H)-one [ka] To a solution of intermediate 87d (1.0 equiv.) in MeOH (0.1-1.0 M) was added NaOH (10 equiv.). The mixture was stirred at 80°C for at least 2 h, after which HCl (1-2 M, 10.0 equiv.) was added and the mixture was stirred at 25°C for 1 h. The reaction mixture was then diluted with HO and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.41 (p, J = 6.9 Hz, 1H), 2.46 (dd, J = 9.5, 6.8 Hz, 2H), 2.25 (dq, J = 13.4, 6.7 Hz, 1H), 1.78 (dq, J = 12.7, 9.3 Hz, 1H), 1.72 - 1.62 (m, 1H), 1.60 - 1.47 (m, 1H), 1.45 - 1.10 (m, 14H), 0.81 (t, J = 6.6 Hz, 3H).
[0408] Intermediate 87e: (R)-4-hydroxydodecanoic acid [ka] To a solution of intermediate 87d (1.0 equiv.) in HO (0.1-0.5 M) was added NaOH (1.0-1.5 equiv.). The mixture was stirred at 20 °C for at least 12 h. The reaction mixture was concentrated under reduced pressure to give a residue, which was used directly in the next step without further purification.
[0409] Intermediate 88f: (R)-4-hydroxydodecanoic acid benzyl ester [ka] To a solution of intermediate 87e (1.0 equiv.) in acetone (0.3 M) was added BnBr (1.0-1.5 equiv.) and TBAB (0.05 equiv.). The mixture was stirred at 60 °C for at least 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was either (1) purified by column chromatography or (2) diluted with saturated NaHCO₃, extracted three times with EtOAc, dried over Na₂SO₄, filtered, concentrated, and then purified by column chromatography. Both methods afforded the product as a yellow oil (54% yield).
[0410] Intermediate 87g: (R)-4-(((4-nitrophenoxy)carbonyl)oxy)dodecanoate benzyl [ka] To a solution of Intermediate 87f (1.0 equiv.) and (4-nitrophenyl)carbonochloridate (3.0 equiv.) in DCM (0.3-1.2 M) was added pyridine (3.0 equiv.) at 0-20°C. The mixture was stirred at 20°C for at least 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was either (1) purified by column chromatography or (2) used in the next step without further purification. The product was collected as a pale yellow oil (36%). 1 H NMR (400 MHz, CDCl3) δ 8.22 - 8.13 (m, 2H), 7.29 (d, J = 2.0 Hz, 2H), 5.06 (s, 2H), 4.80 (tt, J = 7.6, 4.5 Hz, 1H), 2.43 (t, J = 7.5 Hz, 2H), 2.04 (ddt, J = 15.3, 7.8, 3.9 Hz, 1H), 1.92 (dq, J = 14.8, 7.4 Hz, 1H), 1.71 - 1.61 (m, 1H), 1.55 (ddd, J = 14.3, 9.1, 5.2 Hz, 1H), 1.36 - 1.13 (m, 11H), 0.81 (t, J = 6.6 Hz, 3H).
[0411] Intermediate 87h: (R)-4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoate benzyl [ka] To a solution of intermediate 87g (1.0 equiv.) and N'-ethyl-N'-methyl-ethane-1,2-diamine (3.0 equiv.) in MeCN (0.1-0.2 M) was added pyridine (3.0 equiv.) and DMAP (1.0 equiv.). The mixture was stirred at 20°C for 12 hours. The reaction mixture was then concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a yellow oil (88%). 1H NMR (400 MHz, CDCl3) δ 7.60 - 7.23 (m, 5H), 5.04 (s, 2H), 4.77 - 4.64 (m, 1H), 3.15 (t, J = 6.0 Hz, 2H), 2.36 (ddt, J = 12.3, 8.2, 4.3 Hz, 5H), 2.13 (s, 3H), 1.96 - 1.70 (m, 3H), 1.55 - 1.33 (m, 2H), 1.29 - 1.10 (m, 13H), 0.96 (t, J = 7.1 Hz, 3H), 0.80 (t, J = 6.7 Hz, 4H).
[0412] Compound 87: 2-(((R)-4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 87h (1.0 equiv.) in THF (0.1-0.3 M) was added Pd / C (10% w / w, 1.0 equiv.). The mixture was stirred under H2 (15 Psi) at 15-20 °C for 5 h. Upon completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue.
[0413] To a solution of the residue and Intermediate 1c (1.0 equiv.) in DCM (10 mL) was added EDCI (1.0 equiv.), DMAP (0.1 equiv.), and EtN (1.05 equiv.). The mixture was stirred at 15–20° C. for at least 12 h. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was diluted with HO and extracted three times with EtOAc. The combined organic layers were dried over NaSO, filtered, and the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product as a pale yellow oil (61%). 1H NMR (400 MHz, CDCl3) δ 5.40 - 5.14 (m, 8H), 5.08 (s, 1H), 4.69 (s, 1H), 4.21 (dd, J = 11.9, 4.4 Hz, 2H), 4.08 (ddd, J = 12.0, 5.9, 3.3 Hz, 2H), 3.17 (q, J = 6.0 Hz, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.43 - 2.28 (m, 5H), 2.24 (t, J = 7.6 Hz, 4H), 2.14 (s, 3H), 1.98 (q, J = 6.8 Hz, 7H), 1.79 (ddd, J = 42.6, 15.1, 7.5 Hz, 3H), 1.53 (q, J = 7.6 Hz, 8H), 1.33 - 1.06 (m, 37H), 0.97 (t, J = 7.1 Hz, 3H), 0.81 (q, J = 6.3 Hz, 9H). MS:944.1 m / z [M+H].
[0414] Example 88 - Compound 88 Intermediate 88a: (S)-1-(methylamino)-1-oxododecan-4-yl acetate [ka] Intermediate 88a was synthesized in 23% yield from intermediate 87b using the method used for intermediate 87c. 1 H NMR (400 MHz, CDCl3) δ 5.81 (s, 1H), 4.79 (tq, J = 8.5, 3.8 Hz, 1H), 2.73 (d, J = 4.8 Hz, 3H), 2.17 - 2.03 (m, 2H), 1.98 (s, 3H), 1.95 - 1.63 (m, 3H), 1.56 - 1.36 (m, 2H), 1.19 (d, J = 8.4 Hz, 11H), 0.81 (t, J = 6.8 Hz, 3H).
[0415] Intermediate 88b: (S)-5-octyldihydrofuran-2(3H)-one [ka] Intermediate 88b was prepared from intermediate 88a using the method used for intermediate 87d.
[0416] Intermediate 88c: (S)-4-hydroxydodecanoic acid benzyl ester [ka] Intermediate 88c was prepared from intermediate 88b using the method used for intermediates 87e and 87f.
[0417] Intermediate 88d: (S)-4-(((4-nitrophenoxy)carbonyl)oxy)dodecanoic acid benzyl ester [ka] Intermediate 88d was prepared from intermediate 88c using the method used for intermediate 88g.
[0418] Intermediate 88e: (S)-4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoate benzyl [ka] Intermediate 88e was synthesized in 47% yield from intermediate 88e using the method used for intermediate 87h.
[0419] Compound 88: 2-(((S)-4-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 88 was synthesized in 42% yield from intermediate 88d using the method used for compound 87.
[0420] Example 89 - Compound 89 Intermediate 89a: 4-hydroxy-N-methyldecanamide [ka] To a mixture of methanamine hydrochloride (19.83 g, 2.0 equiv.) in DCM (250 mL) was added AlMe (2 M, 152.72 mL, 2.08 equiv.) dropwise under N at 0 °C. The mixture was stirred at 0 °C under N for 2 h. Next, to this solution was added a solution of 5-hexyltetrahydrofuran-2-one (25 g, 1.0 equiv.) in DCM (100 mL) dropwise under N. The mixture was stirred at 20 °C under N for 12 h. The reaction mixture was quenched by the addition of HCl (1 N) at 0 °C. The organic layer was separated, and the aqueous layer was extracted three times with DCM. The combined organic phase was washed three times with brine, dried over anhydrous NaSO, filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography to give the product as a white solid (67%). 1 H NMR (400 MHz, CD3OD) δ 3.50 (td, J = 7.7, 3.8 Hz, 1H), 2.70 (s, 3H), 2.29 (ddt, J = 25.9, 16.6, 6.8 Hz, 2H), 1.77 (dddd, J = 13.3, 9.2, 6.8, 3.9 Hz, 1H), 1.66 - 1.55 (m, 1H), 1.42 (h, J = 4.0 Hz, 3H), 1.39 - 1.25 (m, 8H), 0.95 - 0.87 (m, 3H).
[0421] Intermediate 89b: (S)-1-(methylamino)-1-oxodecan-4-yl acetate [ka] Intermediate 89b was synthesized in 23% yield using the method used for intermediate 87c. 1H NMR (400 MHz, CDCl3) δ 5.70 (s, 1H), 4.79 (tt, J = 8.4, 4.4 Hz, 1H), 2.74 (d, J = 4.8 Hz, 3H), 2.11 (dp, J = 21.3, 7.7, 7.2 Hz, 2H), 1.98 (s, 3H), 1.86 (tdd, J = 13.6, 6.7, 3.2 Hz, 1H), 1.81 - 1.70 (m, 1H), 1.45 (ddp, J = 19.0, 13.6, 6.6, 6.1 Hz, 2H), 1.27 - 1.12 (m, 8H), 0.80 (t, J = 6.7 Hz, 3H).
[0422] Intermediate 89c: (S)-5-hexyldihydrofuran-2(3H)-one [ka] Intermediate 89c was synthesized in 78% yield from intermediate 89b using the method used for intermediate 87d. 1 H NMR (400 MHz, CDCl3) δ 4.48 (ddd, J = 13.7, 7.5, 5.6 Hz, 1H), 2.52 (dd, J = 9.5, 6.9 Hz, 2H), 2.31 (dq, J = 13.4, 6.7 Hz, 1H), 1.91 - 1.80 (m, 1H), 1.80 - 1.68 (m, 1H), 1.58 (dq, J = 13.8, 5.2 Hz, 1H), 1.51 - 1.21 (m, 8H), 0.87 (t, J = 6.6 Hz, 3H).
[0423] Intermediate 89d: (S)-4-hydroxydecanoic acid benzyl ester [ka] To a solution of intermediate 89c (3 g, 1.0 equiv.) in EtOH (25 mL) and HO (5 mL) was added NaOH (1.1 equiv.) under N. The mixture was then stirred at 20 °C under N for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent.
[0424] The resulting residue was subjected to the method used in Intermediate 87f to give the product as a colorless oil (3 g, 50%).
[0425] Intermediate 89e: (S)-4-(((4-nitrophenoxy)carbonyl)oxy)decanoic acid benzyl ester [ka] To a solution of intermediate 89d (3 g, 1.0 equiv.) in DCM (30 mL) was added (4-nitrophenyl)carbonochloridate (3.26 g, 1.5 equiv.) under N2. Then, pyridine (1.74 mL, 2.0 equiv.) was added to the mixture at 0 °C. The reaction mixture was stirred at 20 °C under N2 atmosphere for 1 hour. The reaction mixture was concentrated under reduced pressure, and the solvent was removed to give a residue. The residue was diluted with hexane and filtered. The filtrate was washed three times with H2O. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product (2 g, 42%) as a colorless oil. 1 H NMR (400 MHz, CD3OD) δ 8.23 - 8.13 (m, 2H), 7.37 - 7.18 (m, 7H), 5.39 (s, 1H), 5.03 (s, 2H), 4.47 (s, 1H), 4.00 (q, J = 7.1 Hz, 2H), 2.42 (t, J = 7.1 Hz, 2H), 2.00 (ddt, J = 15.0, 7.6, 3.8 Hz, 1H), 1.85 (dt, J = 14.7, 7.3 Hz, 1H), 1.57 (ddt, J = 21.1, 14.0, 6.8 Hz, 2H), 1.35 - 1.16 (m, 8H), 0.91 - 0.75 (m, 3H).
[0426] Intermediate 89f: (S)-4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)benzyl decanoate [ka] To a solution of intermediate 89e (1.5 g, 1.0 equiv.) in MeCN (15 mL) was added 2-pyrrolidin-1-ylethanamine (1.16 g, 3.0 equiv.), pyridine (819 uL, 3.0 equiv.), and DMAP (413 mg, 1.0 equiv.) under N2. The mixture was stirred at 20 °C under N2 for 5 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with EtOAc and washed five times with 1 N NaHCO3 and three times with HO. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product as a pale yellow oil (0.65 g, 41%). 1 H NMR (400 MHz, CD3OD) δ 7.41 - 7.26 (m, 5H), 5.11 (d, J = 1.1 Hz, 2H), 4.73 (dd, J = 10.9, 5.7 Hz, 1H), 3.26 (dd, J = 6.7, 1.7 Hz, 2H), 2.79 - 2.57 (m, 7H), 2.41 (t, J = 7.4 Hz, 2H), 1.99 - 1.74 (m, 7H), 1.53 (s, 3H), 1.36 - 1.24 (m, 9H), 0.92 - 0.86 (m, 3H).
[0427] Compound 89: 2-(((S)-4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a suspension of Pd / C (10% w / w, 1.0–3.0 equiv.) in THF (0.2–0.5 M) was added Intermediate 89f (1.0 equiv.). The mixture was stirred under an H atmosphere at 15–25°C for at least 5 h. The reaction mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by column chromatography to give the product as a thick brown oil.
[0428] This brown oil was immediately reconstituted in DCM (0.2–0.5 M), followed by the addition of Intermediate 1c (1.0 equiv.), EDCI (1.2 equiv.), DMAP (0.1–0.2 equiv.), and EtN (1.5 equiv.) under N at 0°C. The mixture was stirred at 20°C under N for at least 12 h. The mixture was diluted with HO and extracted three times with EtOAc. The combined organic phases were washed with brine, dried over anhydrous NaSO, filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography to give the product as a colorless oil (23%). 1 H NMR (400 MHz, CDCl3) δ 5.49 - 5.22 (m, 8H), 5.18 (t, J = 5.0 Hz, 1H), 5.08 (s, 1H), 4.69 (s, 1H), 4.22 (dd, J = 11.9, 4.4 Hz, 2H), 4.12 - 4.04 (m, 2H), 3.28 - 3.15 (m, 2H), 2.70 (t, J = 6.5 Hz, 4H), 2.50 (d, J = 6.4 Hz, 2H), 2.44 (s, 3H), 2.32 (s, 2H), 2.25 (t, J = 7.6 Hz, 4H), 1.98 (q, J = 6.9 Hz, 8H), 1.83 (s, 1H), 1.70 (s, 5H), 1.38 - 0.94 (m, 37H), 0.81 (q, J = 6.6 Hz, 9H). MS:928.4 m / z [M+H].
[0429] Example 90 - Compound 90 Intermediate 90a: (R)-4-hydroxydecanoic acid benzyl ester [ka] Intermediate 90a was synthesized in 27% yield from (5R)-5-hexyltetrahydrofuran-2-one using the method used for intermediate 89d.
[0430] Intermediate 90b: (R)-benzyl 4-(((4-nitrophenoxy)carbonyl)oxy)decanoate [ka] Intermediate 90b was synthesized in 57% yield from intermediate 90a using the method used for intermediate 89e.
[0431] Intermediate 90c: (R)-4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)benzyl decanoate [ka] Intermediate 90c was synthesized in 47% yield from intermediate 90b using the method used for intermediate 89f.
[0432] Compound 90: 2-(((R)-4-(((2-(pyrrolidin-1-yl)ethyl)carbamoyl)oxy)decanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 90 was synthesized in 27% yield from intermediate 90c using the method used for compound 89.
[0433] Example 91 - Compound 91 Intermediate 91a: 4-hydroxydodecanoic acid [ka] To a solution of 5-octyltetrahydrofuran-2-one (20 g, 1.0 equiv.) in HO (200 mL) was added NaOH (4.03 g, 1.0 equiv.). The mixture was stirred at 20 °C under a N atmosphere for 12 h. The reaction mixture was concentrated under reduced pressure to remove the HO, yielding the crude product as a white solid (14 g, 65%). 1H NMR (400 MHz, D2O) δ 3.55 (ddd, J = 9.5, 7.5, 4.6 Hz, 1H), 2.19 (qdd, J = 15.0, 9.3, 6.3 Hz, 2H), 1.69 (dddd, J = 13.9, 9.4, 6.4, 4.4 Hz, 1H), 1.59 (dddd, J = 14.0, 9.2, 7.7, 6.4 Hz, 1H), 1.46 - 1.30 (m, 3H), 1.23 (d, J = 6.6 Hz, 11H), 0.86 - 0.77 (m, 3H).
[0434] Intermediate 91b: Benzyl 4-hydroxydodecanoate [ka] To a solution of intermediate 91a (10 g, 1.0 equiv.) in DMF (100 mL) was added BnBr (7.91 g, 1.0 equiv.). The mixture was stirred at 20 °C under a N atmosphere for 2 hours. The mixture was diluted with H O and extracted twice with EtOAc. The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a colorless oil (5.7 g, 40%). 1 H NMR (400 MHz, CDCl3) δ 7.46 - 7.28 (m, 5H), 5.12 (s, 2H), 3.61 (h, J = 4.6 Hz, 1H), 2.51 (td, J = 7.3, 2.9 Hz, 2H), 1.86 (dtd, J = 14.6, 7.4, 3.5 Hz, 1H), 1.76 - 1.59 (m, 3H), 1.42 (q, J = 12.1, 9.1 Hz, 4H), 1.28 (d, J = 11.9 Hz, 12H), 0.88 (t, J = 6.8 Hz, 3H).
[0435] Intermediate 91c: Benzyl 4-(((4-nitrophenoxy)carbonyl)oxy)dodecanoate [ka] To a solution of intermediate 91b (10 g, 1.0 equiv.) and (4-nitrophenyl)carbonochloridate (9.87 g, 1.05 equiv.) in DCM (100 mL) was added pyridine (3.95 mL, 1.5 equiv.) at 0° C. The mixture was stirred at 20° C. under a N atmosphere for 1 hour. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was diluted with HO and extracted three times with EtOAc. The combined organic layers were concentrated under reduced pressure to give the residue. The residue was purified by column chromatography to give the product as a colorless oil (7.5 g, 49%). 1 H NMR (400 MHz, CDCl3) δ 8.30 - 8.21 (m, 2H), 7.48 - 7.26 (m, 7H), 5.22 (d, J = 69.6 Hz, 2H), 4.87 (tt, J = 7.5, 4.5 Hz, 1H), 2.59 - 2.42 (m, 2H), 1.80 - 1.57 (m, 2H), 1.52 - 1.16 (m, 13H), 0.88 (t, J = 6.6 Hz, 3H).
[0436] Intermediate 91d: Benzyl 4-(((2-(dimethylamino)ethyl)carbamoyl)oxy)dodecanoate [ka] To a solution of intermediate 91c (1.0 equiv.) in MeCN (0.1–0.5 M) was added a diamine or aminoalcohol (N',N'-dimethylethane-1,2-diamine (2.0–3.0 equiv.)), pyridine (3.0 equiv.), and DMAP (0.1 equiv.) at 0 °C. The mixture was stirred at 15–25 °C for at least 2 h. Upon completion, the reaction mixture was concentrated under reduced pressure, diluted with HO, and extracted three times with EtOAc. The combined organic layers were concentrated to give a residue that was purified by column chromatography to afford the product as a yellow oil (79%). 1H NMR (400 MHz, CDCl3) δ 7.46 - 7.28 (m, 5H), 5.08 (s, 1H), 4.76 (s, 1H), 3.23 (q, J = 5.9 Hz, 2H), 2.40 (ddt, J = 12.0, 8.9, 4.5 Hz, 4H), 2.21 (s, 7H), 1.94 (d, J = 9.9 Hz, 1H), 1.82 (p, J = 7.6 Hz, 1H), 1.61 - 1.40 (m, 3H), 1.39 - 1.16 (m, 14H), 0.87 (t, J = 6.7 Hz, 3H).
[0437] Compound 91: 2-((4-(((2-(dimethylamino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 91d in THF (0.1-0.5 M) was added Pd / C (10% w / w). The mixture was stirred at 25 °C under 15 psi of H for at least 5 h. The resulting product was diluted in THF and filtered to remove solids. The filtrate was concentrated in vacuo. The residue was purified by column chromatography to give the carboxylic acid intermediate as a brown oil.
[0438] Compound 91 was then synthesized from the resulting oil in 15% yield using the method used for intermediate 90f. 1H NMR (400 MHz, CDCl3) δ 5.44 - 5.26 (m, 8H), 5.27 - 5.20 (m, 1H), 5.12 (s, 1H), 4.75 (s, 1H), 4.28 (ddd, J = 11.9, 4.5, 1.3 Hz, 2H), 4.14 (ddd, J = 11.9, 5.8, 3.4 Hz, 2H), 3.24 (q, J = 5.7 Hz, 2H), 2.77 (t, J = 6.7 Hz, 4H), 2.44 - 2.35 (m, 4H), 2.31 (t, J = 7.6 Hz, 4H), 2.22 (s, 6H), 2.04 (q, J = 6.9 Hz, 8H), 1.97 - 1.84 (m, 2H), 1.80 (dt, J = 14.9, 7.7 Hz, 1H), 1.67 - 1.42 (m, 8H), 1.42 - 1.14 (m, 39H), 0.88 (td, J = 6.8, 5.2Hz, 9H). MS:930.4 m / z [M+H].
[0439] Example 92 - Compound 92 Intermediate 92a: Benzyl 4-((((1-methylpiperidin-4-yl)oxy)carbonyl)oxy)dodecanoate [ka] Intermediate 92a was synthesized in 94% yield from intermediate 91c and 1-methylpiperidin-4-ol using the method used for intermediate 91d. 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 5.11 (s, 2H), 4.73 (dtd, J = 11.8, 5.4, 4.6, 2.7 Hz, 1H), 4.62 (tt, J = 8.6, 4.2 Hz, 1H), 2.68 (s, 2H), 2.48 - 2.37 (m, 2H), 2.29 (s, 5H), 2.01 - 1.84 (m, 4H), 1.78 (dtt, J = 12.5, 8.2, 3.5 Hz, 2H), 1.67 - 1.58 (m, 1H), 1.58 - 1.46 (m, 1H), 1.27 (d, J = 15.6 Hz, 13H), 0.87 (t, J = 6.8 Hz, 3H).
[0440] Compound 92: 2-((4-((((1-methylpiperidin-4-yl)oxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 92 was synthesized in 28% yield from intermediate 92a using the method used for compound 91. 1H NMR (400 MHz, CDCl3) δ 5.39 - 5.21 (m, 8H), 5.21 - 5.16 (m, 1H), 4.65 (d, J = 6.9 Hz, 1H), 4.57 - 4.52 (m, 1H), 4.22 (dd, J = 11.9, 4.3 Hz, 2H), 4.08 (ddd, J = 11.9, 5.8, 4.1 Hz, 2H), 2.70 (t, J = 6.5 Hz, 4H), 2.61 (s, 2H), 2.36 - 2.29 (m, 2H), 2.29 - 2.18 (m, 7H), 2.14 (s, 2H), 1.98 (q, J = 6.8 Hz, 8H), 1.93 - 1.84 (m, 4H), 1.83 - 1.77 (m, 1H), 1.77 - 1.65 (m, 3H), 1.54 (t, J = 7.3 Hz, 13H), 1.33 - 1.12 (m, 41H), 0.81 (td, J = 6.9, 5.3 Hz, 9H). MS:957.4 m / z [M+H].
[0441] Example 93 - Compound 93 Intermediate 93a: Benzyl 4-(((2-(azetidin-1-yl)ethyl)carbamoyl)oxy)dodecanoate [ka] Intermediate 93a was synthesized in 80% yield from intermediate 91c and 2-(azetidin-1-yl)ethanamine using the method used for intermediate 92d. 1H NMR (400 MHz, CDCl3) δ 7.49 - 7.26 (m, 5H), 5.11 (s, 2H), 5.04 (s, 1H), 4.74 (s, 1H), 3.20 (t, J = 7.0 Hz, 4H), 3.11 (q, J = 5.8 Hz, 2H), 2.50 (t, J = 5.9 Hz, 2H), 2.41 (ddd, J = 8.6, 6.7, 3.2 Hz, 2H), 2.10 - 2.00 (m, 2H), 1.96 - 1.88 (m, 1H), 1.82 (d, J = 15.4 Hz, 4H), 1.46 (d, J = 6.9 Hz, 3H), 1.34 - 1.18 (m, 14H), 0.87 (t, J = 6.8 Hz, 3H).
[0442] Compound 93: 2-((4-(((2-(azetidin-1-yl)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 93 was synthesized in 18% yield from intermediate 93a using the method used for compound 91. 1H NMR (400 MHz, CDCl3) δ 5.36 - 5.22 (m, 8H), 5.18 (p, J = 5.0 Hz, 1H), 4.98 (t, J = 5.6 Hz, 1H), 4.68 (s, 1H), 4.22 (ddd, J = 11.9, 4.5, 1.6 Hz, 2H), 4.08 (ddq, J = 11.7, 5.8, 2.8 Hz, 2H), 3.12 (t, J = 7.0 Hz, 4H), 3.05 (q, J = 5.9 Hz, 2H), 2.70 (t, J = 6.4 Hz, 4H), 2.43 (t, J = 5.9 Hz, 2H), 2.31 (ddd, J = 8.8, 6.6, 4.2 Hz, 2H), 2.25 (t, J = 7.6 Hz, 4H), 1.99 (dq, J = 10.0, 6.9 Hz, 10H), 1.88 - 1.68 (m, 3H), 1.59 - 1.36 (m, 7H), 1.34 - 1.11 (m, 42H), 0.86 - 0.77 (m, 9H). MS:942.1 m / z [M+H].
[0443] Example 94 - Compound 94 Intermediate 94a: Benzyl 4-(((2-(piperidin-1-yl)ethyl)carbamoyl)oxy)dodecanoate [ka] Intermediate 94a was synthesized in 68% yield from intermediate 91c and 2-(piperidin-1-yl)ethan-1-amine using the method used for intermediate 91d. 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 5.10 (s, 3H), 4.75 (s, 1H), 3.22 (t, J = 6.0 Hz, 2H), 2.64 (s, 1H), 2.45 - 2.29 (m, 8H), 1.99 - 1.88 (m, 1H), 1.82 (dq, J = 15.0, 8.0 Hz, 1H), 1.48 (dt, J = 53.9, 5.8 Hz, 9H), 1.34 - 1.17 (m, 12H), 0.86 (t, J = 6.7 Hz, 3H).
[0444] Compound 94: 2-((4-(((2-(piperidin-1-yl)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 94 was synthesized in 22% yield from intermediate 94a using the method used for compound 91. 1 H NMR (400 MHz, CDCl3) δ 5.29 (qq, J = 11.7, 6.7 Hz, 8H), 5.18 (p, J = 5.1 Hz, 1H), 5.08 (s, 1H), 4.69 (s, 1H), 4.22 (ddd, J = 11.9, 4.5, 2.2 Hz, 2H), 4.08 (ddd, J = 11.9, 5.9, 3.6 Hz, 2H), 3.18 (q, J = 5.9 Hz, 2H), 2.70 (t, J = 6.5 Hz, 4H), 2.39 - 2.18 (m, 12H), 1.98 (q, J = 6.9 Hz, 8H), 1.91 - 1.79 (m, 1H), 1.79 - 1.68 (m, 1H), 1.61 - 1.33 (m, 15H), 1.33 - 1.10 (m, 42H), 0.81 (q, J = 6.4 Hz, 9H). MS:970.2 m / z [M+H].
[0445] Example 95 - Compound 95 Intermediate 95a: Benzyl 4-(((4-(diethylamino)butoxy)carbonyl)oxy)dodecanoate [ka] Intermediate 95a was synthesized in 83% yield from intermediate 91c and 4-(diethylamino)butan-1-ol using the method used for intermediate 92d. 1 H NMR (400 MHz, CDCl3) δ 7.44 - 7.28 (m, 5H), 5.11 (s, 2H), 4.72 (tdd, J = 7.6, 5.4, 4.0 Hz, 1H), 4.11 (td, J = 6.7, 3.8 Hz, 2H), 2.49 (q, J = 7.1 Hz, 4H), 2.42 (dtd, J = 7.7, 5.1, 4.4, 2.5 Hz, 4H), 1.99 (dddd, J = 14.4, 8.9, 7.0, 4.1 Hz, 1H), 1.89 (dtd, J = 14.7, 8.4, 6.5 Hz, 1H), 1.64 (ddt, J = 17.4, 10.5, 6.2 Hz, 3H), 1.56 - 1.46 (m, 3H), 1.34 - 1.21 (m, 13H), 1.00 (t, J = 7.1 Hz, 6H), 0.87 (t, J = 6.8 Hz, 3H).
[0446] Compound 95: 2-((4-(((4-(diethylamino)butoxy)carbonyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 95 was prepared in 27% yield from intermediate 95a using the method used for compound 91. 1H NMR (400 MHz, CDCl3) δ 5.35 (qdd, J = 10.6, 4.4, 1.7 Hz, 8H), 5.27 - 5.22 (m, 1H), 4.71 (tt, J = 7.6, 2.7 Hz, 1H), 4.28 (dd, J = 11.9, 4.3 Hz, 2H), 4.13 (dtt, J = 10.4, 6.6, 3.7 Hz, 4H), 2.76 (t, J = 6.6 Hz, 4H), 2.50 (q, J = 7.2 Hz, 4H), 2.41 (ddd, J = 15.2, 8.0, 6.4 Hz, 4H), 2.31 (t, J = 7.6 Hz, 4H), 2.04 (q, J = 6.8 Hz, 8H), 1.98 - 1.82 (m, 3H), 1.72 - 1.47 (m, 12H), 1.39 - 1.21 (m, 42H), 1.00 (t, J = 7.1 Hz, 6H), 0.88 (td, J = 6.8, 4.8 Hz, 9H). MS:987.5 m / z [M+H].
[0447] Example 96 - Compound 96 Intermediate 96a: Benzyl 4-(((2-(diethylamino)ethyl)carbamoyl)oxy)dodecanoate [ka] Intermediate 96a was synthesized in 58% yield from intermediate 91c and N',N'-diethylethane-1,2-diamine using the method used for intermediate 91d. 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 5.19 (s, 1H), 5.11 (s, 2H), 4.76 (s, 1H), 3.51 (s, 2H), 3.27 - 3.15 (m, 2H), 2.54 (dd, J = 8.7, 5.9 Hz, 6H), 2.41 (ddd, J = 9.0, 6.9, 2.6 Hz, 2H), 1.94 (d, J = 7.5 Hz, 1H), 1.83 (p, J = 7.3 Hz, 1H), 1.63 - 1.40 (m, 3H), 1.35 - 1.17 (m, 13H), 1.01 (t, J = 7.1 Hz, 6H), 0.87 (t, J = 6.8 Hz, 3H).
[0448] Compound 96: 2-((4-(((2-(diethylamino)ethyl)carbamoyl)oxy)dodecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 96 was prepared in 42% yield from intermediate 96a using the method used for compound 91. 1H NMR (400 MHz, CDCl3) δ 5.29 (qq, J = 11.4, 6.5 Hz, 8H), 5.18 (p, J = 5.2 Hz, 1H), 5.08 (s, 1H), 4.69 (s, 1H), 4.21 (ddd, J = 11.8, 4.5, 2.0 Hz, 2H), 4.08 (ddd, J = 12.0, 5.9, 2.7 Hz, 2H), 3.12 (dt, J = 13.0, 6.3 Hz, 2H), 2.70 (t, J = 6.5 Hz, 4H), 2.45 (q, J = 7.3 Hz, 6H), 2.28 (dt, J = 27.2, 8.0 Hz, 6H), 1.98 (q, J = 6.9 Hz, 8H), 1.83 (s, 1H), 1.78 - 1.68 (m, 1H), 1.54 (t, J = 7.2 Hz, 9H), 1.35 - 1.11 (m, 42H), 0.81 (q, J = 6.3Hz, 9H). MS:958.4 m / z [M+H].
[0449] Example 97 - Compound 97 Compound 97: 2-((5-(((2-(ethyl(methyl)amino)ethyl)carbamoyl)oxy)tridecanoyl)oxy)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] Compound 96 was prepared in 75% yield from intermediate 55d and intermediate 1c using the method used for compound 52. 1H NMR (400 MHz, CDCl3) δ 5.42 - 5.28 (m, 8H), 5.27 - 5.22 (m, 1H), 5.12 (d, J = 5.7 Hz, 1H), 4.76 - 4.67 (m, 1H), 4.28 (dt, J = 11.9, 4.5 Hz, 2H), 4.13 (ddd, J = 12.0, 5.9, 4.5 Hz, 2H), 3.23 (h, J = 7.2, 6.2 Hz, 2H), 2.76 (t, J = 6.6 Hz, 4H), 2.43 (dt, J = 14.5, 6.6 Hz, 4H), 2.35 - 2.27 (m, 6H), 2.19 (s, 3H), 2.04 (q, J = 6.8 Hz, 8H), 1.71 - 1.46 (m, 13H), 1.40 - 1.19 (m, 42H), 1.03 (t, J = 7.1 Hz, 3H), 0.92 - 0.83 (m, 9H). MS: 958.5 m / z [M+H].
[0450] Example 98 Intermediate 98a: 2,2-ジジメチル-3-オキソウンデカンエチル
change
[0451] Intermediate 98b: 2,2-dimethyl-3-oxoundecanoic acid [ka] A mixture of intermediate 98a (15 g, 1.0 equiv.), LiOH (2.10 g, 1.5 equiv.), and KOH (4.92 g, 1.5 equiv.) in EtOH (120 mL) and HO (40 mL) was degassed and purged with N three times. The mixture was then stirred at 40 °C under a N atmosphere for 3 h. The mixture was concentrated to remove EtOH. The pH was then adjusted to 5–6 with HCl (1 M). The mixture was partitioned between HO and EtOAc. The organic phase was separated, washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a yellow oil (5 g, 37%). 1H NMR (400 MHz, chloroform-d) δ 2.46 (t, J = 7.3 Hz, 2H), 1.58 - 1.47 (m, 2H), 1.33 (s, 6H), 1.20 (s, 10H), 0.81 (t, J = 6.6 Hz, 3H).
[0452] Example 99 - Compound 99 Intermediate 99a: 2-(((2,2-dimethyl-3-oxoundecanoyl)oxy)methyl)propane-1,3-diyl(9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) [ka] To a solution of intermediate 53a (12.16 g, 1.1 equiv.) in THF (20 mL) was added intermediate 98b (4 g, 1.0 equiv.), DBAD (8.07 g, 2.0 equiv.), and PPh3 (9.19 g, 2.0 equiv.) at 0 °C. The mixture was stirred at 0 °C for 15 min. The mixture was then stirred at 15 °C under a N2 atmosphere for 16 h. The reaction mixture was diluted with HO and extracted three times with EtOAc. The organic phase was separated, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography to give the product as a yellow oil (3 g, 20%). 1H NMR (400 MHz, CDCl3) δ 5.27 (dtt, J = 10.8, 8.7, 6.1 Hz, 8H), 4.10 (d, J = 6.0 Hz, 2H), 4.03 (d, J = 6.0 Hz, 4H), 2.70 (t, J = 6.4 Hz, 4H), 2.37 (t, J = 7.3 Hz, 2H), 2.23 (t, J = 7.6 Hz, 4H), 1.98 (q, J = 6.8 Hz, 8H), 1.52 (tt, J = 14.2, 7.4 Hz, 8H), 1.31 - 1.17 (m, 46H), 0.85 - 0.77 (m, 12H).
[0453] Intermediate 99b: 2-(((3-hydroxy-2,2-dimethylundec...
Claims
1. Formula IA 【Chemistry 1】 A compound of the formula: wherein, independently for each occurrence: X 1 But, C 1-3 Alkylene or 【Chemistry 2】 and X 2 is selected from O, NH, NMe, and a bond; X 3 But, C 2-4 is alkylene, X 4 But, C 1 is an alkylene or a bond; X 5 But, C 1 is an alkylene or a bond; R 1 But, C 1-3 is alkyl, R 2 But, C 1-3 is alkyl, or R 2 is a nitrogen atom, and R 1 Or X 3 together with any of the carbon atoms of Y 1 is selected from a bond, —CH═CH—, —(C═O)O—, and —O(C═O)—; Y 2 But -CH 2 -CH=CH- and C 3 -C 4 alkylene; R 3 But, H, C 5-7 Cycloalkyl, C 8 -C 10 Alkenyl, and C 3-18 alkyl, R 4 But, C 4-8 is alkyl, The compound or a salt thereof, However, R 2 is Me, and R 3 But linear C 12 is alkyl, and X 1 But, C 2 is alkylene, and X 2 is O and X 3 But, C 3 is alkylene, and X 4 is a bond, and X 5 But, C 1 is alkylene, and Y 1 is cis-CH=CH-, -Y 2 -R 4 But cis-CH 2 -CH=CH-(C 5 -alkyl), then R 1 But, C 2-3 provided that it is alkyl; The compound or a salt thereof.
2. The compound is represented by formula I 【Chemistry 3】 A compound of the formula: wherein, independently for each occurrence: X 1 But, C 2-3 is alkylene, X 2 is selected from O, NH, NMe, and a bond; X 3 But, C 2-4 is alkylene, X 4 But, C 1 is an alkylene or a bond; X 5 But, C 1 is an alkylene or a bond; R 1 But, C 1-2 is alkyl, R 2 But, C 1-2 is alkyl, or R 2 is a nitrogen atom, and R 1 Or X 3 together with any of the carbon atoms of Y 1 is selected from -CH=CH-, -(C=O)O-, and -O(C=O)-; R 3 But, H, C 5-7 Cycloalkyl, and C 3-18 alkyl, R 4 But, C 4-7 is alkyl, The compound, or a salt thereof, However, R 2 is Me, and R 3 But linear C 12 is alkyl, and X 1 But, C 2 is alkylene, and X 2 is O and X 3 But, C 3 is alkylene, and X 4 is a bond, and X 5 But, C 1 is alkylene, and Y 1 is cis-CH=CH-, and R 4 But, C 5 When it is alkyl, R 1 But, C 2 provided that it is alkyl; The compound of claim 1.
3. 3. The compound of claim 1 or 2, wherein the compound is enantiomerically or diastereomerically enriched.
4. X 1 C 2 2. A compound according to any one of the preceding claims which is alkylene.
5. X 1 C 1 The compound of claim 1 which is an alkylene.
6. X 1 is linear C 3 The compound according to any one of claims 1 to 3, which is an alkylene.
7. X 1 is a branched chain C 3 The compound according to any one of claims 1 to 3, which is an alkylene.
8. X 2 4. A compound according to any one of the preceding claims, wherein is NH.
9. X 2 The compound according to any one of claims 1 to 7, wherein is O.
10. X 2 The compound according to any one of claims 1 to 7, wherein is NMe.
11. X 2 The compound according to any one of claims 1 to 7, wherein is a bond.
12. X 3 C 2-3 2. A compound according to any one of the preceding claims which is alkylene.
13. X 3 C 3-4 The compound according to any one of claims 1 to 11, which is an alkylene.
14. R 2 and X 3 and the carbon atoms of, taken together, form a four-membered ring.
15. R 2 and X 3 and the carbon atom of are taken together to form a five-membered ring.
16. R 2 and X 3 and the carbon atom of are taken together to form a six-membered ring.
17. R 2 C 1 The compound according to any one of claims 1 to 15, which is alkyl.
18. R 2 C 2 The compound according to any one of claims 1 to 16, which is alkyl.
19. R 1 and R 2 and are taken together to form a four-membered ring.
20. R 1 and R 2 and are taken together to form a five-membered ring.
21. R 1 and R 2 and are taken together to form a six-membered ring.
22. R 1 C 1 The compound according to any one of claims 1 to 18, which is alkyl.
23. R 1 C 2 The compound according to any one of claims 1 to 18, which is alkyl.
24. R 3 is linear C 8-16 2. A compound according to any one of the preceding claims which is alkyl.
25. R 3 is linear C 7-12 2. A compound according to any one of the preceding claims which is alkyl.
26. R 3 is linear C 7-9 2. A compound according to any one of the preceding claims which is alkyl.
27. R 3 is linear C 3-6 The compound according to any one of claims 1 to 23, which is alkyl.
28. R 3 is a branched chain C 6-10 The compound according to any one of claims 1 to 23, which is alkyl.
29. R 3 C 5-7 The compound of any one of claims 1 to 23, which is cycloalkyl.
30. R 3 C 6 30. The compound of claim 29 which is cycloalkyl.
31. R 3 C 8-10 The compound according to any one of claims 1 to 23, which is alkenyl.
32. R 3 The compound according to any one of claims 1 to 23, wherein is H.
33. R 4 is linear C 5-6 2. A compound according to any one of the preceding claims which is alkyl.
34. X 4 4. A compound according to any one of the preceding claims, wherein is a bond.
35. X 5 C 1 2. A compound according to any one of the preceding claims which is alkylene.
36. The compound is a compound of formula (IA), 2 -R 4 Ga-CH 2 -CH=CH-R 4 2. A compound according to any one of the preceding claims,
37. The compound is a compound of formula (IA), 2 is linear C 3 The compound according to any one of claims 1 to 35, which is an alkylene.
38. Y 1 20. A compound according to any one of the preceding claims, wherein is selected from a bond, -CH=CH-, and -O(C=O)-.
39. Y 1 A compound according to any one of the preceding claims, wherein is selected from -CH=CH- and -O(C=O)-.
40. The compound is represented by formula II 【Chemistry 4】 The compound of claim 1 ,
41. The compound is represented by formula III 【Chemistry 5】 The compound of claim 1 ,
42. The compound of claim 1 , wherein the compound is selected from the following: 【Chemistry 6】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 , or salts thereof.
43. The compound of claim 1 , wherein the compound is selected from the following: 【Chemistry 7】 , or salts thereof.
44. The compound of claim 1 , wherein the compound is selected from the following: 【Chemistry 8】 【change】 【change】 【change】 , or salts thereof.
45. The compound of claim 1 , wherein the compound is selected from the following: 【Chemistry 9】 【change】 【change】 , or salts thereof.
46. The compound of claim 1 , wherein the compound is selected from the following: 【Chemistry 10】 【change】 【change】 , or salts thereof.
47. The compound according to any one of claims 1 to 46, wherein the salt is a pharma- ceutically acceptable salt.
48. 2. The compound according to any one of the preceding claims, wherein the pKa of the protonated form of the compound is from about 5.1 to about 8.
0.
49. 2. The compound according to any one of the preceding claims, wherein the pKa of the protonated form of the compound is from about 5.6 to about 7.
2.
50. 2. The compound according to any one of the preceding claims, wherein the pKa of said compound is from about 5.7 to about 6.
5.
51. 13. A composition comprising a compound according to any one of the preceding claims in a lipid component.
52. 52. The composition of claim 51, wherein the lipid component comprises about 50% by weight of a compound according to any one of claims 1 to 50.
53. 53. The composition of claim 51 or 52, wherein the composition is an LNP composition.
54. 54. The composition of any one of claims 51 to 53, wherein the lipid component comprises a helper lipid and a PEG lipid.
55. 55. The composition of any one of claims 51 to 54, wherein the lipid component comprises a helper lipid, a PEG lipid, and a neutral lipid.
56. 56. The composition of any one of claims 51 to 55, further comprising a cryoprotectant.
57. 57. The composition of any one of claims 51 to 56, further comprising a buffer.
58. The composition of any one of claims 51 to 57, wherein the composition further comprises an aqueous component comprising a biologically active agent.
59. 60. The composition of claim 58, wherein the biologically active agent comprises a polypeptide.
60. 60. The composition of claim 58, wherein the biologically active agent comprises a nucleic acid.
61. 61. The composition of claim 60, wherein the nucleic acid comprises RNA.
62. 62. The composition of claim 60 or 61, wherein the composition has an N / P ratio of about 3 to 10.
63. 63. The composition of claim 62, wherein the N / P ratio is about 6±1.
64. 63. The composition of claim 62, wherein the N / P ratio is about 6±0.
5.
65. 63. The composition of claim 62, wherein the N / P ratio is about 6.
66. 66. The composition of any one of claims 51 to 65, comprising an RNA component, said RNA component comprising mRNA.
67. 67. The composition of claim 66, wherein the RNA component comprises a sequence encoding an RNA-guided DNA-binding agent, such as a Cas nuclease mRNA.
68. 68. The composition of claim 66 or 67, wherein the RNA component comprises a class 2 Cas nuclease mRNA.
69. 69. The composition of any one of claims 66-68, wherein the RNA component comprises a Cas9 nuclease mRNA.
70. 70. The composition of any one of claims 66 to 69, wherein the RNA component comprises modified RNA.
71. The composition of any one of claims 66 to 70, wherein the RNA component comprises a gRNA nucleic acid.
72. 72. The composition of Claim 71, wherein the gRNA nucleic acid is a gRNA.
73. The composition of any one of claims 66 to 72, wherein the RNA component comprises a class 2 Cas nuclease mRNA and a gRNA.
74. 74. The composition of any one of claims 71-73, wherein the gRNA nucleic acid is or encodes a dual guide RNA (dgRNA).
75. 74. The composition of any one of claims 71-73, wherein the gRNA nucleic acid is or encodes a single guide RNA (sgRNA).
76. The composition of any one of claims 71 to 75, wherein the gRNA is a modified gRNA.
77. 77. The composition of Claim 76, wherein the modified gRNA comprises a modification in one or more of the first five nucleotides at the 5' end.
78. 78. The composition of Claims 76 or 77, wherein the modified gRNA comprises a modification in one or more of the last five nucleotides at the 3' end.
79. The composition of any one of claims 58 to 78, further comprising at least one template nucleic acid.
80. 80. A method of gene editing comprising contacting a cell with a composition according to any one of claims 51 to 79.
81. A method of cleaving DNA comprising contacting a cell with a composition according to any one of claims 51 to 80.
82. 82. The method of claim 81, wherein said contacting step generates a single-stranded DNA nick.
83. 82. The method of claim 81, wherein said contacting step produces a double-stranded DNA break.
84. 82. The method of claim 81 , wherein the composition comprises a Class 2 Cas mRNA and a guide RNA nucleic acid.
85. 85. The method of claim 80 or 84, further comprising introducing at least one template nucleic acid into the cells.
86. 86. The method of claim 85, comprising contacting the cell with a composition comprising a template nucleic acid.
87. 87. The method of any one of claims 80 to 86, comprising administering the composition to an animal.
88. 87. The method of any one of claims 80 to 86, comprising administering the composition to a human.
89. 87. The method of any one of claims 80 to 86, comprising administering the composition to a cell.
90. 90. The method of claim 89, wherein the cell is a eukaryotic cell.
91. 81. The method of claim 80, comprising administering an mRNA formulated in a first LNP composition and a second LNP composition comprising one or more of an mRNA, a gRNA, a gRNA nucleic acid, and a template nucleic acid.
92. 92. The method of claim 91, wherein the first and second LNP compositions are administered simultaneously.
93. 92. The method of claim 91, wherein the first and second LNP compositions are administered sequentially.
94. 92. The method of claim 91, comprising administering the mRNA and the gRNA nucleic acids formulated in a single LNP composition.
95. 95. The method of any one of claims 80-94, wherein the gene editing results in a gene knockout.
96. The method of any one of claims 80 to 94, wherein the gene editing results in gene correction.
Citation Information
Patent Citations
Delivery, engineering and optimization of systems, methods and compositions for sequence engineering and therapeutic applications
JP2016501531A
Method for encapsulating nucleic acids in a lipid nanoparticle host
JP2017523965A
Modified amine lipids
JP7547335B2
Lipids and lipid compositions for the delivery of active agents
WO2015095346A1
Lipid nanoparticle formulations for crispr / CAS components
WO2017173054A1
